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ABSTRACT 
 Molecular imaging enables the direct detection of analytes and biomolecular species 
within their native biological environment. Although the field derives from diagnostic 
biomedical imaging, there has been a significant shift over the past couple decades towards using 
imaging to evaluate and discover biology. In general, molecular imaging relies on the 
development of chemical or biochemical tools that accumulate at the site of interest or under 
undergo a selective, observable change following target engagement. Activity-based sensing is a 
powerful expansion of molecular imaging because it measures chemical reactivity rather than 
concentration. Chapter 1 serves as an introduction to molecular imaging with a historical tone. It 
also defines and highlights key examples of binding-based and activity-based sensing probes to 
contextualize the following chapters. Chapter 2 discusses the design and validation of a 
fluorescent probe for detecting cyclooxygenase-2 activity with live cells, as well as the discovery 
of oxygen-dependent regulation that is not observed on the protein expression level. Chapter 3 
summarizes our progress towards the development of photoacoustic probes for imaging nitric 
oxide within live animals. Topics include the preparation of a photoacoustic probe for imaging 
nitric oxide in a small animal model of inflammation, the optimization of the aza-BODIPY dye 
platform to detect cancer-derived nitric oxide, and progress towards a multimodal dye platform 
for photoacoustic and fluorescence imaging. 
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CHAPTER 1: MOLECULAR IMAGING AND ACTIVITY-BASED SENSING: FROM 
BASIC BIOLOGY TO CLINICAL TRANSLATION1 
 
1.1 Background and significance 
 Molecular imaging emerged from the genomic revolution and key advances in biomedical 
imaging. The rapid generation of genomic data and new strategies for in vitro validation identified 
a wealth of molecular markers for human disease. These targets provided an unprecedented 
opportunity for drug development and diagnostic approaches. Molecular imaging aims to utilize 
this molecular information to discover biology, facilitate early disease detection, and guide 
treatment regimen in living specimen.1–4  
Molecular imaging contrast agents were initially non-targeted, but they quickly evolved to 
utilize targeting strategies for selective accumulation. More recently, contrast agents harness 
stimulus-selective binding or reactivity to directly measure target concentration or activity in 
complex, heterogenous systems. These activatable contrast agents substantially increased the 
accessibility and utility of molecular imaging. This chapter will discuss the evolution of molecular 
imaging with a focus on fluorescence and photoacoustic imaging, as well as the development of 
activity-based sensing (ABS) approaches for studying small-molecule and enzyme targets. This 
chapter aims to contextualize the subsequent chapters by introducing the field of molecular 
imaging with a focus on its application for studying biology within living systems (e.g., live cells 
and animals). 
 
1Portions of this chapter are reprinted or adapted with permissions from the following publications: (1) Gardner, S. 
H.; Reinhardt, C. J.; Chan, J. Advances in Activity-Based Sensing Probes for Isoform-Selective Imaging of Enzymatic 
Activity. Angew. Chem. Int. Ed. 2020, 10.1002/anie.202003687.107 Copyright © 2020 John Wiley and Sons, Inc. (2) 
Reinhardt, C. J.; Chan, J. Development of Photoacoustic Probes for in Vivo Molecular Imaging. Biochemistry 2018, 
57 (2), 194–199.108 Copyright © 2018 American Chemical Society.  
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1.2 Molecular imaging 
1.2.1 Origins of molecular imaging    
 
Figure 1.1: Molecular imaging derives from traditional biomedical imaging techniques (left) and early, non-targeted 
contrast agents (iodine-containing contrast agent, ICCM; middle). Molecular imaging provides information about the 
presence and concentration of analytes or biomolecules to complement anatomical data. Images are adapted with 
permission from ref. 5 (left, Copyright © IEEE 2017), ref. 6 (middle, Copyright © IEEE 2012), and ref. 7 (right, 
Copyright © American Chemical Society 2017). 
   
Traditional biomedical imaging measures physical processes (e.g., absorption, scattering, 
relaxation rates) to define structural and/or physiological information. Originally this was based 
on the differential absorption of X-rays in tissue—the basis of X-ray tomography and computed 
tomography (CT). Unfortunately, most targets are indistinguishable using X-rays and require 
exogenous contrast agents for visualization. For example, iodine or barium can be administered 
for vascular and gastrointestinal imaging, respectively. The limited range of X-ray contrast agents 
prompted the widespread development and application of nuclear medicine. Rather than external 
energy sources, nuclear medicine uses radioactive compounds as the radiation source. This 
radiation can be in the form of γ-rays, for single-photon emission computerized tomography 
(SPECT), or the photons that are released after positron annihilation, for positron emission 
tomography (PET). Strategic tracer design provides a platform for selective accumulation at the 
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site of interest using either small molecule (e.g., 99Tm-methylene diphosphonate, 19F-
fluorodeoxyglucose) or biomolecular (e.g., antibody) targeting approaches. These advances, along 
with those in computer science and molecular biology, prompted the shift towards technologies 
that access molecular information to complement the existing anatomical and physiological 
strategies. This field, coined “molecular imaging”, directly links basic biological discovery with 
diagnostic applications2,3,8 and has attracted widespread interest—both within industry and 
academia—as a tool for streamlining fundamental discoveries and drug development, as well as 
for their use as clinical diagnostics.9  
1.2.2 Modalities suitable for molecular imaging 
 
Figure 1.2: Summary of key ionizing and non-ionizing molecular imaging modalities. Depth of the yellow submarine 
represents general accessible imaging depths and order (from left to right) indicates relative sensitivity.  
 
 The goal of molecular imaging is to access biochemical or molecular information in 
unperturbed biological states (e.g., living cells, tissues, or animals). Key imaging modalities 
include SPECT, PET, ultrasound, optical (e.g., fluorescence, bioluminescence), and magnetic 
resonance imaging (MRI).1–4,10 While ionizing methods have proven impactful, clinically relevant 
frequencies and doses have been correlated with an increased risk of cancer.11 For this reason, 
recent efforts have focused on non-invasive and non-ionizing approaches, such as optical,12,13 
acoustic,14 and MRI methods.15–17 It is important to note that sensitivity, resolution, and depth 
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penetration are intrinsically linked. This poses an inherent challenge for any imaging modality 
where methods with the highest sensitivity and resolution are typically limited to the shallowest 
imaging depths and vice versa. For example, optical methods can provide subcellular resolution, 
but are constrained to imaging at millimeter  depths.4,10  Regardless, there has been an 
overwhelming focus on optical contrast agents because of their superior spatiotemporal resolution, 
sensitivity, cost, instrument accessibility (e.g., confocal and two-photon microscopy, in vivo 
fluorescence imaging systems), and wavelength tunability. This has led to a wealth of information 
regarding the development, modulation, and optimization of optical properties.12,18 
 
1.3 Fluorescence activity-based sensing 
1.3.1 Activity-based sensing: Small molecule targets 
 
Figure 1.3: Schematic representation of a chromophore interacting with the target (star) for reversible, binding-based 
sensing or reaction-based activity-based sensing. 
 
Early fluorescence imaging employed fluorescent dyes or proteins to label subcellular 
compartments or proteins in cellular monolayers. Later, stimulus-responsive probes were prepared 
to extend the range of targets that could be interrogated using fluorescence imaging.19 Generally, 
these activatable contrast agents, or probes, undergo a stimulus-induced change that alters its 
photophysical properties. This change can either be in terms of absorption (e.g. extinction 
coefficient) or the propensity to undergo emissive relaxation (e.g., photo-induced electron transfer 
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or Förster energy transfer rates).20  Seminal examples harnessed supramolecular concepts, such as 
selective chelators,21 to modulate the probe’s optical properties.22 This strategy has been widely 
elaborated for the detection of biological metals since its inception.23 Key examples discovered 
phospholipase C-dependent positive feedback between calcium and inositol 1,4,5-triphosphate,24 
identified the calcium-inducing factor,25,26 visualized the zinc spark upon conception,27 and 
illuminated labile copper’s involvement in the locus coeruleus–norepinephrine system.28  
Later, a wide range of reaction-based or ABS probes were established which harness 
chemoselective reactivity as a means of modifying or unmasking the optical handle.13 Perhaps 
expectedly, reliable organic and organometallic chemistries serve as the basis for most ABS 
probes.29 These compounds have also been categorized as chemodosimeters18 or biodosimeters;13 
however, the differences are semantic and insignificant. We elect to use the ABS terminology 
because it highlights the technology’s key feature: the ability to detect the analyte’s or enzyme’s 
activity rather than concentration. This feat significantly increased the breadth of detectable 
species, particularly towards enzyme targets19,32 and reactive signaling molecules (e.g., nitric 
oxide, superoxide).13,30,31 It is important to note that ABS probes are often the only approach for 
performing live-specimen, high resolution imaging of signaling molecules because of targets 
fleeting nature and the lack of approaches for tagging. Notable ABS probes have uncovered the 
role of endogenous formaldehyde in the one-carbon-metabolism system33 and the implication of 
nitroxyl in TRPA1-based noci- and chemo-sensing.34  
1.3.2 Activity-based sensing: Enzyme targets 
Although reliable methods exist for quantifying transcription (e.g., Northern blotting, 
quantitative polymerase chain reaction) and translation (e.g., Western blotting, enzyme-linked 
immunosorbent assay), direct detection of enzymatic activity remains a significant challenge. ABS 
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is a powerful approach to facilitate post-translational monitoring because it provides a direct read-
out of enzymatic activity with a biocompatible detection method.35 Since it is ultimately the 
activity and not the concentration of an enzyme that dictates function, it is crucial to be able to 
directly monitor this within the target’s native cellular environment.36 
 
Figure 1.4: Common detection strategies for studying enzymes ex vivo (blotting, microarrays, RT-qPCR, ELISA) or 
in living systems (binding-based sensing, BBS; activity-based sensing, ABS) at the DNA, RNA, protein, or post-
translational level. Concentration and activity measurement compatibility are indicated with a bolded C or A, 
respectively. 
 
The origins of enzyme ABS date back to early biochemical analyses when substrates were 
prepared for measuring general enzymatic activities (e.g., esterase, phosphatase, galactosidase, 
lipase) in vitro.37–40 More recently, the focus has shifted towards providing probes with cellular 
and live animal compatibilities.41 Rather than chemoselective functionalization, enzyme ABS 
probes utilize enzyme recognition and catalysis to unmask the optical reporter. Therefore, ABS 
strategies can monitor regulation beyond the concentration level and can shed light on previously 
hidden regulatory mechanisms.42 This regulation may operate through post-translational 
modifications, intracellular availability of cofactors or substrates, and/or feedback mechanisms.43–
45  For example, localized biosynthetic pathways (metabolons) can form through chemotaxis and 
alter local substrate availability. This enhances the pathway’s flux beyond what would be observed 
in vitro.46–48  
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ABS probes facilitate exploratory biological experiments, as well as providing a method 
for drug discovery and diagnosis. For example, acyl-protein thioesterase probes uncovered 
cysteine depalmitoylation as a dynamic lipid signaling mechanism in the cytoplasm and 
mitochondria. The live-cell compatibility and spatiotemporal resolution were essential for 
identifying the location and source of the enzymatic activity in these experiments.49–51 On the other 
hand, enzyme ABS probes can be applied for high throughput screening in biochemical or live 
specimen contexts. The latter has clear applications in traditional cell and high-content screening52 
with rapid validation in small animal models.53,54 The same types of probes can then be been 
translated into clinical trials for cancer detection, with several examples as of 2017,55 or serve as 
contrast agents for image-guided surgery.56 
ABS development becomes more complicated when several functionally related, but non-
identical, enzymes exist. These proteins (isoforms) typically display high sequence and structural 
similarities and operate on near-identical substrates. Isoforms often emerge via gene duplication 
or alternative splicing and enable differential regulation of the protein for increased phenotypic 
robustness.57 The ability to distinguish between isoforms is critical for differentiating their function 
because of their distinct expression, activation, and/or substrate preferences. These conditions 
manifest themselves in physiological and pathological contributions that are simultaneously 
operative. Without isoform-selective ABS probes it would be difficult to decipher their relative 
contributions to a specific condition. Exemplary isoform-selective probes have suggested 
peripheral blood cell  MAO-B  activity  as  a  biomarker  for  Parkinson's disease,58 confirmed  that  
the  elevated expression of CE2 in the liver and intestine correspond with increased in vivo 
activity,59 and demonstrated that cancer stem cell populations retain their elevated ALDHA1A 
activity for weeks after implantation.60  
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The major limitation of optical methods is their depth penetration. Typical experiments are 
constrained to millimeter imaging depths due to extensive light scattering in biological tissue and, 
for this reason, are most suitable for endoscopic imaging. In particular, it is the low-intensity, 
emitted light that restricts tomographic applications.61 This can be addressed by increasing the 
wavelengths of the light to limit autofluorescence, absorption, and scattering because shorter 
wavelengths (ultraviolet-visible) are prone to absorption by endogenous chromophores and elicit 
non-trivial amounts of autofluorescence. At longer wavelengths (near-infrared) the scattering 
coefficient dominates and this parameter decreases as a function of wavelength.62–64  Recent efforts 
have focused on accessing probes within the NIR I (600 - 950 nm) or NIR II (1000 - 1700 nm) 
windows, which can reach up to about a centimeter in depth.64,65 
 
1.4 Photoacoustic activity-based sensing 
1.4.1 Basics of photoacoustic imaging 
 
Figure 1.5: Schematic representation of photoacoustic imaging with tissue-penetrant pulsed excitation, non-radiative 
relaxation-induced heating-cooling cycles, ultrasound detection, and signal reconstruction to provide three-
dimensional images in deep tissue. 
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Photoacoustic (PA) imaging offers a promising alternative to purely optical methods by 
combines non-ionizing, tissue-penetrant excitation light with acoustic detection. By detecting 
sound, rather than emitted light, PA imaging overcomes the limited imaging depths associated 
with fluorescence imaging. This enhancement stems from the decreased scattering of sound within 
biological tissue (circa 103-fold less relative to light) and therefore extends high-resolution 
imaging to centimeter depths.66 Since its initial discovery over a century ago,67 this technology has 
grown significantly through advances in instrumental design and data reconstruction methods. 
These improvements have facilitated an impressive range of biological studies, pre-clinical and 
clinical trials.68–70  
 
Figure 1.6: Stylized Jabłoński diagram for relaxation from an excited electronic and/or vibrational state. Vibrational 
energies are represented in their Morse potential. Absorption (1) or emission events (2, fluorescence; 4, 
phosphorescence) are indicated with black arrows, while non-radiative events are presented as red, dotted arrows. 
Intersystem crossing can occur due to spin-orbital coupling between S1 and T1. The non-radiative relaxation between 
a higher energy and lower energy singlet state (internal conversion) is omitted for clarity.    
 
  PA imaging relies on the PA effect to convert incident light into the detectable ultrasound 
signal. Mechanistically, this begins with the light excitation of an endogenous (e.g., hemoglobin, 
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deoxyhemoglobin, or melanin) or exogenous chromophore (e.g., organic dye or nanomaterial). 
Once excited, the chromophore can return to its ground state via radiative relaxation (e.g., 
fluorescence or phosphorescence) or non-radiative decay (Figure 6). In the case of non-radiative 
relaxation, the chromophore releases energy as heat (approximately 1 mK). This rapid increase in 
the local temperature produces a thermoelastic expansion event and a corresponding pressure 
change (approximately 800 Pa). By pulsing the excitation source, it is possible to generate 
fluctuating (megahertz) pressure waves, which propagate through the medium as acoustic waves. 
An array of ultrasound transducers convert the detected sound to electronic signals for 
reconstruction into three-dimensional images.66,71 Selective excitation source, detector, and 
scanning selection allow the researcher to tune the achievable resolution, sensitivity, and imaging 
depths.72 This empirically manifests with experimental resolutions that are about one two 
hundredth of the imaging depth.66   
1.4.2 Origins of activatable photoacoustic probes 
  In principle, any material that absorbs light can produce a PA signal; however, coupling 
signal generation to a specific biological stimulus remained largely unexplored until recently. In 
2010, the first activatable probe was reported for imaging matrix metallo-protease-2 (MMP-2) 
activity. The design employed an MMP-2-selective peptide linker to connect two chromophores. 
Attaching one fragment to a cell-penetrating peptide sequence facilitated targeted uptake of one 
fragment post-cleavage. Selective imaging of the targeted product was achieved by subtracting the 
signal at the two absorbance maxima.73 Although this approach was initially evaluated in tissue-
mimicking phantoms and fibrosarcoma cells, the approach has since been employed for pre-
clinical in vivo imaging74 and elaborated to image other tumor-associated enzymes (e.g., MMP-9 
and MMP-13).74,75 More broadly, this seminal work highlighted that factors beyond extinction 
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coefficient and fluorescent quantum yield affect the PA properties.73 For example, excited-state 
absorption, relaxation kinetics, photobleaching, and triplet state contributions, are also key 
considerations in the context of PA probe development.76–79 At the moment, these prove more 
difficult to predict, and a better connection between the property and chemical structure is required. 
Regardless, substantial progress has been made regarding the development of nanomaterial and 
small-molecule activatable PA probes.71,80–84  
1.4.3 Photoacoustic activity-based sensing  
 
Figure 1.7: Wavelength shifting is a reliable approach for designing activatable PA probes. Reaction between the 
initial probe and the stimulus (analyte or biomolecule) results in either a reversible or irreversible change in the 
absorption and photoacoustic spectra. Selective imaging at of the initial probe (λmax,1) and product (λmax,2) facilitate 
ratiometric imaging. Note that bathochromic shift approaches are equally effective. 
 
PA probe development functions largely as an extension of and complement for optical 
probes. For example, ideal PA probes also absorb within the NIR-I71 or NIR-II windows85 to limit 
scattering and absorption of the incident light62–65  and have been prepared to image a panel of 
small-molecule analytes and enzyme targets.71,80–84  
Wavelength shifting has emerged as a prominent and reliable approach for developing both 
binding-based and ABS probes for PA imaging83 for three main reasons. First, it facilitates 
simultaneous detection of the non-activated and activated states. This approach is called 
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ratiometric imaging and it can be used to overcome imaging artifacts due to heterogeneous dye 
loading or distribution, variability in imaging depths, tissue-dependent signal attenuation, or 
inconsistent irradiation.86 Second, this approach circumvents the uncertainties associated with the 
parameters that influence the PA signal beyond excitation coefficient and fluorescent quantum 
yield.83 Third, wavelength shifting is compatible with most established NIR dye platforms (i.e., 
cyanine, semi-cyanine, aza-BODIPY, squarine, porphyrinoid) and common optical sensing 
mechanisms. For example, binding-based PA probes have imaged pH, metals, and glycans using 
existing, selective receptors.87–94 Noteworthy examples enhanced PA brightness through 
nanoparticle-dye quenching to detect tumor acidity,89 measured pentylenetetrazol-stimulated 
calcium influx in live zebrafish,92 and imaged copper accumulation in murine Alzheimer’s brains 
by forming a stable copper radical complex.94  
The first small-molecule ABS PA probe was reported in 2015 and it enabled the detection 
of copper in tissue-mimicking phantoms.  APC-2 was an aza-BODIPY-based probe featuring a 2-
picolinic ester as a responsive-element for copper(II).95 Following complexation, the divalent 
metal promotes rate-limiting attack by water or hydroxide96 to uncage a phenolate with a 
corresponding 80 nm shift in the wavelength of maximal absorption. This facilitated selective 
imaging of APC-2 and the uncaged product below a centimeter of chicken breast tissue at 697 and 
767 nm, respectively. Since this initial report, the field has focused on increasing the selectivity, 
sensitivity, and range of the detectable species with examples for a range of reactive oxygen,97,98 
nitrogen,99 sulfur,100,101 and metal species.102 For example, chemoselective reactions with 
nanoparticle dopants converted a promiscuous boronic ester trigger into a selective peroxynitrite 
nanoprobe99 and a liposome-based horseradish peroxidase-substrate system enabled efficient 
hydrogen peroxide imaging  in cancer and inflammation.97 Only modest expansion of enzyme 
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targets has been observed over the same time, where they have remained mostly within the protease 
and peptidase families.103–106 
 
1.5 Summary and outlook 
 
Figure 1.8: Molecular imaging provides unique opportunities for in vitro (e.g., high-throughput inhibitor screens, cell 
biology) and in vivo (e.g., animal model development, diagnostics) experimentation. 
 
 Molecular imaging emerged in the 1990’s as a mechanism to harness genomic and 
biological data for personalized medicine and biological investigations. By directly measuring the 
molecular and biochemical contributors, it is possible to expand the obtainable information beyond 
tissue structures. This approach holds promise for earlier diagnostic tests to improve patient 
prognosis and enables direct interrogation within the target’s native complexity. While ionizing 
technologies proved critical for diagnostic medical imaging, their hazards have driven significant 
efforts towards non-ionizing alternatives. In particular, optical imaging has been widely successful 
because of its high resolution (i.e. spatial, temporal, and spectral), sensitivity, affordability, and 
accessibility. ABS probes employ selective (bio)chemistries to detect the target’s activity, rather 
than concentration, to discovery regulatory mechanisms that are only present in living systems. 
More recently, PA imaging has emerged as a complement for purely optical methods by extending 
imaging depths from the millimeter (e.g., cell monolayers, tissue slices) to centimeter range (e.g., 
organoids, whole-organ imaging, live specimen). Current limitations of these fields include the 
range of available probes, accessible imaging depths, translation into the clinic (e.g., diagnostics, 
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image-guided surgery, theranostics), and systematic validation of in vitro conclusions within live 
cells and animals. In the following chapters, we will discuss the development of an isoform-
selective fluorescent probe for cyclooxyengase-2 activity (Chapter 2) and PA probes for detecting 
endogenous nitric oxide in live animal models (Chapter 3). 
 
1.6 Software 
 Figures were prepared using Microsoft PowerPoint, GraphPad Prism (version 6.0 or 8.0), 
and/or Adobe Illustrator (version 22.0.2). Some images were adapted from Servier Medical ART 
(Les Laboratoires Servier, https://smart.servier.com/) with permission.  
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CHAPTER 2: A FLUORESCENT PROBE FOR MONITORING CYCLOOXYGENASE-2 
ACTIVITY IN LIVE CELLS2 
 
2.1 Background and significance 
 One powerful application of molecular imaging is to discover novel regulatory mechanisms 
that are operative only in living systems. Cyclooxygenase-2 (COX-2) is an important 
pharmacological target and potential biomarker for acute and chronic inflammatory conditions. To 
date, nearly all biocompatible detection methods rely on binding-based sensing for detection. As 
a result, only the presence, but not the functionality of the protein can be assessed. To overcome 
this limitation, we sought to develop a fluorogenic substrate that could undergo COX-2-mediated 
activation in a manner similar to the natural substrate. Ultimately, this could investigate regulation 
that exists beyond the protein expression level, facilitate the deconvolution of isoform 
contributions, and possibly be applied for inhibitor screening, lead development, and diagnostics. 
2.1.1 Cyclooxygenase and the prostaglandins  
Cyclooxygenase (COX, E.C. 1.14.99.1) is the biosynthetic enzyme that initiates the 
synthesis of prostaglandins from the linear lipid precursor, arachidonic acid (AA).1–3 After 
production, the prostaglandins function as important lipid-based mediators that regulate 
physiological processes, such as gastric epithelial protection, hemostasis, and sodium 
metabolism.4,5 At higher concentrations the prostaglandins act as potent pro-inflammatory 
compounds through the production of cytokines.6,7 These prostaglandins can be further elaborated 
by a variety of tissue-specific isomerases and synthases to afford the entire gambit of prostanoids 
 
2Portions of this chapter are reprinted or adapted with permissions from the following publication: Yadav, A. K.; 
Reinhardt, C. J.; Arango, A. S.; Huff, H. C.; Dong, L.; Malkowski, M. G.; Das, A.; Tajkhorshid, E.; Chan, J. An 
Activity-Based Sensing Approach for the Detection of Cyclooxygenase-2 in Live Cells. Angew. Chemie Int. Ed. 2020, 
59, 3307–3314.142 Copyright © 2020 John Wiley and Sons, Inc. 
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(AA-derived prostaglandins).5 The prostanoids exert their unique biological activities by binding 
and activating G-coupled protein receptors or nuclear hormone receptors.8 
 
Figure 2.1: Arachidonic acid is the precursor for the lipoxygenase-, cyclooxygenase-, and cytochrome P450 
monooxygenase-derived eicosanoids. Cyclooxygenase, or prostaglandin G/H synthase, catalyzes the oxidation of 
arachidonic acid to PGG2, followed by reduction to PGH2. A range of prostaglandin synthases or thromboxane 
synthase elaborates this intermediate to yield a range of prostanoids with distinct biological activities.  
 
2.1.2 Cyclooxygenase enzymology and pharmacology 
Two isoforms of human COX have been identified (COX-1 and COX-2), which display a 
high level of structural homology (~60% sequence identity).9 Both are glycosylated, heme-
containing homodimers that are embedded on the luminal surface of the endoplasmic reticulum, 
the inner nuclear envelope, or cytosolic face of the cell membrane through contacts with the 
membrane-binding domain. Of the four oligosaccharides, three are present on both isoforms and 
participate in protein folding. The fourth oligosaccharide is unique to COX-2 and facilitates 
proteasomal degradation or trafficking. COX-2’s localization can be altered by stimuli, are 
catalytically active, and facilitate interactions with other related enzymes. For example, the 
calcium-dependent recruitment of cytosolic phospholipase A2α to the nuclear envelope releases 
AA for eicosanoid biosynthesis by COX-2 and the partial colocalization of COX-2 and 
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thromboxane synthase may promote thromboxane synthesis at the endoplasmic reticulum, but not 
the nuclear envelope.10–14  
 
Figure 2.2: (a) Structure of murine COX-2 bound to arachidonic acid (green, PDB: 3HS5) with the heme (red orange) 
and active site Tyr385 (yellow) shown to indicate the location of the peroxidase and cyclooxygenase active sites, 
respectively. Membrane binding domain (blue) and globular portions of the protein (tan) are highlighted for 
orientation. (b) Zoomed in image of the cyclooxygenase active site highlights the proximity of Tyr385 for the initial 
oxidation by the peroxidase activity, as well as the proper orientation for CH abstraction at carbon-13 of the substrate. 
Note the competent orientation was only observed in only the left subunit. (c) Zoomed in image of the peroxidase 
active site cleft the ligating His388.  
 
Both isoforms catalyze the committed step for production of prostaglandin H2 (PGH2) 
through the alkyl-peroxide intermediate prostaglandin G2 (PGG2). The protein’s structure is 
mostly globular and contains distinct cyclooxygenase and peroxidase active sites.  The 
cyclooxygenase active site is proximal to the membrane interface to facilitate substrate binding 
and the peroxidase active site is solvent exposed. Mechanistically, the catalysis begins with the 
peroxidase activity, where oxidation of the active site tyrosine (in the cyclooxygenase active site) 
is coupled to the reduction of hydrogen peroxide, an organic peroxide, or peroxynitrite. Next, the 
active tyrosyl radical (Tyr385) performs a rate-limiting H-atom abstraction from the pro-S 
hydrogen of carbon-13 and templates the peroxidation and cyclization with molecular oxygen to 
yield PGG2 with minor side products.1,15–19 This intermediate is then likely channeled to the distal 
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active site under physiologically relevant conditions20,21 for reduction to PGH2.1,15–19 While the 
protein is a homodimer, it displays half-of-sites reactivity and can be modulated through allosteric 
binding, presumably within the non-active active site.22,23 
 
Scheme 2.1: Cyclooxygenase’s catalytic mechanism for synthesizing PGG2 and PGH2 from arachidonic acid. An 
active-site tyrosyl radical performs a hydrogen atom abstraction from the substrate to generate a carbon-centered 
radical intermediate. The cyclooxygenase active site then templates an efficient peroxidation with molecular oxygen 
before the translocating the intermediate, PGG2, to the peroxidase active site for reduction to PGH2. 
 
The major difference between the two isoforms is their expression profile: COX-1 is 
constitutively expressed in most cell types, whereas COX-2 expression can be either constitutive 
or induced for rapid prostaglandin production depending on the tissue type.2,4,24–27 COX 
overexpression represents a prominent phenotype in inflammation,28,29 neurodegenerative 
disorders,30 and cancer.25,31,32 For example, high expression levels and cross-talk with inducible 
nitric oxide synthase in cancer can correlate with poor clinical outcomes through increased 
angiogenesis, proliferation, and cell migration.33–38 
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Figure 2.3: COX inhibitors display imperfect selectivity at COX-1 and COX-2. Reprinted (adapted) with permission 
from ref. 39. Copyright © 2001 Harcourt Publishers Ltd. 
 
COX inhibition has been successful for treating acute and chronic inflammation. Aspirin 
was serendipitously discovered as a covalent inhibitor with slight preference for a COX-1. Since 
this discovery, a range of inhibitors were reported with ranging isoform selectivity.39 Collectively, 
these drugs are referred to as non-steroidal anti-inflammatory drugs (NSAIDs). After identifying 
COX-1-dependent gastrointestinal toxicity40 there was a push for achieving COX-2 selectivity.8,39 
Moreover, epidemiological analyses and preclinical studies verified that COX-2 selective 
inhibitors, such as celecoxib, could inhibit carcinogenesis and tumor growth, poising them for both 
cancer prevention and treatment.8,31,41 Interestingly, the pro-metastatic contributions of the 
isoforms appear to be context-dependent.36,42,43 Regardless, unexpected dysregulation of COX-1-
derived thromboxane A2 concentrations by COX-2-derived prostaglandin I2 increased the risk of 
heart attack and stroke in patients. This limits the application of NSAIDs for cancer prevention 
and treatment.5,44 Nevertheless, widespread NSAID use and the role of COX-2 in inflammatory 
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disease continues to drive the development of chemical tools for detecting the protein for basic 
biological studies and diagnostic applications. 
2.1.3 Cyclooxygenase detection strategies 
Early studies evaluated COX activity by directly or indirectly quantifying the substrates, 
intermediates, or product as a measure of in vitro enzyme activity (e.g., HPLC, radiochemical 
assays, oxygen electrodes, chromogenic reductants, horseradish peroxidase coupled assays).20,45,46 
Only a limited number of strategies have been introduced for detecting COX-2 in living cells or 
animals. For example, selective inhibitors of COX-2 have been radiolabeled47–53 or appended to 
dyes54,55 for PET/SPECT or fluorescence imaging, respectively. These imaging agents report on 
relative COX-2 expression profiles; however, they remain in a constant ‘on’ state, regardless of 
whether they are bound to COX-2. More recently, activatable fluorescent inhibitors have been 
reported that afford an turn-on response, where protein binding sequesters the inhibitor away from 
the fluorophore, disrupts the inhibitor-mediated fluorescence quenching, and renders the protein-
small-molecule adduct fluorescent.56,57  Despite these notable improvements, these technologies 
only report on whether COX-2 is present, but not whether the enzyme is catalytically active. It is 
important to highlight that a variety of factors beyond concentration can influence COX-2 activity, 
such as substrate concentration, allosteric regulators, and post-translational 
modifications.18,22,23,58,59  To address these limitations, we developed CoxFluor, the first isoform-
selective, activity-based fluorescent probe for COX-2. 
 
2.2 Design and development of CoxFluor 
CoxFluor consists of 3,7-dihydroxyphenoxazine (reduced form of resorufin) linked to AA 
through a cleavable amide bond. We proposed this design with the hypothesis that the lipid tail 
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could serve as a substrate for COX-2 in a manner similar to the AA (Scheme 2.1). After binding 
within the cyclooxygenase active site, the probe could undergo hydrogen atom abstraction by the 
enzyme’s Tyr385, followed by peroxidation and cyclization to afford the CoxFluor-PGG2 
intermediate. Subsequent translocation to the peroxidase active site and oxidation by Compound I 
or II could yield an unstable oxygen-centered resorufin radical followed by dismutation and amide 
hydrolysis to release the fluorescent product and either PGG2 or PGH2 (after reduction, Scheme 
2.2).1,60–62 When proposing this structure, we hypothesized that we could utilize the bulky dye to 
prevent COX-1 binding and catalysis. This was based on previous reports that indicate COX-1 is 
unable to accommodate large groups at the carboxylate2 and that this moiety provides critical 
interactions with Arg120 for binding.63–65 On the other hand, COX-2’s larger substrate pocket and 
expanded substrate scope, including amides, suggested that CoxFluor should be competent for 
catalysis.66  
 
Scheme 2.2: Proposed mechanism of enzyme‐catalyzed resorufin production by COX via a CoxFluor‐PGG2 
intermediate via either compound I (π cationic porphyrin radical) or compound II (oxyferryl). The reaction between 
two CoxFluor‐PGG2 intermediate radicals, dismutation, and hydrolysis are omitted for simplicity. 
 
The synthesis of CoxFluor began with the zinc-mediated reduction of resazurin, followed 
by acetylation with acetic anhydride to afford compound 2.1 in 63% yield over two steps.67 This 
intermediate was then coupled to arachidonoyl chloride in the presence of potassium iodide to 
afford compound 2.2 in 49% yield. Finally, treatment of compound 2.2 with sodium methoxide 
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(generated in situ) facilitated acetyl deprotection and provided CoxFluor in 68% yield (overall 
21% yield over 4 steps, Scheme 2.3). 
 
Scheme 2.3: Synthesis of CoxFluor from resazurin in three steps with an overall 21% yield. 
 
We first evaluated CoxFluor’s response to recombinant human COX-2. Treatment of 
CoxFluor (Φ = 0.29 , ε = 820 M-1cm-1 at 572 nm) with COX-2 resulted in the production of 
resorufin (Φ = 0.55, ε = 73,000 M-1cm-1 at 573 nm)68 and PGH2 (confirmed by LC-HRMS, Figure 
A.1) with a 41-fold fluorescent turn-on response (Figure 2.4a). To confirm that activation was a 
consequence of enzyme-catalyzed oxidation rather than unbiased peroxidase activity, we prepared 
a control compound, Ctrl-CoxFluor, in which the AA lipid was replaced with the saturated lipid 
tail (arachidic acid, Scheme 2.4).  
 
Scheme 2.4: Synthesis of Ctrl-CoxFluor from compound 2.2 in two steps. Overall 25% yield from resazurin. 
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Figure 2.4: (a) Relative fluorescence for CoxFluor (10 μM) incubated with COX-2 (250 nM) and hemin (1 μM) over 
the course of 4 h. (b) Relative fluorescent intensity of CoxFluor and Ctrl-CoxFluor after incubation with COX-2 (250 
nM) and hemin (1 μM)  for 4 h. (c) Michaelis-Menten kinetics for COX-2-catalyzed (50 nM) release of resorufin in 
the presence of hemin (200 nM). (d) Inhibition of COX-2 (250 nM) and hemin (1 μM) by indomethacin (Indo., 10 
μM) and celecoxib (Cel., 10 μM). (e) Relative fluorescence for CoxFluor incubated COX-2 (0.101 U), a panel of 
enzymes (10-fold excess) or (f) panel of reactive oxygen/nitrogen species (500 μM, 50 equiv). All experiments were 
conducted at room temperature in 100 mM Tris HCl buffer (pH 8.0) except MPO, and 5-LOX (additional information 
in the section 2.6.9). All data is reported as the mean ± standard deviation (n = 3) for parts b, d, e and f or the error 
from fitting for part c. Parts a/c and b/d-f were performed according to the fluorimeter and plate reader assays, 
respectively. 
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Ctrl-CoxFluor proved to be unreactive under the same reaction conditions (Figure 2.4b), 
strongly suggesting that the signal enhancement observed for CoxFluor was due to enzymatic 
activity. Under steady state conditions, CoxFluor underwent oxidation to resorufin by COX-2 with 
a kcat of 19 min-1 and Km of 22 μM (Figure 2.4c). The Km value is similar to those obtained for 
arachidonoyl ethanolamide (Km = 24 μM) and is within an order of magnitude of AA (Km = 6 μM). 
The measured rate for turn-over is also within 100-fold of the natural substrate.66 Importantly, 
CoxFluor’s fluorescence response was inhibited by both indomethacin and celecoxib (Figure 
2.4d).  
Isoform selectivity was evaluated by incubating CoxFluor with COX-1 that was isolated 
from bovine vesicles. Only a minimal change in fluorescence was observed over the course of 4 h 
(1.3-fold fluorescence enhancement, 5% of the COX-2 response, Figure A.2). Off-target activation 
was also assessed across a panel of enzymes that possess closely related activities (lipoxygenase, 
peroxidase, catalase), could potentially cleave the amide (esterase), or are capable of metabolizing 
AA analogs (cytochrome P450s).69 Even in the presence of 10-fold excess enzyme, CoxFluor 
displayed good selectivity against all of the tested enzymes (Figure 2.4e). Likewise, no undesirable 
activation was observed when CoxFluor was incubated with various biologically relevant reactive 
oxygen species, reactive nitrogen species, or other cellular oxidants/reductants (Figure 2.4f and 
A.3). Moreover, no bleaching was observed when resorufin was treated with the same panel of 
reactive oxygen and nitrogen species (Figure A.3). Incubation of CoxFluor with COX-2 in the 
presence of glutathione (GSH, 1 mM) maintained significant COX-2-specific fluorescence 
enhancement confirming the potential for use for live-cell imaging (Figure A.4). This is in contrast 
to Amplex® Red-based assays, which display cross-reactivity with GSH in the presence of 
peroxidases70 or direct quenching of the radical intermediate.62 Together, these data suggest that 
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CoxFluor can be utilized to identify and/or evaluate COX-2 inhibitors, overcoming key drawbacks 
in existing methodologies that require radiolabeled compounds, purification of 
intermediates/products, or coupled-enzyme systems.71,72 This also provides further support for the 
formation of a CoxFluor-PGG2 intermediate because both inhibitors bind within the 
cyclooxygenase active site of the protein.73,74 
 
2.3 Mechanistic insights into CoxFluor’s activation by cyclooxygenase-2 
To further investigate the mechanism of CoxFluor activation by COX-2, we employed 
molecular dynamics (MD) and ensemble docking. Previous structures of COX-1 (PDB 5U6X)75 
and COX-2 (PDB 5KIR)76 were selected, ligands were removed and the holoenzyme was 
simulated in explicit water over a period of 200 ns. Importantly, no global differences were 
observed for the peptide backbone across a panel of COX-1 and COX-2 structures, even in the 
presence of ligands and substrate (www.rcsb.org, all root-mean-standard-deviation < 2.5 Å, Table 
A.1–A.2 and Figure A.5).77 Next, CoxFluor was docked into each pose along the simulation 
trajectory to probe the most probable binding modes (based on the predicted binding score),78 
where clear differences in the number and area available for binding were observed both overall 
and within the cyclooxygenase active site of COX-2 as compared to COX-1 (Figure 2.5a–c and 
A.6). This finding is consistent with the difference in solvent accessible surfaces harbored within 
each cyclooxygenase active site.2 CoxFluor also docks in a similar location to the reported 
indomethacin fluorescent inhibitors (Figure A.7),55,79 further supporting the proposed 
cyclooxygenase-dependent release of resorufin (Scheme 2.2). 
To begin to interrogate the sequence of events, CoxFluor and the CoxFluor-PGG2 
intermediate were docked within COX-2. Consistent with the proposed mechanism, CoxFluor 
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binds significantly at the cyclooxygenase active site (66/597 poses at -7 kcal/mol cutoff). On the 
other hand, the CoxFluor-PGG2 intermediate displayed increased binding at the peroxidase active 
site for oxidation by either Compound I or Compound II (356/368 poses at -7 kcal/mol cutoff).  
 
Figure 2.5: Molecular dynamics and ensemble docking studies of (a) COX-1 and (b) COX-2 with CoxFluor (green). 
Initial protein structures were prepared from PDB 5U6X and 5KIR and crystal bound AA (orange) is superimposed 
for comparison from PDB 1DIY and 3HS5, respectively. Structures display an overlay of all CoxFluor docked poses 
with scoring less than or equal to -7 kcal/mol. The heme from the simulation is represented as a ball and stick model 
to distinguish the cyclooxygenase and peroxidase active sites. (c) Percent of CoxFluor poses within the docking score 
binding affinities. (d) Competent binding of CoxFluor within the cyclooxygenase active site. Tyr385 (yellow) is 
oriented for hydrogen atom extraction from either CoxFluor (green) or AA (orange, PDB 3HS5).   
 
This increased selectivity for the CoxFluor-PGG2 intermediate at the peroxidase active site 
is consistent over all spontaneous interactions (Figure A.8). It is important to note that these results 
are consistent with the peroxidase-based oxidation80 of CoxFluor in a similar manner to Amplex® 
Red62 and 2,2′-azinobis(3-ethylbenzothiazolinesulfonic acid by horseradish peroxidase.61,81 
Finally, to confirm that CoxFluor can adopt the requisite conformation for oxidation by the active 
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site Tyr385, CoxFluor was docked within the cyclooxygenase active site and compared to crystal 
bound AA (PDB 3HS5).82 Structural comparisons indicate that CoxFluor can bind within the 
cyclooxygenase active site with proper orientation for oxidation (Figure 2.5d). Similar poses are 
also observed within the larger box that contains both the cyclooxygenase and peroxidase active 
sites. Together, these results suggest that CoxFluor binds within the substrate binding pocket or 
adjacent solvent-exposed sites to undergo oxidation and formation of the CoxFluor-PGG2 
intermediate. After dissociation from the active site, the intermediate displays increased binding 
to the peroxidase active site for oxidation by Compound I or Compound II and subsequent release 
of resorufin.  
 
2.4 Cellular detection of cyclooxygenase-2 activity with CoxFluor 
Prior to performing cellular experiments, we evaluated CoxFluor’s stability and 
biocompatibility. Negligible fluorescence response was observed after 8 h of incubation at room 
temperature or 37 °C (Figure A.9) and typical staining conditions yielded minimal toxicity in HEK 
293T and RAW 264.7 macrophage cells (Figure A.10). Next, we generated a transiently 
transfected HEK 293T cell line over-expressing human COX-2. GSH depletion was performed 
with N-ethylmaleimide (NEM)83 prior to staining because GSH can generate70 or quench radical 
intermediates of other peroxidase-based probes complicating the interpretation of the results.62,84 
Moreover, past work has demonstrated that COX-2 inhibitors (e.g., celecoxib analogs and 
indomethacin) can alter GSH levels,85–88 which is consistent with our initial experimental 
observations (Figure A.11). After incubation with CoxFluor for 3 h we observed a 1.2-fold 
fluorescence increase for transfected cells compared to the control, and no fluorescence 
enhancement was observed upon treatment with indomethacin (Figure A.12).  
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Next, we applied CoxFluor for the detection and imaging of endogenous COX-2 activity 
within RAW 264.7 macrophage cells. As a key player in inflammatory and immune responses, 
macrophages undergo phenotypic changes to pro-inflammatory or anti-inflammatory states upon 
stimulation.89 Because COX-2 activity is the rate-limiting step in prostaglandin biosynthesis (pro-
inflammatory mediators), COX-2 expression and subsequent prostaglandin production can be 
measured in well-established lipopolysaccharide (LPS)-induced inflammation models as a 
biomarker for inflammation.3,90–95 To date, these studies typically rely on mRNA quantification, 
western blot analysis, or downstream product quantification (e.g., ELISA assays) rather than direct 
quantification of COX-2 activity. This is due to the lack of isoform selectivity in current 
cyclooxygenase assays.  
First, we measured the effect of LPS stimulation time on COX-2’s specific activity in RAW 
264.7 macrophage lysates. Variations due to GSH fluctuations were again minimized using NEM, 
which we and others have shown does not affect COX activity (Figure A.13).96  Only a modest 
2.4-fold increase in COX-2 activity was observed within the first 4 h of activation. Over the next 
several hours, the activity increased in a linear fashion to a maximum of 17.6-fold at 19 h (Figure 
A.14). These results are similar to previous reports of prostaglandin biosynthesis within both 
murine94 and human93 macrophage cells under LPS-stimulated conditions. The activity differences 
were then confirmed within live cells using both confocal microscopy (Figure 2.6) and flow 
cytometry (Figure A.15). Rather than using NEM, we pre-treated with buthionine sulfoximine 
(BSO), a γ-glutamylcysteine synthase inhibitor because it is a less cytotoxic alternative.97,98 Under 
these conditions we observed a 1.2-fold fluorescent enhancement for LPS-stimulated cells relative 
to the control using confocal microscopy and a 1.6-fold increase in median fluorescence for cells 
activated for 19 h as compared to 4 h with flow cytometry (Figure 2.6 and A.15). Moreover, 
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monitoring the ratio of fluorescence from CoxFluor stained cells to CoxFluor stained cells treated 
with indomethacin clearly identified COX-2 activity across activation states (M0 versus M1, 
Figure A.15). Of note, we confirmed that CoxFluor could detect activity changes without GSH 
depletion, in which a 1.2-fold increase in activity was observed after 19 h LPS-activation relative 
to 4 h LPS-stimulated cells using flow cytometry (Figure A.16). 
 
Figure 2.6: Confocal imaging of COX-2 activity in (a) control, (b) LPS-stimulated (1 μg/mL), and (c) indomethacin-
treated (Indo., 10 μM), LPS stimulated RAW 264.7 cells after 4 h incubation with CoxFluor (10 μM) at 37 ºC following 
treatment with BSO (began 19 h prior to staining, 200 μM). Scale bar (white) represents 10 μm. (d) Quantified data. 
Values are reported as the mean ± standard deviation (n = 3). Statistical analysis was performed using one-way 
ANOVA (α = 0.05). **, p < 0.01.  
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Figure 2.7: Contour plots of flow cytometry data from live LPS-activated RAW 264.7 macrophage cells stained with 
CoxFluor (10 μM) under (a) normoxic and (b) hypoxic conditions. (c) Quantified median fluorescence for hypoxic 
and normoxic cells. (d) Effect of indomethacin (20 μM) treatment on the ratio of hypoxic to normoxic median 
fluorescence. (e) Median fluorescence of RAW 264.7 macrophage cells stained under 0.1% (red), 1.0% (grey), or 21% 
(blue) oxygen concentrations. (f) ELISA quantification of COX-2 protein expression levels in 25 μg/mL protein 
lysates. Values are reported as the mean ± propagated standard deviation (n = 6 for flow cytometry data; n = 3 
indomethacin inhibition and ELISA data). All staining was performed following treatment with BSO (began 2 h prior 
to staining, 200 μM) and oxygen dependent flow cytometry data was replicated on two separate days. Statistical 
analysis was performed with two-tail Student’s t test for c, one-tail Student’s t test for d, or one-way ANOVA for e (α 
= 0.05). *, p < 0.05, ****, p < 0.0001. 
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Finally, we were interested in asking whether COX-2 activity can be regulated beyond the 
protein level within the native cellular environment. We hypothesized that oxygen concentrations 
may influence COX-2 activity because oxygen acts as a substrate but can also bind the heme 
prosthetic groups in the ferric state, yielding an off-cycle resting state.99  
The effect of oxygen on COX-2 activity was evaluated in RAW 264.7 macrophage cells 
after a 19 h activation with LPS. The cells were then stained under normoxic (approximately 21%) 
or hypoxic conditions (prepared using AneroPack® for < 0.1% oxygen in a sealed container) and 
the fluorescent response was monitored with flow cytometry. Interestingly, higher activity was 
observed under hypoxic conditions, as indicated by a substantial shift in the population’s median 
fluorescence (Figure 2.7a–c). This increase in median fluorescence was COX-2-dependent, where 
indomethacin treatment resulted in a 12% decrease in the ratio of median fluorescence for hypoxic 
to normoxic M1 macrophages (Figure 2.7d). To confirm the result and evaluate the dose-
dependency of oxygen, we repeated the experiment with staining under an atmosphere containing 
1 or 0.1% oxygen. Here we observe an oxygen-dependent decrease in COX-2 activity as a function 
of oxygen (Figure 2.7d–e). This enhanced enzymatic activity was observed without a change in 
COX-2’s protein expression, as measured by ELISA (Figure 2.7f), highlighting the uniqueness of 
CoxFluor from all previously reported, biocompatible detection strategies. 
These results provide strong evidence that the local cellular environment plays a critical 
role in regulating the activity of COX-2. This emphasizes the importance of measuring enzymatic 
activity in addition to measuring transcription and translation levels. To the best of our knowledge, 
this represents the first example in which an ABS approach has revealed activity differences that 
result from regulation beyond the protein expression levels. 
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2.5 Summary and outlook 
CoxFluor represents the first isoform-selective probe for measuring COX-2 activity in 
living systems. Strategic utilization of the bulky resorufin precursor and AA tail provided 
CoxFluor with the requisite selectively for interrogating COX-2 biology in complex mixtures (e.g., 
in the presence of COX-1), where current inhibitors display imperfect selectivity.40 This isoform 
selectivity enables researchers to directly study COX-2 within its native environment and to 
account for factors beyond transcription and translation that influence enzymatic activity.100 Along 
these lines, we report that COX-2 activity can be regulated by oxygen availability within live cells. 
Taken together, these results suggest that CoxFluor will be a powerful tool for evaluating new 
therapeutics and for studying COX-2 in live cells.  
There a range of applications to investigate moving forward. First, we discovered that high 
concentrations of CoxFluor induce cytotoxic effects in a COX-2-dependent manner. Specifically, 
there are cell-type differences in toxicity as measured by the MTT assay after 48 h incubation with 
CoxFluor: HEK 293T IC50 = 24.10 μM (19.90 – 29.67 μM, 95% confidence interval); 4T1 IC50 = 
14.89 μM (13.67 – 16.24 μM,  95% confidence interval); and MDA-MB231 IC50 = 3.235 μM 
(2.995 – 3.496 μM, 95% confidence interval). The increased potency in breast cancer cells agrees 
well with the increased expression relative to non-cancerous cell lines.56,57,101 This is also 
consistent with previous reports regarding anandamide, the ethanolamine ester of AA, where AA-
conjugate metabolism induced toxicity through the production of the downstream prostaglandins 
or their conjugates.102,103 The development of selective COX-2 substrates, rather than inhibitors, 
could serve as a new approach for targeting cancer via COX-2.  
Second, it would be interesting to use CoxFluor to screen for COX-2 activity across a panel 
of cells lines. Normalization of the enzyme activity to protein expression levels could serve to 
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identify other systems where COX-2 is regulated at or beyond the translational level (e.g., between 
cancer types or stem cells versus differentiated cells). Along the same lines, one could validate the 
widespread in vitro data regarding allosteric regulation of COX-2 lipids within live cells.23  
Finally, it is imperative to optimize CoxFluor for non-invasive imaging within living 
systems. To accomplish this goal, it is necessary to shift the optical properties into the NIR range, 
as well as overcome the GSH quenching. A reasonable approach for shifting the absorbance would 
be to increase the electron density within dye. Similar methods have been reported on the xanthene 
dye platform (e.g., replacement of the endocyclic oxygen or extending the conjugation).104–107 
While neither GSH nor agents for depleting cellular GSH (e.g., NEM or BSO) appear to directly 
inhibit COX-2 activity, GSH does regulate the resulting product distribution (i.e., increasing the 
production of 12-hydroxyheptadecatrienoic acid, malondialdehyde, and prostaglandin 
F2α).84,108,109 It is important to note that in vitro conditions used for monitoring the product 
distribution do not account for the oxidizing environment within the endoplasmic reticulum110 and 
that product distributions are an intrinsic problem with COX activity, in which product 
distributions are observed even in the absence of GSH.108 Together, these properties complicate 
experimental design, favoring protocols where the same cell population is directly compared, as 
well as limit direct application in live animal models. One approach would be to tune the redox 
properties of the resorufin dye precursor to outcompete reduction by GSH.  
All in all, CoxFluor opens the door for studying activity-based regulation in live cells, 
proposes the application of COX-2-activatable substrates for targeting cancer, and sets the stage 
for imaging COX-2 activity in live animals. 
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2.6 Experimental methods 
2.6.1 Materials 
Materials were purchased from commercial vendors and used without further purification. 
All deuterated solvents were purchased from Cambridge Isotope Laboratories. Isoamyl nitrite was 
purchased from Acros Organic. Disodium ethylenediaminetetraacetate dihydrate (EDTA) was 
purchased from Alfa Aesar. 13(S)-HpODE, recombinant human 5-lipoxygenase, and methylamine 
hexamethylene methylamine NONOate (MAHMA-NONOate) was purchased from Cayman 
Chemicals. Sodium diethyldithiocarbamate trihydrate (DETC) was purchased from Chem-Impex 
Incorporated. Corning® Supersomes™ Human Monoamine Oxidase A was purchased from 
Corning Inc. Acetone, ammonium chloride, MitsubishiTM AnaeroPackTM-Anaero Anaerobic gas 
generator, bovine serum albumin (lyophilized), dichloromethane, dimethyl sulfoxide, glacial 
acetic acid, oxalyl chloride (Acros), phosphate saline buffer (Corning), sodium bicarbonate, 
sodium carbonate, sodium chloride, sodium hydroxide, sodium perchlorate (monohydrate), and 
Triton X-100 were purchased from Thermo Fisher Scientific. Anhydrous methanol, conc. 
hydrochloric acid, and hydrogen peroxide (30 % v/v) were purchased from Macron Fine 
Chemicals. Zinc dust was purchased from Mallinckrodt Incorporated. Acetic anhydride, adenosine 
triphosphate, anhydrous acetonitrile, anhydrous dichloromethane, anhydrous dimethylformamide, 
arachidic acid, arachidonic acid, β-nicotinamide adenine dinucleotide 2′-phosphate reduced 
tetrasodium salt hydrate (NADPH), calcium chloride, catalase from bovine liver (lyophilized), 
celite 545, copper(II) chloride, esterase from porcine liver (lyophilized), formaldehyde (37 % w/w 
in water), glutathione (reduced), glyoxal (40 % w/w in water), hemin from bovine, hexanes, 
horseradish peroxidase (type 1), L-ascorbic acid, L-cysteine, L-dehydroascorbic acid, 
lipopolysaccharides from Escherichia coli O111:B4 (purified by phenol extraction), manganese(II) 
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chloride, myeloperoxidase from human leukocytes, p-nitrophenylacetate, potassium superoxide, 
propidium iodide, rat liver microsomes (pooled, male), resazurin, sodium acetate, sodium 
hydrosulfide (hydrate), sodium metal, tris base, and trypan blue powder were purchased from 
Millipore-Sigma Aldrich. Porcine hematin was purchased from MP Biomedical LLC. 4-
dimethylaminopyridine, potassium iodide, and sodium sulfate (anhydrous) were purchased from 
Oakwood Chemicals. N-ethylmaleimide was purchased from Pierce Chemical Company. 
Celecoxib, indomethacin, phenol, and resorufin were purchased from Tokyo Chemical Industry. 
L-buthionine-(S,R)-sulfoximine was purchased from Toronto Research Chemicals. 
2.6.2 Instruments and software 
1H and 13C NMR spectra were acquired on a Varian 500 or Carver B500 spectrometer. The 
following abbreviations were used to describe coupling constants: singlet (s), doublet (d), triplet 
(t), or multiplet (m). Spectra were visualized and analyzed using MestReNova (version 10.0) and 
referenced to trace non-deuterated solvent. High-resolution mass spectra were acquired on a 
Waters Q-TOF Ultima ESI mass spectrometer or a Waters Synapt G2-Si ESI/LC-MS spectrometer. 
Ultraviolet-visible spectroscopy was performed on a Cary 60 or NanoDrop 2000 spectrometer. 
Fluorescence spectra were acquired on a QuantaMaster-400 scanning spectrofluorometer or 
SpectraMax M2 plate reader. Ultraviolet-visible spectroscopy and fluorimetry were performed 
with a micro fluorescence quartz cuvette (Science Outlet), sub-mircroquartz fluorimeter cell 
(Starna Cells, Inc.), or 96-well plates (clear or black with flat bottom, Corning). Refractive indices 
were measured using an RHB-32ATC Brix Refractometer. A Strathkelvin oxygen electrode was 
used for measuring cyclooxygenase activity. Cells were visualized on an EVOS FL 
epifluorescence microscope and cellular imaging was performed using a Zeiss LSM 700 confocal 
microscope. A Countess® II FL Automated Cell Counter was used for cell viability assays. Flow 
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cytometry was performed on a BD LSR Fortessa Flow Cytometry Analyzer. Confocal images and 
flow data were analyzed using ImageJ (NIH)111 and FCS Express 6.04, respectively. Data were 
analyzed using Microsoft Excel and GraphPad Prism (version 6.0 or 8.0) and some figures were 
prepared in Adobe Illustrator (version 22.0.2). Crystallographic figures were prepared using UCSF 
Chimera or VMD.112,113 
2.6.3 Synthetic procedures 
Thin-layer chromatography (TLC) was performed on glass-backed TLC plates precoated 
with silica gel containing an UV254 fluorescent indicator (Macherey-Nagel). TLC’s were 
visualized with a 254/365 nm UV hand-held lamp (UVP). Flash silica gel chromatography was 
performed using 0.04 – 0.063 mm 60 M silica (Macherey-Nagel). All glassware used under 
anhydrous reaction conditions were flame-dried under vacuum and cooled immediately before use. 
10H-phenoxazine-3,7-diyl diacetate (2.2): The compound was prepared according to the 
previous report by Kodera and coworkers.67 Briefly, a mixture of resazurin (200. mg, 0.796 mmol, 
1 equiv) and zinc dust (240. mg, 3.67 mmol, 4.6 equiv) in glacial acetic acid (6 mL) was stirred at 
room temperature for 2 h under N2 atmosphere (in the dark). The reaction was concentrated under 
inert atmosphere to afford 2.1, which was immediately dissolved in acetone (4 mL) and treated 
with DMAP (68.4 mg, 0.560 mmol, 0.7 equiv) and then acetic anhydride (0.16 mL, 1.69 mmol, 
2.1 equiv) was added dropwise and stirred under N2 atmosphere in the dark for 3 h. After 
completion, the reaction was concentrated and then purified via silica gel chromatography (20% 
EtOAc/Hexanes) to afford the product as a yellow solid (150. mg, 0.501 mmol, 63% yield). 1H 
NMR (500 MHz, CDCl3) δ 6.45 (dd, J = 8.4, 2.2 Hz, 2H), 6.39 (d, J = 2.0 Hz, 2H), 6.26 (d, J = 
8.4 Hz, 2H), 5.32 (s, 1H), 2.25 (s, 6H). 13C NMR (125 MHz, CDCl3) δ 169.76, 144.59, 142.94, 
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129.24, 116.25, 113.12, 109.88, 21.02. HRMS [M+H]+ calc’d mass for C16H14NO5 = 300.0872, 
found = 300.0879. 
10-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl)-10H-phenoxazine-3,7-diyl diacetate (2.3): A 
solution of 2.2 (61.2 mg, 0.204 mmol, 1.1 equiv) in anhydrous acetonitrile (1.2 mL) was treated 
sequentially with Na2CO3 (23.6 mg, 0.223 mmol, 1.2 equiv) and then arachidonoyl chloride114 
(60.0 mg, 0.186 mmol, 1 equiv) in anhydrous acetonitrile (1 mL) at 0 ºC. The reaction was allowed 
to warm to room temperature before potassium iodide (83.3 mg, 0.502 mmol, 2.7 equiv) was added 
and the mixture was allowed to continue for 5 h under N2 atmosphere in the dark. Once complete, 
the reaction was filtered, washed with EtOAc (3×), concentrated and purified by silica gel 
chromatography (90% CH2Cl2/Hexanes) to obtain the product as an orange solid (53.3 mg, 0.091 
mmol, 49% yield). 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 8.7 Hz, 2H), 6.95 – 6.85 (m, 4H), 
5.45 – 5.25 (m, 8H), 2.84 – 2.73 (m, 6H), 2.59 (t, J = 7.4 Hz, 2H), 2.30 (s, 6H), 2.07 (dq, J = 21.7, 
7.3 Hz, 4H), 1.75 (q, J = 7.4 Hz, 2H), 1.39 – 1.26 (m, 6H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (125 
MHz, CDCl3) δ 171.84, 168.98, 151.18, 148.79, 130.42, 128.93, 128.85, 128.49, 128.12, 128.09, 
127.82, 127.49, 126.74, 125.42, 116.62, 110.80, 33.39, 31.46, 29.27, 27.16, 26.42, 25.58, 25.57, 
25.53, 24.90, 22.52, 21.02, 14.03. HRMS [M+H]+ calc’d mass for C36H44NO6 = 586.3169, found 
= 586.3180. 
CoxFluor: A solution of 2.3 (50. mg, 0.085 mmol, 1 equiv) in anhydrous MeOH (3 mL) was 
treated with Na (2 mg, 0.087 mmol, 1 equiv) at 0 ºC and the reaction was allowed to continue at 
the same temperature for 0.5 h. When complete, the reaction was treated with aq. satd. NaHCO3 
and extracted with EtOAc (3×). The organic layer was dried over anhydrous sodium sulfate and 
purified by silica gel chromatography (1% MeOH/CH2Cl2) to afford the product as an off-white 
solid (29.2 mg, 58.2 μmol, 68% yield). 1H NMR (500 MHz, CD3OD) δ 7.88 (s, 2H), 7.28 (d, J = 
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8.8 Hz, 2H), 6.59 – 6.55 (m, 4H), 5.39 – 5.24 (m, 8H), 2.80 (q, J = 5.4 Hz, 4H), 2.74 (t, J = 6.7 
Hz, 2H), 2.60 (t, J = 7.3 Hz, 2H), 2.04 (dt, J = 11.7, 5.8 Hz, 4H), 1.66 (q, J = 7.3 Hz, 2H), 1.38 – 
1.29 (m, 6H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 173.29, 154.95, 151.90, 
130.52, 128.96, 128.84, 128.55, 128.15, 127.87, 127.52, 125.64, 121.95, 110.44, 104.29, 33.36, 
31.49, 29.69, 29.30, 27.20, 26.51, 25.62, 25.59, 25.55, 25.02, 22.56, 14.07. HRMS [M+H]+ calc’d 
mass for C32H40NO4 = 502.2957, found = 502.2943. 
Arachidoyl Chloride: The material was prepared in an identical manner to arachidonoyl chloride 
and according to a previously reported protocol.114 Briefly, arachidic acid (50 mg, 0.160 mmol, 
1.0 equiv) was dissolved in anhydrous CH2Cl2 (1 mL) and anhydrous DMF (30 μL) and placed 
under N2 atmosphere. The solution was cooled to -5 oC in an ammonium chloride ice bath before 
oxalyl chloride (28 μL, 0.326 mmol, 2.0 equiv) in anhydrous CH2Cl2 (200 μL) was added. The 
reaction was maintained at the same temperature for 4 h and then allowed to sit at -20 oC overnight. 
The reaction was complete according to crude NMR and then it was concentrated. The residue was 
purified by dissolving in anhydrous hexanes, filtering, and re-concentrating the filtrate. The 
material was used without further purification. 
10-icosanoyl-10H-phenoxazine-3,7-diyl diacetate (2.4): 2.2 (49.7 mg, 0.166 mmol, 1.1 equiv) 
in anhydrous acetonitrile (3 mL) was cooled to 0 ºC and treated with Na2CO3 (19.2 mg, 0.181 
mmol, 1.2 eq). A solution of arachidoyl chloride (50. mg, 0.151 mmol, 1 equiv) in anhydrous 
acetonitrile (3 mL) was added dropwise and allowed to warm to room temperature. Next, 
potassium iodide (124 mg, 0.747 mmol, 4.9 eq) was added and the mixture was allowed to stir at 
room temperature for 5 h under N2 atmosphere in the dark. Once complete, the reaction was 
filtered, washed with EtOAc (3´), concentrated and purified by silica gel chromatography (90% 
CH2Cl2/Hexanes) to obtain the product as a white solid (50.0 mg, 84.2 μmol, 55% yield). 1H NMR 
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(500 MHz, CDCl3) δ 7.45 (d, J = 8.6 Hz, 2H), 6.94 – 6.85 (m, 4H), 2.57 (t, J = 7.5 Hz, 2H), 2.30 
(s, 6H), 1.64 (q, J = 7.3 Hz, 2H), 1.24 (m, 32H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (125 MHz, 
CDCl3) δ 172.20, 169.05, 151.24, 148.78, 126.87, 125.45, 116.65, 110.81, 34.06, 31.91, 29.69, 
29.66, 29.63, 29.57, 29.42, 29.38, 29.35, 29.15, 25.30, 22.68, 21.06, 14.12. HRMS [M + H]+ 
calculated mass for C36H52NO6 = 594.3795, found = 594.3806. 
Ctrl-CoxFluor: To a suspension of 2.4 (40. mg, 0.067 mmol, 1eq) in dry MeOH (3 mL) at 0 oC 
was added Na (2 mg, 0.087 mmol, 1.3 equiv) and the reaction was stirred for 0.5 h. After 
completion, the reaction was treated with aq. satd. NaHCO3 and extracted with EtOAc (3´). The 
organic layer was concentrated and purified by silica gel chromatography (1% MeOH/CH2Cl2) to 
afford the product as a white solid (25 mg, 49 μmol, 73% yield). 1H NMR (500 MHz, CDCl3) δ 
7.17 (d, J = 7.5 Hz, 2H), 6.58 – 6.43 (m, 4H), 2.47 (t, J = 7.5 Hz, 2H), 1.53 (q, J = 7.2, 6.7 Hz, 
2H), 1.17 (d, J = 13.3 Hz, 32H), 0.81 (t, J = 6.9 Hz, 3H). 13C NMR (125 MHz, (CD3)2CO) δ 
172.85, 157.04, 152.83, 126.86, 122.80, 110.85, 104.21, 34.34, 32.65, 30.40, 30.37, 30.22, 30.09, 
29.84, 25.96, 23.34, 14.36. HRMS [M+H]+ calc’d mass for C32H48NO4 = 510.3583, found = 
510.3583.  
2.6.4 Photophysical characterization 
Extinction coefficients and fluorescence quantum yields were acquired (n = 3) and reported 
as the average with a relative standard deviation less than 15%. Extinction coefficients were 
acquired by titrating compound in 100 mM Tris-HCl (pH 8.0) within the linear range. Fluorescence 
quantum yields were obtained using the modified method for relative fluorescence quantum 
yield.115 Dye was titrated into the solution and the absorbance and emission were monitored 
(excitation at 540 nm). The absorbance was maintained below 0.1 to limit secondary absorbance 
events.  Total emission spectra were integrated, and the relative quantum yield was calculated 
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relative to Rhodamine B (ϕ = 0.70, ethanol).116 The refractive index of 100 mM Tris-HCl (pH 8.0) 
was measured to be 1.33514. 
2.6.5 Protein expression and purification 
Human COX-2-His6 was expressed82,117 and purified according to previously reported 
protocols.118 The purification of COX-1 was carried out based on previous protocols with minor 
modifications.119,120 Bovine seminal vesicles (~25 g) were obtained from a butcher (Arends Farms 
Meats and Butcher Shop, Ivesdale, IL) and were mechanically homogenized using a Bio-
homogenizer 2-speed (Model no. M133/1281-0) in 50 mL buffer A (50 mM Tris-HCl, 5 mM 
EDTA, 5 mM DETC, 1 mM phenol, pH 8.0). Note that all centrifugation was performed at 4 °C 
on a Sorvall RC 6+ centrifuge with a Fiberlite F21 8x50 y rotor for less than 10,000 rpm and 
Sorvall WX Ultra 80 with a SureSpin 630 rotor equipped with a swinging bucket for more than 
10,000 rpm. Once homogenized, cellular debris was removed via centrifugation at 9,500 rpm for 
15 minutes. The supernatant was collected and centrifuged at 30,000 rpm for 1 h to obtain the 
microsomal pellet containing COX-1. This pellet was resuspended in 50 mL buffer B (50 mM 
Tris-HCl, 1 mM EDTA, 0.1 mM NaClO4, 0.1 mM DETC, 0.5 mM phenol, pH 8.0), using a 
homogenizer, before centrifugation at 30,000 rpm for 1 h. The corresponding pellet was 
resuspended in 50 mL buffer C (50 mM Tris-HCl, 1 mM EDTA, 1 mM phenol, pH 8.0), 10% 
Triton X-100 was added dropwise with stirring until a final concentration of 1% (v/v) was 
obtained, and the resulting solution was allowed to stir for 1 h at 4 °C. A final centrifugation at 
30,000 rpm was performed for 1 h before the supernatant was loaded onto a DEAE-Sepharose 
column (GoldBio) that was previously equilibrated with buffer C. The column was washed with 
40 mL buffer C and then COX-1 was eluted using a stepwise NaCl gradient prepared from different 
ratios of buffer C to buffer D (50 mM Tris-HCl, 1 mM EDTA, 1 mM phenol, 400 mM NaCl, pH 
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8.0). Specifically, the column was washed with sequential 40 mL portions at each concentration 
(90% buffer C – 0% buffer C in 10% steps). A Bradford assay (Thermo Scientific) was used to 
determine which fractions contained eluted protein; these fractions were concentrated and frozen 
after the addition of glycerol (10% v/v final). Porcine hematin (1 mM) was titrated into 
concentrated protein until λ407 stabilized at a maximum. Human CYP2J2 cDNA was obtained from 
OriGene (Catalog No. SC321730) and N-terminally modified.121 This truncated M2D34G-
CYP2J2 was expressed and purified via Ni-NTA chromatography (GoldBio) as previously 
published.121–123 Full length R. norvegicus cytochrome P450 reductase (CPR) was expressed and 
purified via ADP-agarose chromatography (GoldBio) following previously published protocols.124 
Protein concentration for COX-1 and COX-2 (MW = 140 kDa). were determined using the 
bicinchoninic acid assay (BCA Assay, Thermo Fisher Scientific) relative to a bovine serum 
albumin standard according to the manufacturer’s protocol. The molecular weights for all proteins 
were calculated using the ExPASy tool.125 CYP2J2 (MW = 57 kDa, ε = 110 mM-1cm-1 at λ = 417 
nm) and CPR (MW = 77 kDa, ε = 21.4 mM-1cm-1 at λ = 454 nm) were quantified spectroscopically 
using their Soret absorbance. 
2.6.6 Fluorimeter fluorescence assay 
The fluorescence assays were performed in microquartz cuvettes or submicroquartz 
cuvettes with a maximum volume of 600 μL. Reactions were monitored at room temperature using 
540 nm excitation and emission was collected from 550 – 700 nm with a slit width of 1.25 mm. 
Total volumes of the reaction mixtures were maintained at 570 μL. To 100 mM Tris-HCl buffer 
(480 μL, pH 8.0) was added hemin (30 µL, 19 μM in 4% DMSO in 100 mM Tris-HCl, pH 8.0), 
COX-2 (30 μL, 4.75 μM 100 mM Tris-HCl, pH 8.0) and the reaction was initiated with CoxFluor 
(30 μL, 190 µM 10% DMSO in 100 mM Tris-HCl, pH 8.0). Final reaction concentrations were 1 
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μM hemin, 250 nM COX-2 and 10 μM CoxFluor in 100 mM Tris-HCl with 1.26% DMSO (v/v). 
Experiments in the presence of reduced GSH were conducted according to the same procedure, 
but GSH (30 μL, 19 mM in 100 mM Tris-HCl, pH 8.0) was added before the addition of CoxFluor 
for a final concentration of 1 mM. Assays performed in submicroquartz cuvettes were performed 
maintaining the same ratios, but with a final volume of 142.5 μL. 
2.6.7 Plate reader fluorescence assay 
The fluorescence assays were performed at room temperature using 540 nm excitation and 
590 nm emission. Total volume of the reaction mixture was maintained at 190 μL. To 100 mM 
Tris-HCl buffer (160 μL, pH 8.0) was added hemin (10 μL, 3.8 µM in 4% DMSO in 100 mM Tris-
HCl, pH 8.0), COX-2 (10 μL, 950 nM in 100 mM Tris-HCl buffer, pH 8.0) and the reaction was 
initiated with CoxFluor (10 μL, 190 µM in 10% DMSO in 100 mM Tris-HCl, pH 8.0). Final 
reaction concentrations were 200 nM hemin, 50 nM COX-2 and 10 µM CoxFluor in 100 mM Tris-
HCl with 1.26% DMSO (v/v). Inhibition assays were performed according to the same procedure, 
but COX-2 was preincubated with hemin and inhibitor for 0.5 h at 0 °C before initiation with 
CoxFluor. Relative fluorescence enhancement is calculated by comparing to a buffer control with 
10 μM CoxFluor.   
2.6.8 Enzyme selectivity 
Enzyme activity was defined as the amount substrate (μmol) consumed during one minute 
by one milligram of enzyme in 100 mM Tris-HCl at pH 8.0 under saturating conditions.  Enzyme 
concentrations were measured using the BCA assay (Thermo Fisher Scientific) according to the 
published protocol with bovine serum albumin for the standard curve. COX-1 and COX-2 
cyclooxygenase activities were measured using Strathkelvin oxygen electrode with arachidonic 
acid (200 μM). The oxygen electrode was calibrated using 1% sodium sulfite for 0% oxygen and 
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atmosphere equilibrated 100 mM Tris-HCl at pH 8.0 for 100% oxygen.  The reaction was 
monitored at 37 ºC in a glass chamber with a total reaction volume of 1 mL. Hemin (5 μM), phenol 
(1 mM), and COX (2 μg) were added to atmosphere equilibrated buffer and then the reaction was 
initiated with AA (200 μM). Porcine esterase activity was measured spectroscopically at 405 nm 
using p-nitrophenyl acetate (1.5 mM) as the substrate. Bovine catalase activity was measured using 
a discontinuous Amplex® Red-horseradish peroxidase assay to quantify the amount of hydrogen 
peroxide (initially 31.25 μM) remaining after 0.5 h incubation with excitation at 540 nm and 
emission at 590 nm. CYP2J2 activity was measured spectroscopically at 340 nm using cytochrome 
P reductase (3-fold excess), NADPH (1 mM), and arachidonic acid (70 μM) as the substrate. Rat 
liver microsome selectivity was performed at concentrations ranging from 12.5 μg/mL to 200 
μg/mL and the largest turn-on was reported. Horseradish peroxidase activity was measured using 
hydrogen peroxide (31.25 μM) and Amplex® Red (50 μM) as the substrates with excitation at 540 
nm and emission at 590 nm. Myeloperoxidase selectivity was measured using the manufacturer’s 
conditions (50 mM sodium acetate, pH 6.0, 100 mM NaCl) because the lysosomal enzyme is 
inactive at pH 8.0. Selectivity was assessed using 10-fold excess protein (350 μg/mL) and the 
solution was brought to a pH of 8.0 after 4 h with 0.5 M aq. NaOH prior to measurement. 
Monoamine oxidase A selectivity was assessed using human supersomes with 10-fold excess 
protein (350 μg/mL) under the standard COX conditions. 5-lipoxygenase selectivity was 
performed using the manufacturer’s protocol and reported activity. Specifically, the active 
recombinant human protein in the insect cell lysate was diluted for a final activity of 1.01 U in 50 
mM Tris-HCl buffer (pH 7.5) containing 2 mM CaCl2, 1 mM ATP, and 4.6 μM 13(S)-HpODE. 
Prior to measuring the fluorescence, the solution was titrated with 0.5 M aq. NaOH for a pH 8.0. 
When measured, all enzyme activities were confirmed to be under saturating conditions and within 
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the first 20% of the reaction. The selectivity of CoxFluor (10 μM) was monitored after incubation 
with either 0.101 U COX-2 or 1.01 U of the other enzymes, unless noted otherwise above, in 100 
mM Tris-HCl buffer at pH 8.0 using the plate reader with excitation at 540 nm and emission at 
590 nm. Total reaction volume was maintained at 95 μL with a final DMSO concentration of 
1.26% (v/v). Relative fluorescence enhancement is calculated by comparing to a buffer control 
containing 10 μM CoxFluor. 
2.6.9 Analyte selectivity 
Response of CoxFluor (10 μM) to a variety of reactive oxygen, nitrogen, carbonyl, metals 
and sulfur species (1, 3, 5, or 50 equiv) were monitored using the plate reader assay. Total volume 
of the reaction mixture was maintained at 190 μL in 100 mM Tris-HCl buffer (pH 8.0) with a final 
DMSO concentration of 1.26% (v/v). Assays for CoxFluor or resorufin were initiated by the 
addition of the analytes and the reactions were incubated at room temperature for up to 4 h. 
Measurements were recorded at a range of time points, and the relative turn-on was determined 
relative to a buffer control containing 10 μM CoxFluor or resorufin. Superoxide anion was added 
as a solution of potassium superoxide in DMSO. Nitroxyl was generated in situ from a solution of 
Angeli’s salt in degassed 10 mM potassium hydroxide solution. Angeli’s salt was prepared 
according to previously reported literature.126 NO was generated in situ from a solution of 
MAHMA-NONOate in degassed 10 mM potassium hydroxide. Peroxynitrite was prepared 
according to previously reported literature.127 All metals were prepared from their chloride salt. 
Formaldehyde solutions were prepared by depolymerizing saturated aqueous solutions at 100 ºC 
before use. Dehydroascorbic acid was prepared by dissolving the solid at 65 ºC in water before 
cooling to room temperature for use. All other analytes were prepared by dilution or dissolution 
from commercially available sources. 
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2.6.10 Structure preparation for molecular dynamics simulations and ensemble molecular 
docking  
The preferential binding of CoxFluor to COX-2 over COX-1 was probed using ensemble 
docking and molecular dynamics techniques. The structure of sheep COX-1 (PDB 5U6X)75 and 
human COX-2 (PDB 5KIR)76 were obtained from X-ray diffraction data. Before simulations, all 
non-heme cofactors were removed; the heme bound cobalt in COX-2 was replaced with an iron; 
cysteine bridges and the iron histidine were patched and preserved using PSFGEN; and the 
coordinates and topology for missing hydrogens were predicted using PSFGEN.  To validate the 
selected structures, we calculated root mean squared deviation (RMSD) for 5U6X and 5KIR versus 
a myriad of resolved structures using SuperPose (Tables S1-2).128 Additional information can be 
found in Appendix B. 
2.6.11 Equilibrium molecular dynamics simulations of COX-1 and COX-2 
Parameters and protocols for simulations were followed according to literature precedence 
with minor modifications.129,130 Molecular dynamics simulations were performed using NAMD 
2.12131 with the CHARMM36m force field.132 Constant temperature and pressure were maintained 
using Langevin dynamics and Langevin piston Nosé−Hoover methods133,134 at 310 K and 1 
atmosphere, respectively. The particle mesh Ewald (PME) method was used to calculate long-
range electrostatic forces135,136 using a 1 Å grid spacing. The van der Waals interactions were 
evaluated with a cutoff of 12 Å, with a force-based switching scheme after 10 Å. A 2 fs integration 
time step was applied with the SETTLE algorithm.137 VMD 1.9.3 was used for visualization and 
analysis.113 Both COX-1 and COX-2 were first equilibrated for 10 ns with the entire protein 
restrained (1.0 kcal/mol/Å2) to allow for solvation of the protein, followed by progressively 
decreasing harmonic restraints over the course of 10 ns on protein Cα atoms (2.5 ns at 1.0 
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kcal/mol/Å2, 2.5 ns at 0.75 kcal/mol/Å2, 2.5 ns at 0.50 kcal/mol/Å2, 2.5 ns at 0.25 kcal/mol/Å2). 
This was followed by 200 ns production simulation without restraints. RMSD was calculated using 
MDAnalysis138,139 for the simulation trajectories against AA bound crystal structures of COX-1 
(PDB 1DIY)140 and COX-2 (PDB 3HS5)82 to confirm no major deviations. Additional information 
can be found in Appendix B. 
2.6.12 Ensemble molecular docking  
Ensemble docking of CoxFluor to COX-1 and COX-2 was performed using AutoDock 
Vina.78 The previously discussed simulations were used to sample the dynamics of COX-1 and 
COX-2 for docking. Because both COX-1 and COX-2 are homodimers in the crystallographic 
state it was possible to double the sampling time by overlaying the monomers throughout the 
docking process for a total of 400 ns sampling time (200 ns sampling time for docking to each 
monomer). For each snapshot, a 26 × 26 × 26 Å3 cube containing both the cyclooxygenase and 
peroxidase active sites was used to fully sample the suspected binding sites. Each snapshot was 
docked with an exhaustiveness of 10, yielding a maximum of 4000 docked poses. These poses 
where then characterized based on location and binding affinities. To determine the location of the 
binding, poses were grouped based off of their proximity to the iron, within the heme, where 
greater than 8 Å was defined as cyclooxygenase binding (confirmed that this cutoff was consistent 
with structural understanding of the protein). The same protocol for docking was implemented for 
the CoxFluor-PGG2 intermediate. Docking within the cyclooxygenase site was performed within 
a 22 × 22 × 22 Å3 cube using the same protocol where the box only included the cyclooxygenase 
active site. Using the VMD plugin Multiseq,141 a STAMP structural alignment was done on 5U6X 
and 1DIY, as well as on 5KIR and 3HS5 to identify relevant AA positions in COX-1 and COX-2 
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respectively, followed by visualization in PYMOL (Version 1.7.0.0; Schrodinger, LLC). 
Additional information can be found in Appendix B. 
2.6.13 CoxFluor, Ctrl-CoxFluor & resorufin stability assays 
Stability assays were performed for a 10 µM solution of each compound in a series of 
buffers/solvents (100 mM Tris-HCl at pH 8.0, DMEM with 10% FBS, DMEM without serum and 
DMSO). Stability was assessed at room temperature or at 37 °C and in the presence or absence of 
ambient light. Fluorescence was measured using the plate reader with excitation at 540 nm and 
emission from 560 – 700 nm and the relative turn-on was determined by the change of fluorescence 
intensity at 590 nm.  
2.6.14 Cell culture 
HEK 293T and RAW 264.7 macrophage cells were acquired from ATCC and Prof. Elvira 
de Mejia (Food Science and Human Nutrition, UIUC), respectively. Cells were cultured in phenol-
red free Dulbecco’s modified eagle medium (DMEM, Corning) supplemented with 10% fetal 
bovine serum (FBS, Sigma Aldrich), and 1% penicillin/streptomycin (Corning). Incubation with 
0.25% trypsin containing EDTA and phenol red (GibcoTM, Fisher Scientific) or manual scrapping 
is used for passaging for HEK 293T and RAW 264.7 macrophage cells, respectively. Cells were 
incubated at 37 °C with 5% CO2. Experiments were performed in 4-well chambered cover glasses 
(Lab-Tek, Thermo Scientific), 96-well plates (Nunc, Thermo Scientific), or 6-well plates (BioLite, 
Thermo Scientific). 
2.6.15 Trypan blue exclusion cytotoxicity assay  
6-well plates were seeded with 300,000 cells per well (2 mL of 150,000 cells/mL) and 
incubated at 37 °C with 5% CO2 for 48 to 72 h (~60–80% confluent). Media was removed and 
replaced with either 5, 10, or 25 μM CoxFluor in fresh serum-free DMEM media (1.25% DMSO 
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v/v final concentration). After 6 h the media was removed, and cells were trypsinized with 200 μL 
0.25% trypsin-EDTA for less than 5 minutes at 37 °C. The trypsin was quenched with the addition 
of 1.8 mL DMEM media containing 10% FBS and the cells were mixed thoroughly before diluting 
1:1 with trypan blue (0.4% in PBS w/v). Percent viability was measured using a Countess® II FL 
Automated Cell Counter (Thermo Fisher Scientific), where the parameters were optimized to 
identify live and dead cells. Viability was calculated by the relative to the vehicle control. 
2.6.16 MTT cytotoxicity assay  
96-well plates were seeded with 20,000 cells per well (200 μL of 100,000 cells/mL, RAW 
264.7 macrophage) or 25,000 cells per well (200 μL of 125,000 cells/mL, HEK 293T cells) and 
incubated at 37 °C with 5% CO2 for 72 h (~90% confluent). Media was removed and fresh serum-
free DMEM media containing 0, 5, 10, or 25 μM CoxFluor (1.25% DMSO final v/v) was added. 
The media was removed at various time points (3 or 6 h) and replaced with 200 μL 20∶1 mixture 
of FBS-free DMEM and (3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT, 
5 mg/mL stock in PBS). The cells were incubated for 4 h under the same conditions and then the 
medium was removed and replaced with DMSO (200 μL/well). The absorbance of each well was 
recorded after a 1:5 dilution in DMSO at 555 nm on a microplate reader. Viability was calculated 
by the absorbance relative to the vehicle control. 
2.6.17 HEK 293T transfection with human COX-2 
The plasmid containing human COX-2 (pcDNA3.1-hPTGS2-2flag) was purchased from 
Addgene (Catalog# 102498, deposited by Prof. Jun Yu, The Chinese University of Hong Kong).32  
The plasmid was isolated from a single colony that was grown to turbidity overnight at 37 °C in 
Luria broth (LB) media with 100 μg/mL ampicillin (5 mL) using the GeneJET plasmid Miniprep 
(Thermo Scientific) according to the manufacturer’s protocol (the plasmid was eluted with Milli-
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Q water rather than the elution buffer). Plasmid concentration was determined using the 
absorbance at 260 nm on a NanoDrop 2000 spectrometer. Prior to plating onto 4-well chambered 
cover glasses, the surface exposed substrate was coated with R&D Systems™ Cultrex Poly-L-
Lysine (Fisher Scientific) according to the manufacturer’s protocol (allowed to dry > 3 h). Plates 
were seeded with 175,000 cells per well (500 µL of 350,000 cells/mL in DMEM media 
supplemented with 10% FBS) and allowed the cells to incubate for 40 h at 37 °C with 5% CO2 
(60–70% confluent). Transfections was performed using Lipofectamine 3000 (Thermo Fisher 
Scientific) according to the manufacturer’s protocol. Briefly, 180 µL of transfection master mix 
was prepared by a 1:1 dilution of lipofectamine 3000 reagent (5.4 µL in 90 µL Opti-MEM™ 
Reduced Serum Media) and DNA complexed to P3000 reagent (1,800 ng plasmid with 3.6 µL 
P3000 in Opti-MEM™ Reduced Serum Media) and the master mix was allowed to incubate at 
room temperature for 5 to 10 minutes. Media was removed from each well and replaced with 500 
µL Opti-MEM™ Reduced Serum Media followed by the addition of 20 μL transfection master 
mix. After 48 h incubation at 37 °C with 5% CO2 (~90–100% confluent) the cells were subjected 
to experimental conditions for imaging.  
2.6.18 Confocal fluorescence live-cell imaging of human COX-2 transfected HEK 293T cells  
Transfections were performed using the Lipofectamine 3000 reagent according to the 
aforementioned protocol. Control wells were treated the same as the transfected wells without the 
addition of the transfection master mix. The media was removed from each well and replaced with 
serum-free DMEM media containing 10 μM CoxFluor or 10 μM CoxFluor with 10 μM 
indomethacin (1% DMSO final concentration). Cells were incubated at 37 °C with 5% CO2 before 
imaging with excitation at 555 nm and emission collected from 565–700 nm. Each well was 
imaged using a Zeiss LSM 700 confocal microscope (n = 3 technical replicates; n = 4 biological 
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replicates). For GSH knockdown experiments, the initial media change was performed with 1 mM 
NEM (0.1 % DMSO final concentration) in serum-free DMEM media and the cells were allowed 
to incubate for 30 minutes before proceeding to the staining with CoxFluor. Images were 
quantified over the entire imaging window, without any processing, using ImageJ (v. 1.51, NIH). 
All publication images were processed using identical parameters and false colored (LUT: jet.lut) 
in ImageJ.111 
2.6.19 RAW 264.7 macrophage activity assays  
6-well plates were seeded with 250,000 cells per well (2.0 mL of 125,000 cells/mL) and 
the cells were allowed to incubate at 37 °C with 5 % CO2 for 72 h (~70–80% confluent). The media 
was removed and replaced with serum-free DMEM (1.98 mL). Lipopolysaccharide was added in 
PBS (20 μL 100 μg/mL for final concentration of 1 μg/mL) at 2, 4, 6, 8, 10, 19, and 24 h (n = 3 
biological replicates) prior to lysis. Control wells were prepared by adding PBS without LPS at 
the 24 h time point. The media was removed, and the cells were lysed by adding CelLytic M (200 
μL, Millipore-Sigma) and mixing for 15 minutes at room temperature. The solution was mixed 
well via pipette followed by vortex for 10 seconds. Cellular debris was removed by centrifugation 
using a Fisher Scientific accuSpin Micro 17R centrifuge at 6,000 rpm for 10 minutes (4 °C). The 
samples were stored at 4 °C and activity was measured immediately. Activity was measured 
according to a modified fluorimeter assay with excitation at 540 nm, emission at 590 nm, and slit 
width of 0.8 mm. Specifically, to a solution of 888 μL 100 mM Tris-HCl buffer (pH 8.0) and 100 
μL lysate was added 10 μL 100 mM N-ethylmaleimide (1 mM final concentration) and the solution 
was allowed to incubate at room temperature for 1 minute. The reaction was initiated with 2 μL 2 
mM CoxFluor (4 μM final concentration, 1.2% DMSO final) and the kinetics were monitored over 
2 minutes. Rates were measured within the linear region (usually the first 30 seconds after initiating 
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the reaction). A calibration curve was constructed with resorufin in buffer containing 1 mM N-
ethylmaleimide, 10% CelLytic M, and a final DMSO concentration of 1.2%. Total protein 
concentration was measured using the BCA assay (Thermo Fisher Scientific) to calculate COX-
2’s specific activity. 
2.6.20 Confocal fluorescence live-cell imaging of lipopolysaccharide-activated RAW 264.7 
macrophages 
The surface exposed substrate of 4-well chambered cover glasses was coated with R&D 
Systems™ Cultrex Poly-L-Lysine (Fisher Scientific) using the manufacturer’s protocol. Plates 
were seeded with 180,000 cells per well (500 µL of 360,000 cells/mL in DMEM media 
supplemented with 10% FBS) and were allowed to incubate for 38 h at 37 °C with 5% CO2 (70–
80% confluent). The media was removed and replaced with serum-free DMEM media containing 
0.2 mM BSO and either PBS or 1 μg/mL lipopolysaccharide in PBS (500 µL final volume). The 
cells were incubated under these conditions for 17 h at 37 °C with 5% CO2. Next, the media was 
replaced with the same conditions with or without indomethacin (10 μM) for 2 h at 37 °C with 5% 
CO2 (500 µL final volume containing 0.2% DMSO final concentration). Finally, the cells were 
stained under identical conditions supplemented with 10 μM CoxFluor (500 µL final volume 
containing 1.5% DMSO final concentration). After incubation at 37 °C with 5 % CO2 for 4 h, each 
well was imaged using a Zeiss LSM 700 confocal microscope (n = 3 technical replicates; n = 4 
biological replicates). Images were quantified over the entire imaging window, without any 
processing, using ImageJ (v. 1.51, NIH). All publication images were processed using identical 
parameters and false colored (LUT: jet.lut) in ImageJ.111 
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2.6.21 Flow cytometry of lipopolysaccharide-induced COX-2 expression in RAW 264.7 
macrophages  
RAW 264.7 macrophage cells (300,000 cells, 2 mL of 150,000 cells/mL) were seeded into 
6-well plates and incubated for 48 to 72 h under standard conditions for a final confluency of ~60–
80%. The media was removed and replaced with serum-free DMEM (1.98 mL) followed by LPS 
(1 μg/mL final concentration, 20 μL of 100 μg/mL in PBS) at 4 or 19 h before collection. Cellular 
GSH was depleted 2 h prior to collection via treatment with BSO (0.2 mM final concentration, 40 
μL 10 mM solution in 1:1 DMSO: serum-free DMEM, 1% DMSO final concentration). Cells were 
collected by treatment with 0.5 mL 0.25% trypsin-EDTA for less than 5 minutes at 37 ºC and then 
the trypsin was inactivated with 1.0 mL DMEM media containing 10% FBS. The solution was 
partitioned for two samples, which were subsequently collected via centrifugation at 6,000 rpm at 
4 ºC in 1.6 mL Eppendorf tubes. The media was removed, and cells were resuspended in 0.2 mM 
BSO either with or without 10 μM CoxFluor (1 mL, 1.5% DMSO final concentration in serum-
free DMEM) for 90 minutes at 37 ºC with agitation. When performing inhibition studies, the 
aforementioned staining solutions were prepared with 20 μM indomethacin without affecting the 
final concentration of DMSO. After staining, cells were pelleted using the aforementioned 
procedure and were resuspended in PBS. Samples were stored on ice prior to analysis on a BD 
LSR Fortessa Flow Cytometry Analyzer with 561 nm excitation and 582/15 emission bandpass 
filter. Dead cells were excluded from the analysis by staining samples (~300 μL) with propidium 
iodide (1 μL of 1 mg/mL in deionized water) for 5 to 10 minutes at room temperature before 
analysis with 561 nm excitation and 595 nm longpass dichromic mirror and 610/20 emission 
bandpass filter. Data was gated for cells according to side and forward scatter areas, live cells using 
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the forward scatter area versus PE-Texas Red area, and for single cell events using the forward 
scatter width versus side scatter area. Replicate numbers correspond to biological replicates.    
2.6.22 Flow cytometry measurement of COX-2 activity in RAW 264.7 macrophages under 
AneroPack® hypoxic conditions  
RAW 264.7 macrophage cells (300,000 cells, 2 mL of 150,000 cells/mL) were seeded into 
6-well plates and incubated for 48 to 72 h under standard conditions for a final confluency of ~60–
80%. The media was removed and replaced with serum-free DMEM (1.98 mL) followed by LPS 
(1 μg/mL final concentration, 20 μL of 100 μg/mL in PBS) 19 h before collection. Cellular GSH 
was depleted 2 h prior to collection via treatment with BSO (0.2 mM final concentration, 40 μL 
10 mM solution in 1:1 DMSO: serum-free DMEM, 1% DMSO final concentration). Cells were 
collected by treatment with 0.5 mL 0.25% trypsin-EDTA for less than 5 minutes at 37 ºC and then 
the trypsin was inactivated with 1.0 mL DMEM media containing 10% FBS. The solution was 
partitioned for two samples, which were subsequently collected via centrifugation at 6,000 rpm at 
4 ºC in 1.6 mL Eppendorf tubes. The media was removed, and cells were resuspended in 0.2 mM 
BSO with 10 μM CoxFluor (1.0 mL 1.5% DMSO final concentration in degassed serum-free 
DMEM) and incubated for 90 minutes at 37 ºC in a sealed container either with or without an 
AneroPack® (Mitsubishi Gas Company). When performing inhibition studies, the aforementioned 
staining solutions were prepared with 20 μM indomethacin without affecting the final 
concentration of DMSO. After staining, cells were pelleted in 1.6 mL Eppendorf tubes using the 
aforementioned procedure and were resuspended in degassed PBS. Samples were stored on ice 
prior to analysis on a BD LSR Fortessa Flow Cytometry Analyzer with 561 nm excitation and 
582/15 emission bandpass filter. Dead cells were excluded from the analysis by staining samples 
(~300 μL) with propidium iodide (1 μL of 1 mg/mL in deionized water) for 5 to 10 minutes at 
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room temperature before analysis with 561 nm excitation and 595 nm longpass dichromic mirror 
and 610/20 emission bandpass filter. Data was gated for live cells the forward scatter higher versus 
PE-Texas Red area, and for single cell events using the forward scatter width versus side scatter 
area. Replicate numbers correspond to biological replicates.   
2.6.23 Flow cytometry measurement of COX-2 activity in RAW 264.7 macrophages under 
variable oxygen concentrations  
RAW 264.7 macrophage cells (500,000 cells, 2 mL of 250,000 cells/mL) were seeded into 
6-well plates and incubated for 48 h under standard conditions for a final confluency of ~80%. The 
media was removed and replaced with serum-free DMEM (1.98 mL) followed by LPS (1 μg/mL 
final concentration, 20 μL of 100 μg/mL in PBS) 19 h before collection. Cellular GSH was 
depleted 2 h prior to collection via treatment with BSO (0.2 mM final concentration, 40 μL 10 mM 
solution in 1:1 DMSO: serum-free DMEM, 1% DMSO final concentration). Cells were collected 
by treatment with 0.5 mL 0.25% trypsin-EDTA for less than 5 minutes at 37 ºC and then the trypsin 
was inactivated with 1.0 mL DMEM media containing 10% FBS. Three wells were pooled (1.5 
mL × 3) for a final volume of 4.5 mL cell suspension before partitioning into three tubes (one tube 
per oxygen concentration) for centrifugation at 6,000 rpm at 4 ºC in 1.6 mL Eppendorf tubes. The 
media was removed, and cells were resuspended in 0.2 mM BSO with 10 μM CoxFluor (1.5 mL, 
1.5% DMSO final concentration in pre-equilibrated serum-free DMEM; media was equilibrated 
for ~24 h at the desired oxygen concentration followed by ~2 h re-equilibration following the 
addition of BSO; CoxFluor was added immediately before use to prevent any photo-oxidation). 
The resulting cell suspension was incubated for 90 minutes at 37 ºC under ~21, 1.0, or 0.1% oxygen 
with 5% CO2 in an ultra-low cell attachment six well plate (Corning® Costar®) to facilitate rapid 
oxygen exchange. After staining, cells were pelleted using the aforementioned procedure and were 
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resuspended in PBS. Samples were stored on ice prior to analysis on a BD LSR Fortessa Flow 
Cytometry Analyzer with 561 nm excitation and 582/15 emission bandpass filter. Dead cells were 
excluded from the analysis by staining samples (~300 μL) with propidium iodide (1 μL of 1 mg/mL 
in deionized water) for 5 to 10 minutes at room temperature before analysis with 561 nm excitation 
and 595 nm longpass dichromic mirror and 610/20 emission bandpass filter. Data was gated for 
live cells the forward scatter higher versus PE-Texas Red area, and for single cell events using the 
forward scatter width versus side scatter area.  Replicate numbers correspond to biological 
replicates.   
2.6.24 Enzyme-linked immunosorbent assay (ELISA) for mouse COX-2  
Protein concentration was measured directly from the same samples as the Flow Cytometry 
Measurement of COX-2 Activity in RAW 264.7 Macrophages under Variable Oxygen Conditions. 
The ELISA was performed using the SimpleStep ELISA Mouse COX2 ELISA Kit (ab210574, 
Abcam) according to the manufacturer’s protocol. Briefly, cells were washed with cold PBS (1.0 
mL ´ 2) and then lysed in cold 1X Cell Extraction Buffer PTR for 20 minutes at 0 ºC. The debris 
was removed via centrifugation at 18,000 × g for 20 minutes at 4 ºC and the supernatants were 
collected and stored at -80 ºC prior to use. Protein concentration was measured using the BCA 
Assay (Thermo Fisher Scientific) according to the manufacturer’s protocol and the lysate was 
diluted with 1X Cell Extraction Buffer PTR for a final concentration of 25 μg/mL total protein. 
Cell lysate (50 μL) and then Antibody Cocktail (50 μL) were added to each well in duplicate and 
the sealed plate was incubated with vigorous shaking (400 rpm) for 1 h at 22 ºC. After binding, 
each well was washed thoroughly with 1X Wash Buffer PT (350 μL ´ 3). TMB Substrate (100 
μL) was added to each well and allowed to incubate in the dark with vigorous stirring for 10 
minutes at 22 ºC before quenching with Stop Solution (100 μL). The optical density was measured 
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at 450 nm and the protein concentration was interpolated according to a standard curved (prepared 
in duplicate). Protein concentrations are reported for the COX-2 concentration in a 25 μg/mL total 
protein stock. 
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CHAPTER 3: DEVELOPMENT OF PHOTOACOUSTIC PROBES FOR DETECTING 
ENDOGENOUS NITRIC OXIDE IN INFLAMMATION AND CANCER3 
 
3.1 Background and significance 
Small-molecule biomarkers are intriguing targets for biology evaluation and diagnostic 
applications. Nitric oxide (NO) was the founding member of the gasotransmitters (gaseous 
signaling molecules) and it is implicated as a key player in most biological and pathological 
processes. An expansive collection of optical probes has been reported to detect NO. While these 
purely optical approaches facilitated many biological discoveries, they have also illuminated 
inconsistencies between cell- and animal-based studies. These conflicting conclusions are most 
likely due to complex regulatory mechanisms that are only present within the intact system. We 
proposed that photoacoustic (PA) probes could limit these inconsistencies by non-invasively 
detecting NO within live animal models. This work could serve as a template for the rational 
development of activatable PA probes, a platform to optimize NIR dyes for PA imaging, and to 
begin to interrogate NO’s biology in the context of cancer (e.g., source, dynamics, localization, 
etc.).  
3.1.1 Nitric oxide biology 
Reactive oxygen, nitrogen, and sulfur species represent a major class of biological signaling 
molecules.1–3 NO, carbon monoxide, and hydrogen sulfide are a subset of this class that are 
collectively referred to as the gasotransmitters due to their gaseous nature.4 NO was the first 
 
3Portions of this chapter are reprinted or adapted with permissions from the following publications: (1) Reinhardt, C. 
J.; Zhou, E. Y.; Jorgensen, M. D.; Partipilo, G.; Chan, J. A Ratiometric Acoustogenic Probe for In Vivo Imaging of 
Endogenous Nitric Oxide. J. Am. Chem. Soc. 2018, 140, 1011–1018.142 Copyright © 2018 American Chemical 
Society. (2) Reinhardt, C. J.; Xu, R.; Chan, J. Nitric Oxide Imaging in Cancer Enabled by Steric Relaxation of a 
Photoacoustic Probe Platform. Chem. Sci. 2020, 11, 1587–1592.143 Copyright © 2020 Royal Society of Chemistry. 
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gasotransmitters identified and it was characterized for its role in the regulation of vascular tone 
in the 1980s.5–8 Since then, NO has been implicated in a wide range of pharmacologically 
important processes, such as  inflammation,9 neuronal signaling,10–12 and cancer.13–15 Moreover, 
its signaling proceeds through distinct mechanisms.16 A general and underappreciated conclusion 
from these works is that there are intrinsic connections between the concentration, cellular 
environment, and resulting biological effects of NO.1 For example, high concentrations of NO are 
antitumoral, while low concentrations promote angiogenesis and tumor growth.13,14,17–22 Along 
these lines, nitric oxide synthase (NOS) can serve as an early biomarker for a range of cancer types 
(e.g., breast, prostate, lung, colorectal), but its correlation with clinical stages depends on the 
cancer type.23–27 Additionally, NO biology is intrinsically linked to the local oxygen availability, 
where biosynthesis is regulated by molecular oxygen (see section 3.1.2) and NO is chemically 
elaborated to other reactive nitrogen species via reactive oxygen species (including molecular 
oxygen).19,28–30 
 NO can either directly or indirectly exert the aforementioned biological effects. NO can 
directly bind to soluble guanylyl cyclase—at a distal heme—and promote a conformational change 
with a concomitant increase in the catalytic activity. The cyclic GMP then exerts a range of 
biological affects through protein kinases, phosphodiesterases, and ion channels. Alternatively, 
NO can ligate the heme of cytochrome P450s or cytochrome c oxidase, thereby inhibiting the 
protein’s activity and increasing the availability of molecular oxygen within the cell.29 More 
recently, dinitrosyl iron complexes (DNICs) were identified as the most abundant NO sink within 
the cell. The complexation stabilizes the free-radical and tunes the reactivity. DNICs can form with 
different biological thiols (e.g., cysteine, glutathione)18,31,32 and display antioxidative and 
nitrosothiol-generating activities.33,34 On the other hand, NO can indirectly nitrate electron-rich 
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aromatic amino acids (e.g., tyrosine and tryptophan), nitrosate or nitrosylate proteinaceous thiols 
(a potential intermediate prior to disulfide formation), or function in lipid oxidation.29,35 Together, 
these signaling pathways are choreographed by the concentration, reactivity, and interconversion 
of NO with proteinaceous and non-proteinaceous targets.  
3.1.2 Nitric oxide biosynthesis 
NO is biosynthesized by NOS through the oxidation of L-arginine to L-citrulline under 
normoxic conditions (Scheme 3.1). The NOS family includes an inducible, calcium-independent 
isoform (iNOS), which is primarily linked to the immune response, and constitutively expressed, 
calcium-dependent isoforms (nNOS and eNOS), which are linked to homeostatic maintenance.36 
The subcellular localizations are cell-type and isoform specific. Dysregulation of the proteins 
localization can result in pathological effects given NO’s short half-life. The enzyme’s localization 
and activity are well-regulated through co- or post-translational modifications (e.g., acylation, 
phosphorylation) or protein-protein interactions. These modifications enable targeting to the 
cytosol, plasma membrane, cytoskeleton, Golgi, mitochondria, peroxisome, nucleus, caveolae and 
potentially the endo- and sarcoplasmic reticulum.37,38 
 
Scheme 3.1: Nitric oxide is biosynthesized by nitric oxide synthase in a two-step reaction from L-arginine. 
 
Paradoxically, NO is one of the smallest natural products, but it requires a notably large 
(approximately 300 kDa homodimer) and complex enzyme with three substrates (molecular 
oxygen, L-arginine, NADPH) and at least five cofactors/prosthetic groups (FAD, FMN, 
calmodulin, tetrahydrobiopterin, and heme) for its biosynthesis. NOS monomers are composed of 
a fused cytochrome reductase and cytochrome P450 domain.36,39 All three isoforms coordinate the 
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complicated five-electron oxidation of L-arginine with heme reduction coupled through 
choregraphed two-electron and one-electron reduction events. Electrons are shunted through the 
reductase domain from NADPH through the flavodomain (FAD and FMN) and into the heme, 
which is promoted through a calmodulin-mediated conformational change in calcium dependent 
isoforms (Figure 3.1).  
 
Figure 3.1: (a) Schematic of NOS’s structural domains from the N to C terminus, including the L-arginine (Arg), 
heme (H), tetrahydrobiopterin (BH4), and calmodulin binding sites (CaM) in the oxygenase domain and flavin 
mononucleotide (FMN), flavin adenine dinucleotide, and nicotinamide adenine dinucleotide phosphate binding sites 
in the reductase domain. S correspond to cysteine residues that are involved with zinc (grey) binding or ligation of the 
heme. (b) Structure of eNOS (PDB: 2NSE) bound to L-arginine (green) at the heme (red orange), in proximity to the 
tetrahydrobiopterin cofactor. 
 
The initial catalytic cycle yields the N-hydroxylated product (NG-hydroxy-L-arginine, L-
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NHA), presumably through direct oxidation with anionic Compound 0. The subsequent oxidation 
of L-NHA to L-citrulline is initiated by the ferric superoxide radical abstracting the N-H hydrogen 
atom followed by nucleophilic attack of the peroxide at the carbon. Decomposition of the resulting 
tetrahedral intermediate affords the NO and L-citrulline (Scheme 3.1).40–42 The tetrahydrobiopterin 
cofactor appears to be involved, but not required, for dimer formation, and essential for catalysis.  
Specifically, the it is believed to perform both the reduction of the ferrous dioxygen intermediate 
and the oxidation of the ferrous nitroxyl intermediate to afford the product.43,44 NO can also be 
enzymatically by nitrite reductases (e.g., deoxyhemoglobin, deoxymyoglobin, mitochondrial 
reductases) under hypoxic conditions.45–47 These enzymes are likely the source of the “non-
enzymatically” nitric oxide observed in the ischemic heart that causes NO-mediated tissue 
damage.48 
3.1.3 Nitric oxide detection strategies 
Due to its various roles in physiological and pathological processes, the identification, 
detection, and quantification of NO continues to be an active area of research. In vitro and ex vivo 
analyses are limited in their ability to recapitulate the native system. For this reason, it is essential 
to develop new methods for the performing non-invasive, in vivo detection of NO with high 
spatiotemporal resolution. The current arsenal of NO donors49 and ex vivo analyses have provided 
most of the previously described information; however, many outstanding questions remain. 
Current methods for detecting NO are inadequate for in vivo applications. For example, the 
colorimetric Griess assay is useful for analyzing NO in cell lysates; however, this is performed 
indirectly via detection of nitrite and nitrate and requires acidic conditions that are not 
biocompatable.50 NO’s globin-based reactivity can be hijacked to evade the requirement of cell 
lysis; however, the poor permeability of hemoglobin limits its application to measuring NO after 
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it has diffused from live cells.51 In contrast, techniques such as electron paramagnetic resonance 
(EPR) spectroscopy52 and magnetic resonance imaging (MRI)53 have been employed for NO 
detection at relevant imaging depths; however, these approaches are limited by low resolution and 
sensitivity, respectively.54 Indeed, this approach facilitated the discovery of NO that was not 
derived from NOS.48 Electrochemical analyses (e.g., amperometry) display some of the highest 
sensitivity (pM) and are arguably the most quantitative methods; however, this does not translate 
well for imaging with tissue because it requires invasive procedures and can only detect NO in 
direct contact with the probe.55–57 
 
Figure 3.2: Timeline highlighting key examples of optical NO probes. As the field evolved, the tools moved away 
from cell lysates (Griess assay)58 into the extracellular space (methemyoglobin, PDB = 1JYZ),59 and eventually into 
live cells, tissue slices, and animals (DAF, NRNO, and geNOPs).60–62 The structure of geNOPs is adapted with 
permission from ref. 62. Copyright © 2016 Springer Nature. 
 
Optical methods, such as luminescence63 and fluorescence imaging,64 are non-invasive and 
provide high-resolution and high-contrast at shallow imaging depths.54 As a result, a diverse palette 
of reaction-based fluorescent probes has been developed, primarily for cellular studies (Figure 
3.2). In principle, many of the red-shifted and multiphoton congeners can be employed for in vivo 
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imaging, but these studies require invasive surgical procedures,65 are confined to peripheral 
limbs,66 and/or suffer from limited resolution66,67 due to the scattering of emitted light. Several 
other fluorescent NO probes have been applied to living animals; however, these examples 
necessitate specimen sacrifice for ex vivo analysis of the tissue slices.61,68–71 Photoacoustic (PA) 
imaging is a non-invasive imaging modality with the potential to overcome these challenges by 
coupling the precision of optical imaging with the deep tissue capabilities of ultrasound imaging 
(see Chapter 1 for additional information). 
 
3.2 Design and development of APNO-5 
It is essential to satisfy six general design criteria to optimize in vivo performance of small-
molecular activatable PA probes. First, a probe must exhibit maximal absorption in the NIR-I or 
NIR-II72 window to ensure incident light penetrates deep within tissue without significant 
attenuation. Second, it should possess a large extinction coefficient (greater than 104 M-1 cm-1) and 
low quantum yield since absorptivity and non-emissive relaxation are proportional to PA signal 
intensity. Third, it must react with the target in a rapid and highly selective manner. Rapidity and 
selectivity must be considered in terms of the target and detection strategy (i.e., catalytic, 
stoichiometric, or super-stoichiometric). NO is present at low abundance (nM–µM steady-state 
concentration range) and has a short biological lifetime (seconds to minutes depending on 
concentration and oxygenation).73 Fourth, a probe should be optimized for ratiometric imaging, 
which is necessary to account for imaging artifacts (see section 1.4. for additional information).74 
Fifth, the probe must display favorable pharmacokinetic and pharmacodynamic properties, such 
as rapid uptake by the region of interest. Finally, the probe should be biocompatible and produce 
minimal effects on the native biological system.75  
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To this end, we rationally developed and synthesized a panel of Acoustogenic Probe(s) for 
Nitric Oxide (APNO). We began by incorporating the o-phenylenediamine (OPD) functionality60 
onto the aza-BODIPY dye platform to afford APNO-1 (Figure 3.3). This scaffold and trigger were 
selected over the various alternatives because of the platform’s well-documented photo- and chem-
ostability and the overwhelming number of OPD examples.63 We rationalized that strategic 
positioning of the trigger facilitate an NO-mediated perturbation of the push-pull system and a 
concomitant hypsochromic (blue) shift in the wavelength of maximum absorbance (λmax). 
Empirically, a shift greater than 50 nm is desirable for ratiometric imaging such that each form can 
be selectively irradiated to produce a corresponding PA signal.  
 
Figure 3.3: Structures, triggers, and sensing mechanisms for the panel of APNO (red) and tAPNO (blue). R = Me 
(APNO-1, APNO-2, APNO-3, and APNO-4) or tetraalkylammonium polyethylene chain (APNO-5). 
 
Treatment of APNO-1 with NO resulted in a 55 nm blue-shift from 731 nm to 676 nm 
(Figure C.1). When APNO-1 and turned-over APNO-1 (tAPNO-1) were excited at 740 nm and 
680 nm, respectively, a ratiometric turn-on PA response of 7.4-fold was observed (Figure C.2). 
Experimental excitation wavelengths differ from the reported λmax values due to a combination of 
instrumental range (680–950 nm) and experimentally larger PA ratio. Although the observed 
ratiometric response would be sufficient to detect most analyte targets, we deemed it essential to 
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improve this property further due to the low biological abundance of NO. Additionally, the 
preparation of APNO-1 was hampered by decomposition of key synthetic intermediates which 
resulted in low overall yields.  
Next, we turned our attention towards developing probes that rely on NO-mediated 
deamination.76,77 Specifically, APNO-2 features an electron-rich o-aminophenol moiety that 
undergoes NO-mediated diazonium formation and subsequent homolytic bond cleavage to afford 
tAPNO-2 (Figure 3.3). It was rationalized that the removal of the strongly electron-donating 
aniline would have a larger effect on the wavelength than triazole formation. Treatment of APNO-
2 with NO resulted in a 59 nm blue-shift from 735 nm to 676 nm (Figure C.1) and 13.1-fold 
ratiometric turn-on response when irradiated at 750 nm and 680 nm (Figure C.2). While this 
improvement in the dynamic range may have been sufficient, it was limited by the requirement of 
super-stoichiometric quantities of N2O3 and slow reaction kinetics. Specifically, the reaction 
proceeds via an N-nitroso intermediate (which was detected via fluorescence) followed by slow 
reaction with an additional equivalent of N2O3, diazonium formation, and decomposition to yield 
the product.76 These properties significantly reduce the sensitivity of APNO-2 and complicate the 
PA imaging results. Of note, we also prepared APNO-3, a constitutional isomer; however, it 
suffered from pH dependence near neutral pH (Figure C.3). 
In light of the rapid N-nitroso formation, we reasoned that mono-alkylation of the reactive 
aniline could enhance the reactivity, as well as block the necessary rearrangements for diazonium 
formation and deamination. This led to the development of APNO-4 which features an N-
methylaniline nucleophile trigger (Figure 3.3). The hydroxyl group was replaced with a methoxy 
substituent for synthetic ease and to prevent possible pH dependence. While there are examples of 
photoinduced electron transfer (PET)-based fluorogenic probes relying on NO-responsive 
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secondary anilines in the literature;70,71,78 APNO-4 represents the first probe (for any imaging 
modality) that employs N-nitrosation for modulation of a push-pull system and ratiometric 
imaging, to the best of our knowledge. We observed rapid formation of the anticipated N-nitrosated 
product (tAPNO-4) and a significant 86 nm blue-shift of the λmax from 764 nm to 678 nm upon 
treatment with NO (Figure C.1); however, tAPNO-4 was poorly soluble in aqueous solutions. This 
resulted in inconsistent results due to aggregation and precipitation. To overcome this limitation, 
we developed APNO-5, a positively charged analog featuring a PEGylated tetraalkylammonium 
group to improve solubility, prevent dye aggregation, and facilitate uptake in vivo. 
Table 3.1: Photophysical characterization of APNO and tAPNO in ethanolic 20 mM potassium phosphate buffer (pH 
7.4, 50% v/v). a Measured relative to dimethoxy aza-BODIPY (Φ = 0.32, CHCl3). b Not determined: tAPNO-3 displays 
pH dependence under these conditions. c Not determined: tAPNO-4 precipitated out of solution. Data is reported as 
the average of experimental replicates (n = 3) with less than 15% error. 
 
 
 
Each APNO was synthesized by coupling two 4-nitro-1,3-diphenylbutan-1-one analogs 
under Paal-Knorr cyclization conditions, followed by boron chelation to afford the aza-BODIPY 
dye platform.79 Synthetic procedures for each compound, including authentic tAPNO-5, can be 
found in Appendix C.  
As anticipated, APNO-5 reacted rapidly with NO to afford the N-nitrosated product 
(tAPNO-5) with a significant 91 nm blue-shift of the λmax from 764 nm to 673 nm. This was the 
largest wavelength shift observed in the APNO series (Figure 3.4). The extinction coefficient of 
APNO-5 was sufficiently large (3.2 х 104 M-1 cm-1) to ensure the generation of strong PA signals 
in vivo (Table 3.1). Selective irradiation of APNO-5 and tAPNO-5 at 770 nm and 680 nm, 
APNO λmax  (nm) 
ε 
(M-1cm-1) Φ tAPNO λmax (nm) ε (M-1cm-1) Φ 
1 731 3.30 × 104 0.0065 1 676 3.71 × 104 0.14 
2 735 7.40 × 104 0.0006 2 676 6.93 × 104 0.12 
3 679 2.20 × 104 0.0708 3 678 2.28 × 104 0.09 
4 764 3.70 × 104 0.0003 4 678 n.d. n.d. 
5 764 3.20 × 104  0.0003 5 673 3.30 × 104 0.23 
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respectively, resulted in an 18.6-fold ratiometric PA turn-on response in tissue-mimicking 
phantoms (Figure 3.4). Additionally, the improved aqueous solubility due to appendage of the 
tetraalkylammonium PEG group enhanced its properties for ratiometric PA imaging. 
  
Figure 3.4: (a) Normalized absorbance spectra of 2 μM APNO-5 (red) and tAPNO-5 (blue). (b) APNO-5 (2 μM) 
fluorescence enhancement following 1 h treatment with excess (100 equiv) reactive metal (red), carbonyl (green), 
oxygen (blue), or nitrogen (purple) species (c) PA spectra of 10 μM APNO-5 (red) and tAPNO-5 (blue). (d) PA images 
of 10 μM APNO-5 and tAPNO-5 at 680 and 770 nm. All spectra and assays were performed in ethanolic 20 mM 
potassium phosphate buffer (pH 7.4, 50% v/v).  Data presented as mean ± standard deviation (n = 3) for (b-c). 
 
Insoluble aza-BODIPY dyes are known to form J-aggregates and nanoparticles, where the 
λmax is red-shifted relative to the non-aggregated form.80 Because our strategy relies on selective 
excitation using specific wavelengths, it is essential to minimize the formation of wavelength-
shifted aggregates. To verify this, we monitored the degree of aggregation as a function of 
surfactant concentration at a fixed dye concentration. At 2 μM, aggregation was attenuated at 
concentrations as low as 0.1% surfactant for APNO-5, whereas APNO-4 required ≥ 10% (Figure 
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C.4). Moreover, the tetraalkylammonium PEG appendage increased the water solubility of APNO-
5 and tAPNO-5, as indicated by clogP values of 3.8 and 3.8, relative to 7.6 and 7.3 for APNO-4 
and tAPNO-4 (Table C.2). Since the calculation methods are unable to account for charge, APNO-
5 and tAPNO-5’s predicted values should serve as over-approximations of the true values.81 This 
structural feature was also required for APNO-5 to permeate deep into tissue after subcutaneous 
administration into live mice. Other congeners pooled at the injection site and showed minimal 
response owing to poor tissue uptake (data not shown). 
Next, we determined that the fluorescence quantum yields of APNO-5 and tAPNO-5 were 
sufficiently low (Table 3.1). This is ideal for PA imaging since the quantum yield is inversely 
proportional to the intensity of the PA signal. Nevertheless, we conducted selectivity assays using 
fluorimetry due its sensitivity and dynamic range. Treatment of APNO-5 with excess NO (100 
equiv) resulted in a significant 174.4-fold fluorescence enhancement, whereas other reactive 
nitrogen species (RNS) (e.g., nitroxyl and peroxynitrite) did not elicit an appreciable response 
(Figure 3.4b). This is important because NO can rapidly convert into other RNS under biological 
conditions (besides N2O3, the hypothesized nitrosating species).70 Importantly, most reported NO 
triggers react with N2O3 rather than directly with NO. While this decreases sensitivity, it is 
suggested to prevent perturbation of NO signal transduction.60 When APNO-5 was treated with a 
panel of oxidants, no oxidation of the aza-BODIPY core nor the N-methylaniline trigger was 
observed. Finally, the reactivity of APNO-5 was assessed against a series of key biological 
carbonyl species including formaldehyde (FA), ascorbic acid (AA), dehydroascorbic acid (DHA), 
and glyoxal to test for side-reactivity and false turn-on via Schiff base formation (Figure 3.4b). 
Even with large stoichiometric excesses of each carbonyl no cross-reactivity was observed. Note 
that similar selectivity was observed for the other members of the series (Figure C.5). 
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We then determined the chemo- and photo-stability of APNO-5 in the interest of supporting 
in vivo imaging over extended periods (hours to days). First, the absorption spectra of a solution 
of APNO-5 was monitored over the course of five days. During this time, no significant 
decomposition of the probe was observed. Next, we subjected a solution of APNO-5 to continuous 
irradiation with an OPO laser at 770 nm for 60 min. Under these conditions, minimal 
photobleaching was observed (Figure C.6). Interestingly, it was discovered that tAPNO-5 
undergoes photo-induced denitrosylation when continuously irradiated; however, only moderate 
signal loss is observed (< 30%) under standard imaging conditions (confirmed by UV-Vis; Figure 
D.1). Moreover, since APNO-5 is released as the product during prolonged irradiation, it is 
reasonable to predict minimal decrease in sensitivity. This would later serve as the blueprint for 
the development of an NIR light induced NO donor with an integrated PA monitoring, in which 
the nucleophilicity of the methylaniline was limited to prevent NO back-capture (additional 
information regarding light-induced denitrosylation and methods for performing EPR NO trapping 
studies can be found in Appendix D).82  
After confirming the requisite selectivity, solubility, and stability, the probe’s 
biocompatibility and subcellular localization were assessed. First, RAW 264.7 macrophages were 
incubated with APNO-5 (1 and 5 μM) for 3, 6, and 24 h. Biocompatibility was assessed in terms 
of membrane integrity (trypan blue assay) and cell metabolism (MTT assay). Both assays indicated 
that APNO-5 was minimally cytotoxic at a concentration of 5 μM, with greater than 79% viability 
observed after 24 hours (Figure C.7). Next the localization was determined via colocalization 
studies with organelle-specific dyes (LysoTracker GreenTM, MitoTracker® Green, and ER-
Tracker® Green) within RAW 264.7 macrophages. Based on the overlap between APNO-5 and 
each of the trackers, it was clear that APNO-5 broadly localizes throughout the cell (except the 
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nucleus) with slight preference for the lysosome and mitochondria (Figure C.8). 
 
3.3 Detection of nitric oxide in a murine subcutaneous inflammation model  
As mentioned previously, the non-invasive detection of NO in vivo remains a significant 
challenge despite the general availability of NO-specific fluorescent probes. To evaluate the utility 
of APNO-5 for the detection of NO in live animals, we turned our attention to an LPS-induced 
murine inflammation model. This system was selected because mice show similar inflammatory 
responses to LPS as humans, making it a useful model for inflammation.83  
 
Figure 3.5: Representative PA images of APNO-5 responding to endogenous NO within a murine LPS-induced 
inflammation model. Images of APNO-5 (68 μg/kg) in a mouse flank following subcutaneous LPS or saline treatment. 
APNO-5 and tAPNO-5 were selectively imaged at 770 (red) and 680 (blue) nm, respectively. Scale bar represents 2 
mm. 
 
Mice were treated with either LPS or a saline vehicle control via subcutaneous injection 
into their flank. Following background scans, the dye was administered in the same location as the 
treatment. APNO-5 and tAPNO-5 were irradiated at 770 nm and 680 nm, respectively, and the 
change in ratiometric signal was monitored over time. Following administration, we observed 
significant pooling of the probe at the injection site. The initial broad absorbance band of APNO-
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5 in the injection solution resulted in a ratio of ~1.07 at 1 h. Diffusion of the PA signal shortly 
thereafter (2 h) indicated uptake into the surrounding tissue. At this time, we observed conversion 
of APNO-5 to afford tAPNO-5 in LPS-treated animals as determined by an increase in the 
ratiometric PA signal to ~1.2, which remained constant for the remainder of the experiment. In 
contrast, the PA ratio for the saline-treated mice was ~0.9 and did not change throughout the 
experiment (Figure 3.5). The initial decrease in PA ratio for the control animal can be attributed 
to sharpening of APNO-5’s absorbance profile following uptake and solubilization within the 
tissue. This was confirmed by monitoring the absorbance profile in the absence and presence of 
rat liver microsomes, a source of membrane lipids and proteins for association, and the PA 
spectrum of APNO-5 in a mouse as a function of time (Figure C.9). Taken together, this represents 
a 1.89-fold signal enhancement at 680 nm and 1.31-fold ratiometric response and after 5 h (Figure 
3.6).  
 
Figure 3.6: (a) Single wavelength (PAI680) and (b) ratiometric imaging (PAI680/PAI770) of endogenously produced NO 
within an LPS-induced murine inflammation model over 5 hours. Data presented as mean ± standard deviation (n = 
8). Statistical analysis between LPS and saline treated mice was performed using two-way ANOVA (α = 0.05). LPS 
and saline ratiometric signals were compared at each time point using Sidak’s multiple comparison test (α = 0.05). *, 
p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. 
 
To confirm that the signal was a result of APNO-5 nitrosation and not LPS-induced changes 
in endogenous chromophores (e.g., oxyhemoglobin, deoxyhemoglobin), PA spectra were acquired 
following LPS or saline treatment both in the presence and absence of dye. As expected, LPS 
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induces a small increase in ratiometric signal in the absence of dye; however, it does not account 
for the total signal enhancement (Figure C.10). This data, together with our in vitro results, 
provides compelling evidence that APNO-5 is capable of detecting endogenously generated NO 
in vivo. 
 
3.4 Reflection on APNO-5’s performance and areas for improvement 
PA imaging is an emerging imaging technology that has the potential to perform non-
invasive molecular imaging in deep tissue. In this work, we rationally developed a series of NO-
responsive probes for PA imaging. Since we installed most common aerobic NO triggers on a 
single dye platform, it was possible to systematically compare OPD-, deamination-, and N-
nitrosation-based sensing mechanisms (all products confirmed via LC-MS, Figure C.11–C.14). It 
is clear that the OPD-based trigger is a reasonable approach if triazole formation can be coupled 
to a robust readout. This is in contrast to some reports implicating cross-reactivity with ascorbic 
acid and dehydroascorbic acid.84 This suggests that the side reaction is probe dependent, as we did 
not observe any response to these two carbonyl species, nor with glyoxal. While our work 
demonstrates that NO-mediated deamination can be expanded, it is limited by the requirement of 
super-stoichiometric amounts of NO and may proceed through meta-stable intermediates that 
would complicate interpretation. We found the N-nitrosation trigger to be the best of the three 
triggers examined. When the N-alkyl amine is sufficiently nucleophilic, the reaction with NO is 
rapid and gives rise to a single product with predictable chemostablity.49 We also performed 
mechanistic studies regarding the sensing mechanism on the TokyoGreen85 dye platform (see 
Appendix C for synthetic information), in which our results confirm that both deamination and N-
nitrosation sensing mechanisms are oxygen-dependent and do not proceed with cysteine or 
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glutathione DNICs (Figure C.15). After exposing the probe-DNIC solutions to air, we only 
observed fluorescence enhancement in cysteine DNIC conditions. This suggests that these DNICs 
may be less stable, releasing NO over the course of the experiment, and that NO biology may have 
significant crosstalk with iron metabolism and redox signaling. Prior to this work, it was unclear 
whether the DNICs could serve as NO source. 
It is important to note that while APNO-5 was able to detect NO concentrations relevant to 
the immune response (high nM–μΜ steady-state concentration, millimolar range over the course 
of the experiment), it was ineffective for NO detection in cancer (103-fold lower concentrations). 
For this reason, it is essential to enhance the sensitivity of the probe platform for imaging within 
deeper tissue and at lower NO concentrations.21 Two areas for improvement were to decrease the 
propensity to undergo photo-denitrosylation and access more efficient irradiation of the N-
nitrosated product. 
It is important to note that only a handful of approaches have been successfully employed 
for increasing the sensitivity and ratiometric properties of small-molecule PA probes. Specifically, 
increasing the electron density within the aza-BODIPY86 and conformational restriction of the 
pendant phenyl rings87 have led to improved designs for ratiometric, activatable PA probes 
compared to non-ratiometric88 or poorly ratiometric probes.89 While successful in the selected 
example, increasing electron density may not be trivial, depending on the application. On the other 
hand, conformational restriction yields reliable red-shifts (approximately 30 nm per fusion) but 
increases the molecular weight (26 Da per fusion) and cLogP of the dye platform (increase from 
the parent aza-BODIPY cLogP = 7.8 to conformationally restricted aza-BODIPY cLogP = 8.2–
8.6).  Together, these properties decrease the probability of passive uptake into the cell and increase 
propensity for aggregate formation and peak broadening. 
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Figure 3.7: Examples of previous and current approaches for the optimization of aza-BODIPY PA probes. Yellow 
circles denote past locations of optimization, while red pentagons indicate the location for steric relaxation. SR-APNO-
3, the lead compound, undergoes oxidative N-nitrosation and a wavelength shift for ratiometric PA imaging. 
Representative images of SR-APNO-3 and t-SR-APNO-3 (10 μM) at λblue (690 nm) and λred (790 nm) in a tissue-
mimicking phantom. R = CH2-C2H3N3-PEG3-N(CH3)4I. 
 
We decided to investigate the photophysical effects of planarizing the pendant aromatic 
rings on the aza-BODIPY core by relaxing steric clash. We generally refer to this approach as 
“steric relaxation for planarization” with the corresponding PA platform being named SR-aza-
BODIPY for sterically relaxed aza-BODIPY (Figure 3.7). Specifically, we proposed to replace the 
phenyls with thiophenes because the average diameter is ~75% the size. Similar thiophene-
modified aza-BODIPYs have been previously prepared and analyzed using X-ray crystallography 
and UV-Vis spectroscopy.90–93 These studies confirmed a substantial planarization of the dye 
backbone and red shifting. However, their applicability to activity-based sensors and PA imaging 
remain unexplored. Moreover, we hypothesized that incorporation of sulfur atoms would induce 
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the heavy-atom effect, causing a reduction in fluorescence quantum yield and increase in PA 
signal. Herein, we report the optimization of APNO-5 via the systematic replacement of the 1- and 
7- position phenyl rings with thiophenes and the application of the optimized compound for 
imaging cancer-derived NO in live animal models.    
 
3.5 Computational investigations into the feasibility of “steric relaxation for planarization” 
To investigate the feasibility of this approach, we utilized density functional theory (DFT) 
and time-dependent DFT (TD-DFT) to study the effect of thiophene substitution on the dihedral 
angle and predicted absorption of the dyes (calculated in implicit methanol solvent). The method 
was validated by comparing the dihedral angle between the planes of the aromatic rings and the 
aza-BODIPY core to previous experimental data in which the computational and experimental 
data were in good agreement (~28° and ~18°, respectively, Figure C.16a–d).90,91 
 
Figure 3.8: Computational investigation of the effect of thiophene replacement on the structural and absorptive 
properties of the SR-APNO series. Locations of the thiophenes and phenyls are indicated in parentheses (left indicates 
the same side of the molecule as the o-methoxy-methylaniline trigger, right indicates the anisole-containing side of 
the molecule). The solubilizing PEG chain was truncated to a methyl for computational analyses. 
 
Replacement of the phenyls with thiophenes resulted in a decreased dihedral angle with a 
corresponding ~25 nm red shift per thiophene. Importantly, we observed an inverse linear 
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relationship between the calculated dihedral angle and experimental absorption maximum, 
suggesting the dihedral angle is predictive (R2 = 0.60, Figure C.16e). 
With the validated computational workflow, the probes and N-nitrosated products were built 
in silico with the polyethylene solubilizing group truncated to a methyl for computational analyses. 
The geometries were optimized, and the wavelength of maximal absorbance was calculated for 
each compound. In all cases, we observed a near complete decrease (8°, 80% of the disubstituted 
analog’s effect) in dihedral angle after replacing a single phenyl and a 14 nm red shift per thiophene 
(Figure 3.8). Additionally, inverse correlations were observed between the dihedral angle and 
wavelength of maximal absorbance for both the initial probe (R2 = 0.64) and the N-nitrosated 
product (R2 = 0.59). These trends were consistent with the results from gas phase optimized 
geometries with the universal force field (R2 = 0.60, 0.90) and B3LYP hybrid functional (R2 = 
0.69, 0.90), suggesting that these should be sufficient for predicting the effect of steric interactions 
on the aza-BODIPY’s wavelength (Figure C.16e). 
 
3.6 Development and characterization of SR-APNO 
Encouraged by the computational results, we prepared both singly substituted constitutional 
isomers, SR-APNO-1 and SR-APNO-2, and the disubstituted analogue, SR-APNO-3, using 
similar chemistry to APNO-5 (see Appendix C for detailed synthetic information).  
Table 3.2: Photophysical properties of APNO-5 and the SR-APNO series. λmax and ε are reported in methanol and Φ 
is reported in ethanolic 20 mM potassium phosphate buffer (pH 7.4, 50% v/v). Data is reported as the average of 
experimental replicates (n = 3) with less than 15% error. 
 
SR-
APNO 
λmax  
(nm) 
ε 
(M-1cm-1) Φ t-SR-APNO λmax  (nm) ε (M-1cm-1) Φ 
1 775 3.38 × 104 0.004 1 685 2.25 × 104 0.26 
2 770 3.18 × 104 0.015 2 688 1.56 × 104 0.17 
3 790 7.24 × 104 0.002 3 704 5.31 × 104 0.10 
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Photophysical characterization indicated that all probes and N-nitrosated products displayed 
maximal absorbance at greater than 680 nm, maintained high extinction coefficients and low 
quantum yields, and exhibited pH-independent absorbance and fluorescence properties (Table 3.2, 
Figure 3.9, C.17, and C.18). The NO-mediated nitrosation was confirmed using high resolution 
mass spectrometry, in which clean conversion was observed by liquid chromatography mass 
spectrometry for each compound (Figure C.19–C.21). As anticipated, each probe underwent rapid 
oxidation to afford the blue-shifted product. Incorporation of two sulfurs into the chromophore 
resulted in a decrease in N-nitrosated product’s fluorescence quantum yield, presumably due to the 
heavy atom effect, and the planarization resulted in an increase in molar absorptivity due to more 
efficient orbital overlap. Striking similarities between the two constitutional isomers confirmed 
that the planarization is not dependent on the location relative to the trigger (consistent with our 
computational predictions, Table 3.2 and Figure C.17–C.18). This is in contrast to the 
conformational restriction approach in which the location of restriction effects both the 
photophysical and PA properties.87 The SR-APNO series, along with previous reports,90–93  
indicate that planarization via steric relaxation is similarly efficient for red-shifting the absorbance 
(15 versus 0–30 nm following one modification; 30–67 nm versus 0–52 nm following two 
modifications).87,94,95 
To evaluate the effect on the PA properties, the maximal ratiometric responses were 
measured for each compound following N-nitrosation (Figure 3.9 and C.17). Interestingly, neither 
SR-APNO-1 nor SR-APNO-2 resulted in any increase in sensitivity. On the other hand, SR-
APNO-3 was 4.4-fold more sensitive than the parent molecule with a 44-fold maximal ratiometric 
PA turn-on response. It is important to note that the increased sensitivity arises from more efficient 
detection of the N-nitrosated product rather than changes in the initial probe (Figure 3.9b). 
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Figure 3.9: (a) Quantified PA ratios (λblue/λred) for each probe (red) and the corresponding N-nitrosated products (blue). 
(b) Theoretical maximal ratiometric PA responses for APNO-5, SR-APNO-1, SR-APNO-2, and SR-APNO-3 before 
and after nitrosation (25 μM dye, 500 equiv NO derived from MAHMA-NONOate). (c) UV-Vis (2 μM) and (d) PA 
spectra (10 μM) of SR-APNO-3 (red) and t-SR-APNO-3 (blue). All experiments were performed at room temperature 
in ethanolic 20 mM potassium phosphate buffer (pH 7.4, 50% v/v, final DMSO concentration is < 1.25% v/v).  Data 
is reported as the mean ± standard deviation (n = 3). λblue/λred (nm): APNO-5, 680/770; SR-APNO-1, 680/780; SR-
APNO-2, 680/780; SR-APNO-3, 690/790. 
 
With the ideal probe in hand, SR-APNO-3’s applicability for NO imaging was evaluated. 
First, SR-APNO-3 and t-SR-APNO-3 were compared using UV-Vis spectroscopy and PA 
tomography, where maximal PA ratiometric responses were observed at 690 and 790 nm (Figure 
3.9c–d). Changing the percent ethanol content of the buffer resulted in different ratiometric 
responses to NO; however, N-nitrosated product was observed at all tested concentrations (0–80% 
ethanol, Figure C.22a–b). The spectral changes were consistent with the formation of J-aggregates 
under aqueous conditions, which has been observed previously with the aza-BODIPY dye platform 
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and APNO-5.80 Comparison between reactions performed in the presence and absence of ethanol 
suggest that the differences in ratiometric response occur due to differences in reaction depending 
on aggregation state and lower sensitivity due to beak broadening (Figure C.22c–d). Next, the 
selectivity of SR-APNO-3 was confirmed against a panel of reactive metals, carbonyl, oxygen, 
sulfur, and nitrogen species. The panel of potential cross-reactive biomolecules was selected due 
to the possibility of binding to the thiophenes or oxidation of the trigger, which could lead to false 
positives. Importantly, no changes were observed via fluorescence or UV-Vis (Figure C.23). 
Finally, the photostability of SR-APNO-3 and the corresponding N-nitrosated product were 
measured using an OPO laser for irradiation. All of the SR-aza-BODIPYs were photostable 
(greater than intensity 90% remaining after 60 s) and the N-nitrosated products showed reasonable 
stability towards denitrosylation (greater than 50% over 30 s, typical imaging is ~10 s per 
wavelength, Figure C.24). t-SR-APNO-3 proved to be the most photostable product. This finding 
is consistent with the proposed denitrosylation mechanism which includes photoinduced electron 
transfer from the chromophore into the N-NO bond, followed by NO release.96,97 More broadly, 
this suggests that tuning intersystem crossing rates can be used to optimize both N-nitrosation-
based NO probes and photo-activatable NO donors.82 
The biocompatibility of SR-APNO-3 was assessed in RAW 264.7 macrophages and 4T1 
murine breast carcinoma cells, where good viability was observed (Figure C.25). The cellular 
performance was then investigated in 4T1 cells to confirm uptake and sufficient reactivity for 
intracellular detection. Cells were stained with SR-APNO-3, washed to remove excess probe, and 
then incubated with DEA-NONOate. The cells were collected, and the cell pellet was imaged using 
PA tomography. Quantification revealed a dose-dependent ratiometric response (Figure C.26).  
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3.7 Detection of nitric oxide in a murine intramuscular inflammation model 
Next, SR-APNO-3 was applied for imaging LPS-induced inflammation in BALB/c mice. 
To more accurately simulate the deeper tissue involved in cancer imaging, inflammation was 
induced through intramuscular administration of LPS rather than the subcutaneous model reported 
in our initial report. Under these conditions, APNO-5 was no longer able to detect NO. On the 
other hand, a statistically significant increase was observed using SR-APNO-3 after 3 h (Figure 
3.10 and C.27). These results are consistent with the in vitro characterization, where SR-APNO-3 
was shown to be more sensitive than APNO-5. Mice were then co-administered SR-APNO-3 and 
L- NG-monomethyl-arginine (L-NMMA), a pan-selective nitric oxide synthase inhibitor,98 to 
confirm that the signal enhancement was a result of NO. Under these conditions, we observed a 
12% reduction in the ratiometric response (Figure 3.10b and C.27). This suggests that SR-APNO-
3 could serve as a tool for evaluating anti-inflammatory small molecules within live mouse models. 
 
Figure 3.10: (a) APNO-5 (50 μM, 25 μL) and (b) SR-APNO-3 (50 μM, 25 μL) PA imaging of NO in an intramuscular 
LPS-induced inflammation model. Statistical analysis was performed using (a) an unpaired t test (α = 0.05) or (b) 
Dunnet’s multiple comparisons (α = 0.05). *, p < 0.05. Data is reported as the mean ± standard deviation (APNO-5, n 
= 5; SR-APNO-3: saline, n = 7; LPS, n = 8; L-NMMA, n = 4).  
 
3.8 Detection of nitric oxide in a heterotopic breast cancer model 
As previously mentioned, NO plays a key role in cancer biology, where high concentrations 
are initially biosynthesized by macrophages to elicit anti-tumoral effects. After this brief window 
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of inflammation, emerging evidence suggests that the tumor microenvironment decreases 
macrophage motility, thereby trapping the macrophages within the tumor. These immune cells, 
often referred to as tumor-associated macrophages, produce lower levels of NO which promote 
tumor progression, angiogenesis and premetastatic potential.99  
 
Figure 3.11: SR-APNO-3 PA imaging of cancer-derived NO. (a-c) Representative image overlays corresponding to 
the N-nitrosated product (690 nm, blue) and SR-APNO-3 (790 nm, red) after 6 h subcutaneous or intratumoral 
administration (25 μL, 50 μM, 15% DMF in saline v/v). (d) Quantified relative ratiometric PA at 3 and 6 h. Statistical 
analysis was performed using 2-way ANOVA (α = 0.05) between the flank, tumor, and L-NMMA inhibited tumor. 
Relative ratiometric signals were compared to the tumor at each time point using Sidak’s multiple comparison test (α 
= 0.05). *, p < 0.05; **, p < 0.01. Data is reported as the mean ± standard deviation (flank, n = 11; tumor, n = 18; L-
NMMA, n = 9). Scale bar represents 2.0 mm. 
 
After local administration of SR-APNO-3 we observed a clear difference in the ratiometric 
PA response between the flank and tumor indicating that the probe was N-nitrosated. After 6 h, a 
1.22-fold increase in the relative ratiometric PA response was observed between the flank and 
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tumor. To confirm these results, we deemed it necessary to inhibit NO biosynthesis within the 
tumor, where co-administration of L-NMMA and SR-APNO-3 resulted in an 81% decrease in the 
relative ratiometric PA response (Figure 3.11 and C.28). This represents the first example of where 
the PA imaging of cancer-derived NO has been validated using a NOS inhibitor.  To confirm that 
the signal change was not due to changes in any endogenous absorbers (e.g., hemoglobin or 
deoxyhemoglobin), we performed an intratumoral injection of L-NMMA without SR-APNO-3. 
Under these conditions, we observed no change in the relative ratiometric PA response (Figure 
C.29). Together, these imaging studies demonstrate that SR-APNO-3 can be applied to facilitate 
deep tissue imaging of cancer NO, where concentrations are approximately three orders of 
magnitude less than those found in acute inflammation. 
 
3.9 Reflection on SR-APNO-3’s performance and areas for improvement  
This represented the first systematic optimization of the aza-BODIPY dye platform that 
interrogates the effect of relieving steric interactions for dye planarization and PA signal 
optimization. A computational model was validated for predicting the effect of steric relaxation on 
the dihedral angle, which was confirmed experimentally. Replacement of a phenyl with a 
thiophene resulted in a circa 15 nm shift in the absorbance maxima, regardless of where the 
replacement was in comparison to the trigger. This contrasts with the conformational restriction 
approach, in which the location was essential for obtaining desirable PA properties. Replacing 
both aromatic rings with thiophenes had an additive effect and yielded the optimal compound, SR-
APNO-3, which was 4.4-fold more sensitive than the parent molecule, APNO-5.  SR-APNO-3’s 
increased sensitivity allowed for higher ratiometric responses in an intramuscular inflammation 
model and the first successful detection of cancer-derived NO with a small-molecule PA contrast 
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agent. This small molecule approach for PA probe optimization is in contrast to recent 
nanoparticle-based examples which focus on for enhancing the sensitivity of NO-responsive PA 
by co-administering inert or analyte-selective probes for internal calibration or added 
sensitivity.100,101  
Although SR-APNO-3 extended the accessible concentrations of detectable NO to 
nanomolar steady-state concentrations, this work also highlighted two necessary areas for 
improvement. The first problem is the unpredictable biodistribution of aza-BODIPY dyes, in 
which the properties depend significantly on the installed trigger. For example, Hyp-1 and 
photoNOD-1 can be administered systemically, but rHyp-1, photoNOD-2, APNO-5, and SR-
APNO-3 require local administration.82,86,88,102 This is of particular importance because the 
majority of the aforementioned dyes differ by a single functional group (e.g., methoxy versus 
diethyl aniline). The second problem is the lack of sensitivity that has been achieved in small 
animal models. Even with significant improvements obtained in vitro (greater than three-fold 
increase in the maximal ratiometric PA response), the live animal performance of the small 
molecule activatable PA probes remain low (approximately 1.2-fold).87 This facilitated the 
detection of catalytic and super-stoichiometric stimuli; however, the limited dynamic range limits 
(semi)-quantitation and increases the required sample sizes for statistical analysis. We proposed 
that selecting a dye platform with superior pharmacokinetics and fluorescence capabilities could 
overcome these shortcomings. This prompted our investigation into the cyanine dye platform. 
 
3.10 Development of a multimodal nitric oxide probe for fluorescence and photoacoustic 
imaging 
 Our initial investigations had elected to use the aza-BODIPY due to its superior photo- and 
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chemo-stability; however, we have discovered that probes built on this scaffold have unpredictable 
pharmacokinetics. Of the current dye families that possess desirable PA properties, (semi)-
cyanines, aza-BODIPYs, squarines, and porphyrinoids,75 the cyanine platform stands out because 
of their widespread success in optical imaging,103,104 favorable biodistribution profiles,105,106 and 
successful translation into the clinic (e.g., indocyanine green).  
Cyanine dyes are classically defined as two nitrogen containing heterocycles that are linked 
(conjugated) through an odd number of carbons and where one of the nitrogen is positively 
charged.107 Several targeted and activatable cyanine PA probes have emerged over the past ten 
years for imaging metals, reactive oxygen species, and enzyme targets.108–112 The major limitation 
of this dye platform is its poor stability. The best-known decomposition occurs due to their 
propensity to undergo rapid photobleaching via type II photosensitization. Upon photoexcitation, 
the cyanines are poised for intersystem crossing to the lowest triplet state. Molecular oxygen then 
serves as excellent quencher (109 L mol-1 s-1) via triplet-triplet energy transfer and this generates 
the ground state dye, as well as singlet oxygen. The proximity of this electrophilic oxygen 
promotes oxidation at the most nucleophilic site of the cyanine (typically the enamine), dioxetane 
formation, and cleavage to yield two carbonyl fragments.113,114 Alternatively, electron rich 
cyanines are prone to oxidation by reactive oxygen species115 or photobleaching through type I 
photosensitization mechanisms, where photo-induced electron transfer to molecular oxygen yields 
the superoxide radical for oxidation at the most electrophilic site.116 
We began by attempting to translate our work on the aza-BODIPY platform as a framework 
for the cyanine probe. We had previous screened the most common NO sensing mechanisms when 
preparing the APNO series and determined that the N-nitrosation was optimal, both in terms of 
kinetics and the wavelength shift (which is correlated to the maximum ratiometric PA response).  
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The first example of an NO cyanine probe based was published in 2005 and employed an 
“off-on” fluorescence response following triazole formation.68 Since then, an N-nitrosation-based 
optical sensor was reported on the Cy7 dye, in which N-nitrosation occurs at a meso methylamine 
to elicit a wavelength shift. This probe facilitated the detection of endogenous NO in live mice 
with NIR I fluorescence imaging; however, the optical properties are not compatible with the 
excitation range of lasers in commercially available tomographers (minimal absorbance at and 
above 680 nm).117 We hypothesized that we could address this, and potential mitigate cross-
reactivity with reactive oxygen species or cytochrome P450-dervied cytotoxic products, by 
trapping the N-nitroso on a less nucleophilic and sterically accessible aniline. To test this 
hypothesis, we design and synthesized the cyanine-based NO probe, CyAPNO, in three steps from 
4-nitrophenol. First, 4-nitrophenol was alkylated with propargyl bromide and then reduced with 
stannous chloride to afford the aniline. The test compound, CyAPNO, was then obtained in 16% 
yield by alkylating the intermediate with the meso-chlorinated dye, Cyanine-Cl (Scheme 3.2). 
 
Scheme 3.2: Generalized synthesis for the CyAPNO in three steps from 4-nitrophenol with a 12% overall yield. 
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Figure 3.12: (a) Normalized absorbance spectra of CyAPNO (blue) and tCyAPNO (red). (b) CyAPNO (5 μM) 
fluorescence enhancement following 1 h treatment with excess (100 equiv) reactive metal (red), carbonyl (green), 
oxygen (blue), or nitrogen (purple) species with the exception of hydroxyl radical and peroxynitrite (10 equiv). (c) 
Relative fluorescence observed following exogenous NO administration or (d) endogenous hypoxic NO stimulation 
in 4T1 breast cancer cells. All spectra and assays were performed in 50 mM HEPES buffer (pH = 7.4) containing 
0.1% CrEL (v/v).  Relative fluorescence intensity was compared using an unpaired t test (α = 0.05). *, p < 0.05; **, p 
< 0.01. Data presented as mean ± standard deviation (n = 3) for (b-c).  
 
Initial studies were performed using absorbance (as a proxy for PA) and fluorescence 
spectroscopy. Treatment of CyAPNO with NO resulted in a substantial 77 nm shift of the λmax. 
Ideal wavelengths were experimentally identified from the absorbance and fluorescence spectra. 
Under these conditions, we observed a 57-fold and 7.5-fold maximal ratiometric absorbance and 
fluorescence response. These responses were selective for NO and non-responsive across a range 
of reactive metal, oxygen, nitrogen, and metal species, confirming that the secondary aniline 
trigger maintains its functionality on the bulky cyanine dye platform (Figure 3.12).  
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As expected, both CyAPNO and tCyAPNO display some pH dependence (pKa = 8.5); 
however, only modest changes are observed below pH = 8.0 (Figure 3.30). Moreover, CyAPNO’s 
reactivity was sufficient to detect exogenous (from DEA-NONOate) and endogenous hypoxia-
promoted NO in 4T1 breast cancer cells (Figure 3.12c).15 More broadly, this strongly suggests that 
oxygen-dependent NO sensing mechanism do not hinder the ability to detect NO under typical 
hypoxic conditions.  Inhibitor or siRNA studies targeting iNOS would strengthen this conclusion, 
but we proceeded to confirm whether CyAPNO was compatible with systemic (retro-orbital) 
injection because of its limited photostability (50% signal lost after approximately 3 h in buffer, 
Figure C.31). 
CyAPNO was evaluated in a similar model to the SR-APNO-3 cancer imaging studies; 
however, the imaging was performed earlier to interrogate uptake shortly after the tumor 
vasculature is considered sufficient (approximate tumor volume of 100 mm3 rather than 300 mm3). 
This extends the period of time where one could study relative NO concentrations as a function of 
tumor progression. The CyAPNO concentration was selected to maximize the dose with 
reasonable organic cosolvent and the excitation and emission filter tests were selected based on 
maximal ratiometric responses following subcutaneous injection of authentic CyAPNO and 
tCyAPNO samples into the flank (50 μL of 50 μM solution in saline, 2.5% DMSO v/v). After 
administration (t = 0 h) we observed a sharp decrease in the fluorescent ratio of tCyAPNO to 
CyAPNO, both in the tumor and flank. This is consistent with systemic distribution with gradual 
uptake in the tumor (t = 0.5–5 h). Between 5 and 108 h, we observed the accumulation of 
tCyAPNO only in the tumor with a maximum 1.9-fold ratiometric response relative to the flank (t 
= 36 h). The probe cleared after ~204 h (Figure 3.13). Encouraged by these findings, we sought to 
improve on the dye platform’s photostability with the hopes of increasing the dynamic range. 
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Figure 3.13: (a) Ratiometric fluorescence imaging of NO in a heterotopic 4T1 breast cancer model following systemic 
administration of CyAPNO (100 μL, 100 μM, retro-orbital) (b) Representative image of fluorescence corresponding 
to tCyAPNO in the flank (left) and tumor (right).Fluorescence intensity corresponding to CyAPNO is similar in the 
flank at tumor. Data presented as mean ± standard deviation (n = 3). 
 
3.11 Progress towards a photostable dye for multimodal fluorescence and photoacoustic 
imaging following systemic administration 
 Several solutions have emerged to address this poor photostability with a central theme: 
decrease nucleophilicity to prevent photodecomposition via type II photosensitization. Generally, 
an inductive approach is employed, in which electron withdrawing functional groups are 
introduced in conjugation114,116,118 with or at the reaction center.113,119 Electron withdrawing group 
introduction would also likely decrease the N-nitrosated product from releasing NO through photo-
electron transfer-based homolysis, further enhancing its sensitivity.82,97,120 We were particularly 
intrigued by functionalization at the reaction site because polyfluorination of the cyanine decreased 
the extinction coefficient, increased the fluorescence quantum yield, and altered aggregation 
behaviors. These would be detrimental for PA probe development and are not readily explained 
We proposed that fluorination at the site of the reaction, rather than cyano-substitution,113,119 would 
serve as the smallest perturbation and should therefore limit any photophysical changes. 
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Scheme 3.3: Retrosynthetic analysis for the synthesis of F2-Cyanine-Cl using nucleophilic fluoride sources. 
 
The fluorinated cyanine scaffold was approached in a similar fashion to the non-fluorinated 
parent compound, in which 1-alkyl-2,3,3-trimethyl-3H-indol-1-ium is subjected to a Knoevenagel 
condensation reaction with the Vilsmeier-Haack product, (E)-2-chloro-3-
(hydroxymethylene)cyclohex-1-ene-1-carbaldehyde. Preliminary efforts to directly fluorinate the 
1-alkyl-2,3,3-trimethyl-3H-indol-1-ium or indole with radical or electrophilic fluorine sources 
proved unsuccessful. Thus, we proposed a novel retrosynthesis approach to the indoline through 
oxidative condensation between a fluorohydrin and aniline or reductive cyclization between an α-
fluoroketone. We elected to proceed through the fluorohydrin as this is readily available via 
regioselective fluoride opening of an epoxide with nucleophilic fluoride and nucleophilic sources 
(e.g., mineral fluoride salts, ammonium fluoride salts) tend to be significantly cheaper than 
electrophilic (e.g., N-fluoropyridinium triflate, Selectfluor, NSFI) fluorination reagents. The 
epoxide could then be prepared directly from the aldehyde through Johnson-Corey-Chaykovsky 
epoxidation. The requisite aldehyde could be accessed in six steps from commercially available 2-
nitrophenylacetic acid (Scheme 3.3).  
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Scheme 3.4: Progress towards the synthesis of F2-CyAPNO in 14 steps from 2-nitrophenylacetic acid. 
 
The sequence began with Fisher esterification of 2-nitrophenylacetic acid in acidic methanol 
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methyl iodide and sodium hydride to afford compound 3.58 in a 91% yield. It is possible to directly 
treat 2-nitrophenylacetic acid with excess methyl iodide and sodium hydride; however, these 
conditions are less cost effective. Efforts to selectivity reduce the ester proved unsuccessful (AlH3, 
limiting amounts of DIBAL-H, NaBH4-CeCl3, etc.) and resulted in significant reduction of the aryl 
nitro or poor yield. This is likely due to the steric hinderance proximal to the ester. Ester hydrolysis 
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carboxylic acid 3.59 could be ready isolated by precipitation in water. Next, the carboxylic acid 
was activated as an acyl iodide (in situ from the acid chloride) prior to Wienreb amide formation 
with N,O-dimethylhydroxylamine. Note that reduction to the alcohol, followed by oxidation to the 
aldehyde with pyridinium chlorochromate has been reported previously;121 however, our reaction 
sequence scaled more efficiently (decagram scale in single pass).  Direct epoxidation of the 
aldehyde was achieved under Johnson-Corey-Chaykovsky conditions with trimethylsulfonium 
iodide and sodium hydride in THF, providing the required terminal epoxide, 3.62, in modest 50% 
yield. The major decomposition pathway was identified as producing, 1-(1-methoxyprop-1-en-2-
yl)-2-nitrobenzene, presumably resulting from deprotonation at the methyl, epoxide opening, and 
subsequent methylation. Attempts to decrease this side reaction were unsuccessful due to the poor 
reactivity of the sterically hindered aldehyde. 
Regioselective epoxide opening was performed with TREAT-HF in TEA (for a 1:1 ratio of 
TEA to HF). These conditions had previously been reported for favoring SN2 fluorination at the 
terminal carbon.122,123 The isolated fluorohydrin underwent smooth oxidation by PCC to afford the 
α-fluoroketone 3.64 in 84% yield. A variety of reductants were screened for the selective reduction 
of the nitro in the presence of the ketone; however, defluorination (iron, zinc) or N-oxide formation 
(palladium on carbon with hydrogen gas, stannous chloride monohydrate) prohibited access to the 
desired product. Titanium trichloride could reduce the N-oxide intermediate and, somewhat 
surprisingly, did not result in dehalogenation.124 Moreover, titanium trichloride afforded efficient 
access to indoline 3.65 directly from nitroaryl 3.64 in 77% yield. Alkylation of the indoline with 
ethyl halides or pseudo-halides (X = Br, I, or triflate) resulted in either decomposition, 
dehalogenation, or no reaction depending on the temperature. To overcome this, we reduced the 
imine with sodium borohydride to increase the product’s stability. While similar reactivity was 
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observed across the panel of electrophiles, we identified that treatment with allyl bromide, in the 
presence of potassium hydroxide, afford the product at room temperature for the non-fluorinated 
analog (67% yield). We are optimistic that these conditions can be translated to yield the tertiary 
amine, 3.67, in reasonable yields. Current efforts are focused on the allylation and screening 
oxidants that can facilitate in situ oxidation of 3.67 to the desired indolium followed by direct 
Knoevenagel condensation to afford the fluorinated platform. This would circumvent the isolation 
of the unstable and reactive intermediate. With the desired F2-Cyanine-Cl dye in hand, we would 
assess its photophysical properties, stability profile, and PA compatibility. The final NO probe 
could be synthesized in a similar manner as CyAPNO to yield the final product F2-CyAPNO. 
 
3.12 Summary and outlook 
 There has been significant progress over the past decade regarding the design and 
application of activatable PA probes (see section 1.4.3).75,102,125–129 NO’s complex regulation and 
diverse biological activities make it a prime target for molecular imaging. This is particularly true 
in the context of cancer, in which oxygen distribution, reactive oxygen species, and NOS crosstalk 
with other pro-inflammatory mediators serve to generate distinct phenotypes. Our initial goal was 
to development a PA probe that could detect NO at inflammatory concentrations (nM–μM steady-
state concentration) in live animals. This was achieved by modifying the aza-BODIPY dye 
platform with most common NO triggers. The N-nitrosation sensing mechanism was identified as 
optimal because it yielded the largest maximal ratiometric PA response. This lead compound, 
APNO-5, was applied for the detection of NO in an LPS murine inflammation model and further 
established target-induced wavelength shifting as a reliable method for PA probe development. 
Unfortunately, APNO-5’s sensitivity was not sufficient for detecting NO at lower concentrations 
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because of the poor spectral overlap between the N-nitrosated product and the excitation source on 
commercially available PA tomographers.  
We tackled this hurdle by devising a new approach, termed “steric relaxation for 
planarization”, to enhance the aza-BODIPY dye platform PA performance. A computational 
model was prepared for ad hock evaluation of the approach and this was experimentally validated. 
The disubstituted probe, SR-APNO-3, proved to be the best and displayed a 4.4-fold and 1.1-fold 
increases in ratiometric PA response (relative to APNO-5) within tissue-mimicking phantoms and 
an intramuscular LPS murine inflammation model, respectively. SR-APNO-3 enabled the first 
validated detection of NO in a murine 4T1 breast cancer model. While the 1.2-fold ratiometric PA 
response was sufficient for detection and validation with an inhibitor, it is insufficient for semi-
quantitative comparisons and not compatible with systemic administration. As it stands, SR-
APNO-3 has applications as a potential molecular imaging-based extension for inflammation 
animal models.  This would serve to expand the current methods to provide information about the 
mechanism, where NO is often a direct or indirect target of anti-inflammatory compounds.130 
From our work on the aza-BODIPY dye platform, it appears that the ratiometric responses 
are constrained to 2-fold ratiometric responses using commercially available PA tomographers. 
Moreover, the parameters dictating biodistribution and systemic compatibility remain unclear. 
This prompted investigations towards a cyanine-based multimodal fluorescence and PA dye 
platform because of their wide success in optical imaging and reasonable biodistributions in living 
specimen. Rather than rival methods, we proposed their complementary to access increased 
dynamic range, superior deep tissue resolution and three-dimensional information with a single 
activatable contrast agent. Preliminary studies employing a N-nitrosation-based cyanine probe, 
CyAPNO, provided promising results regarding probe localization following retro-orbital 
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injection and the ability to detect cancer-derived NO. However, poor photostability remains a 
challenge, particularly when performing multiple excitations with different imaging modalities. 
We devised a generalizable NIR I fluorinated cyanine platform to combat this instability and we 
are within two to three steps from the F2-Cyanine-Cl dye platform with an additional step to access 
the multimodal NO probe, F2-CyAPNPO. Current efforts are focused on completing the synthesis. 
Future efforts should focus on completing the synthesis of F2-Cyanine-Cl and comparing 
the photophysical properties between the fluorinated and non-fluorinated platforms. A benchmark 
of success would be a 10% decrease in the photobleaching rate–as this is comparable to previous 
optimization strategies–while maintaining the large extinction coefficient (approximately 106 M-1 
cm-1) and low–moderate quantum yields.113,114,116,118,119 Additionally, N-nitrosated F2-CyAPNO’s 
stability against denitrosylation should be similar to SR-APNO-3. Ideally, this would enhance the 
ratiometric fluorescence signal for semi-quantitation of relative NO concentrations, while still 
achieving useful, three-dimensional data regarding the location within the tumor 
microenvironment. Together, these optimized properties should increase the signal-to-noise 
observed using JW41, a recent hydrogen peroxide cyanine probe for fluorescence and PA imaging, 
in which 40% conversion of the probe to the uncapped product corresponded to a 1.5-fold and 2-
fold ratiometric fluorescent and PA responses. Note that these ratios are from the isosbestic point 
to a wavelength corresponding to background, rather than those selected to maximize the signal 
difference between probe and product, and should serve as an underestimate the JW41’s 
sensitivity.112  
There are many of future directions to consider for this project after a suitable probe is 
acquired, particularly in the realm of cancer biology. For example, examining the concentration 
and distribution of NO as a function of tumor progression. This could shed light on the timing and 
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regulatory mechanisms that drive the transition between anti-tumor and pro-tumor activity, as well 
as the source (i.e., iNOS, eNOS, nNOS, or nitrite reductases) and distribution throughout the 
tumor. Parallel amperometric and histochemical analyses could complement the imaging data to 
confirm the dynamics and spatial information. Investigations regarding the clinical relevance are 
also warranted. Chiefly those that compare and validate if activatable probes are superior to their 
non-targeted and targeted counterparts. In summary, the development of NO-selective probes 
facilitated the non-invasive imaging of NO within live mice, established new approaches for dye 
optimization, and set the stage for new biological discoveries and clinical applications. 
 
3.13 Experimental Methods 
Experimental protocols and information are included below in the following order and 
combined whenever possible: general materials, instrument, and software information; in vitro 
characterization; cell-based studies; and then in vivo experiments.  
3.13.1 Materials 
Materials were purchased from commercial vendors and used without further purification. 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dichloromethane, DIBAL-
H in heptane, isoamyl nitrite, propargyl bromide (80% w/w in toluene), and triethylamine were 
purchased from Acros Organic. Hydrogen was purchased from Airgas. 1,3-Dimethylbarbituric 
acid, 4’-hydroxyacetophenone, 4’methoxyacetophenone, and ninhydrin were purchased from AK 
Scientific. Allyl bromide, nitromethane, sodium hypochlorite (14.5% available chlorine in water), 
and tetraethyleneglycol were purchased from Alfa Aesar. Ammonium acetate and sodium nitrate 
were purchased from Amersco. All deuterated solvents were purchased from Cambridge Isotope 
Laboratories. Diethylamine NONOate (DEA-NONOate), methylamine hexamethylene 
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methylamine NONOate (MAHMA-NONOate) and sodium α-oxyhyponitrite (Angeli’s salt) were 
purchased from Cayman Chemicals. Tris(3-hydroxypropyltriazolylmethyl)amine was purchased 
from Click Chemistry Tools. 4’-Hydroxy-3’-nitroacetophenone was purchased from Combi-
Blocks. Anhydrous ethanol (Decon Lab), ammonium chloride, chloroform, copper sulfate 
pentahydrate, Cremophor EL (Fluka), diethyl ether, ethyl acetate, glacial acetic acid, n-butanol, 
phosphate saline buffer (Corning), o-phosphoric acid, potassium phosphate dibasic, potassium 
phosphate monobasic, sodium bicarbonate, sodium chloride, and toluene were purchased from 
Fisher Scientific. Agarose LE (Molecular Biology Grade) was purchased from Gold 
Biotechnology. ER-Tracker™ Green, LysoTracker® Green DND-26, MitoTracker® Green FM 
were purchased from Life Technologies. Acetonitrile, anhydrous methanol, concentrated 
hydrochloric acid, hydrogen peroxide (30% v/v) and sodium hydroxide were purchased from 
Macron Fine Chemicals. Ammonium acetate, 2-aminophenol, 4’-fluoro-3’-nitroacetophenone, 4-
dimethylaminopyridine, 4-methoxyacetophenone, aluminum trichloride, 4-bromo-3-
methylaniline, carbonyldiimidazole, di-tert-butyl dicarbonate, diisopropylethylamine, ethylene 
dichloride, methanesulfonyl chloride, methyl iodide, N,O-dimethylhydroxylamine, potassium 
carbonate, potassium hydroxide, potassium iodide, pyridinium chlorochromate, sodium ascorbate, 
sodium azide, sodium sulfate (anhydrous), tetrakis(triphenylphosphine)palladium(0), thiophene-
2-carbaldehyde, tin(II) chloride dihydrate, trimethylsulfonium iodide, and triphenylphosphine 
were purchased from Oakwood Chemicals. 1,4-Dioxane, acetyl chloride, ammonia (7 M in 
methanol), ammonium iron sulfate (Mohr’s salt), anhydrous acetonitrile, anhydrous 
dichloromethane, anhydrous dimethylformamide, anhydrous dimethysulfoxide, anhydrous 
tetrahydrofuran, benzaldehyde, boric acid, boron trifluoride dietherate, n-BuLi in hexanes (2.5 M), 
t-BuLi in pentanes (1.7 M) celite 545, copper(II) chloride, dimethylamine (40% w/w in water), 
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dipropylamine, formaldehyde (37% w/w in water), glyoxal (40% w/w in water), HEPES, hexanes, 
indocynanine green, iron(II) sulfate heptahydrate, iron(III) chloride (anhydrous),  iron powder, L-
ascorbic acid, L-dehydroascorbic acid, lipopolysaccharides from Escherichia coli O111:B4 
(purified by phenol extraction), L-NG-monomethyl-arginine  acetate salt (L-NMMA), 
manganese(II) chloride, nitric oxide, palladium on carbon (10% w/w), potassium permanganate, 
potassium superoxide, propargyl bromide (80% w/w in toluene), rat liver microsomes (pooled, 
male), sodium borohydride, sodium hydride (60% dispersion in mineral oil), sodium ascorbate, 
sodium nitrite, thionyl chloride, titanium(III) chloride, tosyl chloride, TREAT-HF, trifluoroacetic 
acid, and trypan blue powder were purchased from Sigma Aldrich. Fluorinated ethylene propylene 
(FEP) tubing (wall thickness 0.01”, inner diameters 0.08” and 0.12”) was purchased from 
McMaster-Carr.  
3.13.2 Instruments and software 
1H, 13C, 11B, and 19F NMRs were acquired on Varian 400, Varian 500, or Carver B500 
spectrometers. The following abbreviations were used to describe coupling constants: singlet (s), 
doublet (d), triplet (t), quartet (q), quintet (quint), multiplet (m), and broad singlet (bs). Spectra 
were visualized and analyzed using MestReNova (version 10.0). High-resolution mass spectra 
were acquired with a Waters Q-TOF Ultima ESI mass spectrometer and a Waters Synapt G2-Si 
ESI/LC-MS mass spectrometer equipped with a PDA detector (200–500 nm). Ultraviolet-visible 
(UV-Vis) measurements or spectra were recorded on a Cary 60 spectrometer or SpectraMax M2 
plate reader (Molecular Devices). Fluorescence spectra were acquired on a QuantaMaster-400 
scanning spectrofluorometer with micro fluorescence quartz cuvettes (Science Outlet) or a 
Denovix QFX fluorometer for performing measurements under anoxic conditions. Refractive 
indices were measured using an RHB-32ATC Brix Refractometer. Cellular imaging was 
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performed on either an EVOS FL epifluorescence microscope or a Zeiss LSM 700 Confocal 
Microscope and analyzed using NIH ImageJ131 (version 1.6 or 1.8) or Zen software. Photoacoustic 
imaging was performed using the Endra Nexus 128 or Endra Nexus 128+ photoacoustic 
tomography system (Ann Arbor, MI, USA), and the data were analyzed using either OsiriX 
(version 8.0) or Horos (version 3.0) imaging software. Final PA images were prepared in OsiriX 
(version 8.0), Horos (version 3.0) or NIH ImageJ131 (version 1.6 or 1.8). Note that the instrument 
was modified to the Endra Nexus 128+ specifications after publishing the work on APNO. 
Additional data analysis was performed using Microsoft Excel or GraphPad Prism (version 6.0 or 
8.0). Mettler Toledo SevenCompact pH meter was used for pH measurements. Some final figures 
were prepared in Adobe Illustrator (version 22.02.02). Crystallographic figures were prepared 
using UCSF Chimera.132 
3.13.3 General synthetic methods 
All materials were purchased from commercial vendors and used without further purification. 
Specific information regarding the material’s sources can be found in the Supporting Information. 
Thin-layer chromatography (TLC) was performed on glass-backed TLC plates precoated with 
silica gel containing an UV254 fluorescent indicator (Macherey-Nagel). TLC’s were visualized 
with a 254/365 nm UV hand-held amp (UVP). Flash silica gel chromatography was performed 
using 0.04 – 0.063 mm 60 M silica (Macherey-Nagel). Non-commercially available anhydrous 
solvents were dried over 4 Å molecular sieves activated via heating under a vacuum at 300 °C. All 
glassware used under anhydrous reaction conditions were flame-dried under vacuum and cooled 
immediately before use. When required, solutions were degassed by bubbling nitrogen through the 
solution for a minimum of 20 minutes. Saturated solutions of NO were generated by bubbling 
gaseous NO from the reaction between iron sulfate heptahydrate and sodium nitrite at 100 °C  
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through the desired, degassed solvent (27 g iron sulfate heptahydrate and 12.5 g of sodium nitrite 
for ~2.5 L of NO).133 Detailed synthetic procedures can be found in Appendix C and are provided 
in the following order for ease of access: APNO-1, APNO-2, APNO-3, APNO-4, APNO-5, TG-2 
(deamination-based TokyoGreen probe), TG-3 (N-nitrosation-based TokyoGreen probe), SR-
APNO-1, SR-APNO-2, SR-APNO-3, CyAPNO, and F2-CyAPNO. 
3.13.4 Photophysical characterization  
Extinction coefficients and fluorescence quantum yields were acquired in experimental 
triplicates. N-nitrosated products were generated by reacting APNO with NO (500 equiv from 
MAHMA-NONOate solution in ethanolic 20 mM potassium phosphate buffer, pH 7.4, 50% v/v) 
or SR-APNO with NO (150 equiv from MAHMA-NONOate solution in ethanolic 20 mM 
potassium phosphate buffer, pH 7.4, 50% v/v or 60 equiv in methanol, generated from ~15 mM 
saturated methanolic solution) for greater than 1 h at room temperature, where complete 
conversion was confirmed via UV-Vis spectroscopy. Extinction coefficients were acquired by 
titrating or diluting compound into chloroform, methanol or ethanolic 20 mM potassium phosphate 
buffer (pH = 7.4, 50% v/v) within the linear range (typically absorbance values 0.05 – 1.50, final 
DMSO concentration < 1%). Fluorescence quantum yields were obtained using a modified method 
for relative fluorescence quantum yield.134 Samples were prepared in ethanolic 20 mM potassium 
phosphate buffer (pH 7.4, 50% v/v, final DMSO concentration < 1%) and sequentially diluted (n 
> 4) while monitoring both absorbance and fluorescence. Absorbance was kept low (< 0.1) to 
prevent secondary absorbance events. Relative quantum yields were calculated relative to 
dimethoxy aza-BODIPY (ϕ = 0.36, chloroform)94 with refractive indexes of 1.445 and 1.3573 for 
chloroform and ethanolic 20 mM potassium phosphate buffer (pH 7.4, 50% v/v), respectively. All 
SR-APNO samples were excited at 640 nm and the emission was monitored from 660–890 nm 
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with a slit width of 2.0 mm.  
3.13.5 Reaction between APNO or SR-APNO and nitric oxide  
APNO were dissolved in ethanolic 20 mM potassium phosphate buffer (pH = 7.4, 50% 
v/v) and treated with MAHMA-NONOate (prepared in degassed 10 mM aq. KOH) at room 
temperature or with NO (g) until a color change was observed. SR-APNO were dissolved in 
ethanolic 20 mM potassium phosphate buffer (pH = 7.4, 50% v/v) and treated with MAHMA-
NONOate (prepared in degassed 10 mM aq. KOH) at room temperature or were treated methanolic 
NO (~10 mM, ~60 equiv) in anhydrous methanol for less than 5 minutes at room temperature 
before the solution was purged under high vacuum and then concentrated under vacuum. CyAPNO 
was dissolved in 50 mM HEPES (pH 7.4, 0.1% CrEL v/v) and treated with MAHMA-NONOate 
(prepared in degassed 10 mM aq. KOH). 
3.13.6 Selectivity studies  
Unless otherwise noted, APNO or SR-APNO were pre-incubated at 37 °C in an ethanolic 
20 mM potassium phosphate buffer (pH = 7.4, 50% v/v) for at least 15 min. CyAPNO was pre-
incubated at 37 °C in an 50 mM HEPES buffer (pH = 7.4) containing CrEL (0.1% v/v) for at least 
15 min. The initial absorbance and/or fluorescence was measured follow by the addition of 100 
equiv (APNO, CyAPNO) or 200 equiv (SR-APNO) of various reactive metals, oxygen, nitrogen, 
and carbonyl species. After addition, the reaction was sealed and incubate at 37 °C (APNO for 1 
h, CyAPNO for 0.5 h) or room temperature (SR-APNO for 1 h). Final measurements were 
recorded, and the relative turn-on was determined by the sum of intensity over the total range of 
emission. Fe(II) selectivity studies were performed in ethanolic 20 mM HEPES buffer (pH 7.4, 
50% v/v) to prevent oxidation. All metal solutions were prepared from their chloride salt in water 
with the exception of Fe(II) which was prepared from FeSO4·(H2O)7. Aqueous formaldehyde 
 116 
solutions were depolymerized by heating to solution to 100 °C for greater than 15 min before use. 
Aqueous dehydroascorbic acid solutions were prepared by heating at 60 °C for greater than 15 min 
before use. Aqueous perchlorate, nitrite, and nitrate solutions were prepared for their 
corresponding sodium salts. Superoxide anion was added as a solution of potassium superoxide in 
DMSO. Nitroxyl was generated in situ from a solution of Angeli’s salt in degassed 10 mM 
potassium hydroxide solution. NO was generated in situ from a solution of MAHMA-NONOate 
in degassed 10 mM potassium hydroxide. Hydroxyl radical was generated via Fenton chemistry 
between Mohr’s salt (solution in degassed 1 M aqueous hydrochloric acid) and hydrogen peroxide. 
Fe(II), nitroxyl, and hydroxyl radical selectivity assays were performed under nitrogen to prevent 
oxidation. Peroxynitrite was synthesized according to a literature report.135 All other analytes were 
prepared by dilution from commercially available sources. 
3.13.7 PA imaging in tissue-mimicking phantoms  
Tissue phantoms were prepared by mixing agarose (4 g) in a solution of 2% reduced fat 
milk (2 mL) and deionized H2O (78 mL). The mixture was heated in a microwave oven until a 
viscous gel was produced (30 seconds), the gel was then mixed and reheated for an additional 15   
30 s to ensure homogeneity. The gel was transferred to a custom Teflon mold made to fit within 
the Endra bowl system with hypodermic steel tubing inserted to prepare channels for placing FEP 
tubes (0.08” diameter) containing the samples. After cooling the gel for a minimum of 1 hour at 4 
°C, the phantom was removed from the mold. Sample solutions (200 µL) were pipetted into FEP 
tubing (0.08-inch diameter) and sealed by folding over the ends and securing with a short length 
of 0.12-inch diameter FEP tubing. APNO (10 µM) or SR-APNO (25 µM for theoretical maximum 
ratiometric comparisons; 10 µM for PA spectra) was dissolved in an ethanolic 20 mM potassium 
phosphate buffer (pH 7.4, 50% v/v). t-APNO-5 and t-SR-APNO were generated by reacting 
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APNO-5 or SR-APNO with NO (500 equiv NO from MAHMA-NONOate) for greater than 1 h at 
room temperature (complete conversion was confirmed by UV–vis). Images were acquired using 
Step and Shoot mode with 120 angles and 10 pulses per angle (APNO) or continuous mode with 
6 second rotation time (SR-APNO). PA spectra were measured in the same solvent at 10 nm 
intervals, and signal was integrated over the total range of signal. Mean signals are reported as the 
average of the two samples and the experiment was performed in experimental triplicate. Fresh 
samples were prepared for each tAPNO-5 wavelength to limit photo-induced cleavage of the N-
nitrosated product. 
3.13.8 Photostability studies 
APNO or SR-APNO and the corresponding N-nitrosated product (20 μM for APNO 
manuscript or 25 µM for SR-APNO manuscript) photostability were measured at their PA 
maximum in potassium phosphate saline with CrEL (0.1% v/v, APNO manuscript) or ethanolic 
20 mM potassium phosphate buffer (pH 7.4, 50% v/v, SR-APNO manuscript) using the OPO laser 
used in the Nexus 128+ PA tomographer. Samples were irradiated discontinuously, and 
measurements were acquired in Step and Shoot mode (APNO manuscript, 120 angles and 10 
pulses per angle) or continuous mode with a 6 s rotation time (SR-APNO manuscript). The mean 
signal was acquired, the average PAI was obtained for the two tubes, and relative signals were 
calculated according to the initial PA signal. Data is reported as the mean ± standard deviation (n 
= 3). CyAPNO and tCyAPNO stability was assessed under ambient conditions. Dye (5 μM) was 
incubated at 37 °C in diluted plasma, diluted serum, or 50 mM HEPES buffer (pH 7.4) containing 
0.1% CrEL and the absorbance (500 – 900 nm) was monitored at 1, 2, 4, 6, and 18 h and compared 
to the initial spectra (pre-incubated  for 15 min in the dark for proper solubilization).  
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3.13.9 Mechanistic insights about deamination- and N-nitrosation-based NO sensing 
 All experiments performed under anoxic conditions were performed in an anaerobic 
chamber (Coy) equilibrated with a nitrogen-hydrogen (5%) mixture maintained at less than 1 ppm 
molecular oxygen. Solutions were degassed (3×) using freeze-pump-thaw technique before 
transferring into the chamber. Solids and solutions were pre-equilibrated overnight before use. 
Assays were performed with the following ratios with a final buffer concentration of 50 mM 
HEPES pH 7.4: 500 eq of analyte, DNIC is 1:1:4 Fe:NO:RSH (1μM dye, 500 μM NO or 250 μM 
MAHMA NONOate, 500 μM iron sulfate heptahydrate, 2000 μM RSH). DNIC were prepared by 
incubating the iron source with the thiol for at least 5 min prior to the addition of dye and allowed 
to incubate at room temperature for 1 hour. Samples were then exposed to air and allowed to 
proceed for at room temperature for an additional hour. Normoxic samples were run in parallel for 
comparison. 
3.13.10 Computational details 
Structures were built using Avagadro136 and were optimized using the universal force 
field137 until it converged. Further geometry optimizations were performed sequentially using 
density functional theory using Guassian 3, 9, or 16. First, the structure was optimized using 
B3LYP138,139 with the 6-31(d) basis set in the gas phase followed by B3LYP with the 6-31(d) basis 
set in implicit methanol solvent. All resulting structures were identified as a ground state by 
calculating the stretching frequencies. Dihedral angles were measured, using Chimera 
visualization software,132 as the positive angle between the plane defined by all of the heavy atoms 
within the aza-BODIPY core and the plane defined by all heavy atoms in the ring of interest. 
Dihedral angles were reported as an average if the structure was symmetrical. UV-Vis spectra were 
calculated from the solvent optimized structure using time-dependent self-consistent frequencies 
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density functional theory using the CAM-B3LYP functional140 and 6-31(d) basis set for only 
singlet excitations in an implicit methanol solvent. 
3.13.11 Cell culture 
4T1 murine mammary carcinoma cells and 264.7 RAW macrophage cells were acquired 
from ATCC and Prof. Elvira de Mejia (Food Science and Human Nutrition, UIUC), respectively. 
Cells were cultured in phenol red free RPMI 1640 medium or Dulbecco’s modified eagle medium 
(DMEM, Corning) supplemented with 10% fetal bovine serum (FBS, Sigma Aldrich), and 1% 
penicillin/streptomycin (Corning). Cells were incubated at 37 °C with 5% CO2. Cells were 
passaged using manual scraping (264.7 RAW macrophage cells) or trypsin (0.25% trypsin with 
0.1% EDTA in HBSS without calcium, magnesium, and sodium bicarbonate, Corning, 4T1 murine 
mammary carcinoma cells) at least every 3 days. Cells were incubated at 37 °C with 5% CO2 
unless specified otherwise. Experiments were performed in 4-well chambered cover glasses (Lab-
Tek, Thermo Scientific), 6-well plates (Nunclon Delta Surface, Thermo Scientific), or 96-well 
plates (Nunclon Delta Surface Flat Bottom, Thermo Scientific).  
3.13.12 Trypan blue cytotoxicity assay 
6-well plates were seeded with 300,000 cells per well (3 mL of 100,000 cells/mL) and 
incubated at 37 °C with 5% CO2 for 48 h (~60% confluent). Media was removed and fresh DMEM 
with 10% FBS (3 mL) was applied followed by addition of 7.5 µL vehicle control (DMSO) or 
APNO-5 for a final concentration of 1 or 5 µM. After 3, 6, and 24 h, cells were suspended by 
scraping, pelleted via centrifugation at 1000 × g for 5 min and the supernatant was discarded. The 
cell pellet was re-suspended in PBS (300 µL) and mixed 1:1 with trypan blue (0.4% w/v stock in 
PBS). The mixture was allowed to incubate for 1-3 min at room temperature and then unstained 
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(viable) and stained (nonviable) cells were counted using a hemocytometer. Viability was 
calculated as the percent viable cells for the experimental condition relative to the vehicle control.  
3.13.13 MTT cytotoxicity assay 
A 96-well plate was seeded with 20,000 cells per well (200 µL of 100,000 cells/mL) and 
incubated at 37 °C with 5% CO2 for 24 h (~60–70% confluent). Media was removed and fresh 
serum-free RMPI 1640 containing vehicle control (DMSO), APNO, or SR-APNO (0.5% DMSO 
or 1.25% DMSO v/v for APNO and SR-APNO, respectively). At various times, the media was 
removed and replaced with 200 µL 20∶1 mixture of FBS-free RMPA 1640 and (3- (4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT, 5 mg/mL stock in PBS). The cells 
were incubated for 4 h under the same conditions and then the medium was removed and replaced 
with DMSO (100 µL/well). The absorbance of each well was recorded at 555 nm on a microplate 
reader. Viability was calculated by the absorbance relative to the vehicle control. 
3.13.14 PA imaging of exogenous nitric oxide in 4T1 murine breast cancer cells 
A T75 flask of 4T1 murine mammary carcinoma cells was seeded and allowed to grow to 
confluency (~90%) over 36 h. The cells were trypsinized, suspended in a 15 µM solution of SR-
APNO-3 (RMPI 1640 serum-free media with 0.75% DMSO final concentration) and 2 × 106 cells 
were distributed into each 1.6 mL Eppendorf tube. The cells were stained for 1 h at 37 °C with 
agitation. After staining, the cells were collected via centrifugation (6,000 rpm, 5 min, 4 °C), 
washed with PBS (1 mL, same protocol as collection) to remove free dye, and then resuspended 
in PBS (450 µL). Samples were treated with control (50 µL 10 mM KOH), 1 mM DEA-NONOate 
(50 µL 10 mM DEA-NONOate in 10 mM KOH), or 5 mM DEA-NONOate (50 µL 50 mM DEA-
NONOate in 10 mM KOH) and were allowed to incubate with rocking for 2 h at room temperature. 
The cells were pelleted via centrifugation (6,000 rpm, 5 min, 4 °C) and imaged directly in the 1.6 
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mL Eppendorf tube. Images were acquired at the appropriate wavelengths (SR-APNO-3: 790 nm; 
t-SR-APNO-3: 690 nm) using continuous mode with a 6 s rotation time. Quantification of each 
cell pellet is reported as the average of the mean signals over the entire area of interest (12.1 mm, 
slices 130 – 256). 
3.13.15 Epifluorescence imaging of exogenous nitric oxide in 4T1 breast cancer cells 
 6 well plates were seeded with 150,000 4T1 murine mammary carcinoma cells (3 mL of 
50,000 cell/mL) in RPMI 1640 media containing 10% FBS and allowed to incubate at 37 °C with 
5% CO2 for 24 h. The media was removed, and the cells were stained with CyAPNO (5 μM) in 
serum-free RPMI 1640 media for 90 min under the same conditions. After staining was complete, 
the solution was removed, and the cells were washed with PBS (1.0 mL) and incubated with DEA-
NONOate (0.1 or 1 mM) in PBS for 1 h at 37 ºC. Each well was imaged (n = 3) were imaged using 
the Cy7 filter cube (EVOS fluorescence microscope) and analyzed using ImageJ (NIH).131 The 
average fluorescence was measured as the mean of five randomly selected cells and the error is 
reported between biological replicates (n = 3). 
3.13.16 Epifluorescence imaging of nitric oxide under AneroPack® Hypoxic Conditions 
 24 well plates were seeded with 25,000 4T1 murine mammary carcinoma cells (0.5 mL of 
50,000 cell/mL) in RPMI 1640 media containing 10% FBS and allowed to incubate at 37 °C with 
5% CO2 for 24 h. The media was removed, and the cells were stained with CyAPNO (5 μM) in 
serum-free RPMI 1640 media for 90 min under the same conditions. After staining was complete, 
the solution was removed, and the cells were washed with PBS (0.5 – 1.0 mL) and incubated in 
serum-free RPMI media for 6 h at 37 ºC in a sealed container either with or without an AneroPack® 
(Mitsubishi Gas Company). When performing inhibition studies, the aforementioned solutions was 
prepared with L-NG-nitroarginine (L-NNA, 10 μM, non-selective NOS inhibitor). Each well was 
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imaged (n = 3) were imaged using the Cy7 filter cube (EVOS fluorescence microscope) and 
analyzed using ImageJ (NIH).131 The average fluorescence was measured as the mean of five 
randomly selected cells and the error is reported between biological replicates (n = 3). 
3.13.17 Live-subject statement  
All animal experiments were performed with the approval of the Institutional Animal Care 
and Use Committee of the University of Illinois at Urbana–Champaign, following the principles 
outlined by the American Physiological Society on research animal use.  
3.13.18 Saline preparation and in vivo injection formulation 
Sterile saline was prepared by dissolving sodium chloride (90 mg) in Milli-Q water (10 
mL) and filtering the resulting solution through a Millex-GS 0.22 µm sterile filter. For all in vivo 
injections, a 3.4 mM solution of APNO-5 in DMF was prepared and diluted into sterile saline for 
a final concentration of 17 µM (0.5% DMF).  
3.13.19 PA imaging in a subcutaneous LPS-induced murine inflammation model 
All animal experiments were performed with the approval of the Institutional Animal Care 
and Use Committee of the University of Illinois at Urbana-Champaign, following the principles 
outlined by the American Physiological Society on research animal use. Six to eight week-old 
BALB/c mice were obtained from Jackson Laboratory. Lipopolysaccharide was dissolved in 
sterile saline at a concentration of 1 mg/mL. Hair was removed from the flanks using depilatory 
cream, and then mice were challenged subcutaneously with either 4 mg/kg of LPS or an equi-
volumetric amount of saline in the flank. After 3.5 hours, mice were anaesthetized using isoflurane, 
and background PA signals were acquired at 680 nm and 770 nm. After an additional 0.5 hours, a 
17 μM solution of APNO-5 in sterile saline containing 0.5% DMF was subcutaneously injected 
into the same flank at 68 μg/kg (80 μL for 20 g mouse). PA signals were monitored every hour for 
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5 hours in triplicate at 680 nm and 770 nm. Average PA intensities were acquired over the total 
volume of interest (1 cm3) and the triplicates were averaged. PA spectra were acquired after 5 h 
with excitations every 10 nm under the same conditions as previously described, either with or 
without the administration of APNO.  
3.13.20 PA imaging in an intramuscular LPS-induced inflammation in BALB/c mice 
Six to eight-week-old BALB/c mice were obtained from Jackson Laboratory and 
intramuscularly administered lipopolysaccharide in a saline solution (4 mg/kg). After 4 h, APNO-
5 or SR-APNO-3 (50 µM, 25 µL) was administered intramuscularly in a sterile saline solution 
(0.9% NaCl in sterile water) containing 15% DMF (v/v). Inhibition assays were performed by 
preparing the aforementioned dye solution in sterile saline containing 35 mM L-NMMA for co-
administration. Images were acquired in technical replicates (n = 2) at the appropriate wavelengths 
using continuous mode with a 6 s rotation time. Quantification of each image is reported as the 
average of the mean signals of the technical replicates over the entire area of interest (12.1 mm, 
slices 130–256). For more clear representation, images corresponding to the probe and N-
nitrosated products were colored independently and then overlaid using Horos software. 
3.13.21 PA imaging of 4T1 murine breast cancer-derived nitric oxide in BALB/c mice with SR-
APNO-3 
Six to eight-week-old BALB/c mice were obtained from Jackson Laboratory and 4T1 
subcutaneous tumors (5 × 104 cells, 50  µL of 1 × 106 cells/mL in 1:1 serum-free RPMI 1640 media 
and Matrigel) were implanted and allowed to grow for 26 days for a final volume of ~300–400 
mm3. Tumor volumes were measured using a caliper method141 and the body weight was 
monitored over the course of the experiment. SR-APNO-3 (50 µM, 25 µL) was administered 
intratumorally or subcutaneously in a sterile saline solution (0.9% NaCl in sterile water) containing 
 124 
15% DMF (v/v). Inhibition assays were performed by preparing the aforementioned dye solution 
in sterile saline containing 35 mM L-NMMA for co-administration. Images were acquired in 
technical replicates (n = 2) using continuous mode with a 6 s rotation time. Quantification of each 
image is reported as the average of the mean signals of the technical replicates over the entire area 
of interest (12.1 mm, slices 130–256). Reported samples sizes correspond to the number of 
biological replicates (animals). For more clear representation, images corresponding to the probe 
and N-nitrosated products were colored independently and then overlaid using Horos software. 
3.13.22 In vivo imaging system (IVIS) imaging of 4T1 murine breast cancer-derived nitric oxide 
in BALB/c mice with CyAPNO 
Five to seven-week-old BALB/c mice were obtained from Jackson Laboratory and 4T1 
subcutaneous tumors (1 × 105 cells, 100  µL of 1 × 106 cells/mL in serum-free RPMI 1640 media) 
were implanted and allowed to grow for 18 days for a final volume of ~100 mm3. Tumor volumes 
were measured using a caliper method141 and the body weight was monitored over the course of 
the experiment. CyAPNO (10 µM, 100 µL) or the vehicle control were administered retro-orbitally 
in a sterile saline solution (0.9% NaCl in sterile water) containing 10% DMSO (v/v). Images were 
acquired with excitation and emission filters corresponding to CyAPNO (675/760 nm) and 
tCyAPNO (745/840 nm). The fluorescence was monitored in the flank and the tumor and the ratio 
was monitored over time (up to 8.5 days for clearance). Reported samples sizes correspond to the 
number of biological replicates (animals). 
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APPENDIX A: CHAPTER 2 SUPPLMENTAL FIGURES AND TABLES4 
 
 
Figure A.1: (a) LC-HRMS analysis of the crude reaction between CoxFluor (10 μM), COX-2 (250 nM), and hemin 
(1 μM) in 100 mM Tris-HCl buffer (pH 8.0). The products were extracted with EtOAc after incubation at room 
temperature for 4 h and the organic layer was concentrated under vacuum. Products were separated on a CORTECSTM 
UPLC C18 column (1.6 μm, 2.1 by 50 mm) with a linear gradient using a combination of solvent A (95% water, 5% 
acetonitrile, 0.1% TFA) and solvent B (95% acetonitrile, 5% water, 0.1% TFA) at a flow rate of 0.5 mL/minute. 
Gradient protocol in minutes: 0–0.5 (100% A); 0.5–6 (20% A); 6–8 (100% B); 8–8.1 (80% A); and 8.1–10 (80% A). 
High resolution spectra for (b) resorufin (HRMS [M - H]- calc’d mass for C12H6NO3 = 212.0348, found = 212.0355) 
and (c) PGH2 (HRMS [M - H]- calc’d mass for C20H31O5 = 351.2172, found = 351.2171) were observed. 
 
4Portions of this appendix are reprinted or adapted with permissions from the following publication: Yadav, A. K.; 
Reinhardt, C. J.; Arango, A. S.; Huff, H. C.; Dong, L.; Malkowski, M. G.; Das, A.; Tajkhorshid, E.; Chan, J. An 
Activity-Based Sensing Approach for the Detection of Cyclooxygenase-2 in Live Cells. Angew. Chemie Int. Ed. 2020, 
59, 3307–3314.36 Copyright © 2020 John Wiley and Sons, Inc. 
 135 
 
Figure A.2: Representative time-course of CoxFluor fluorescence spectra after treatment with (a) COX-2 or (b) COX-
1 over 4 h (red line indicates final time point, normalized to initial timepoint). (c) Comparison of final fluorescence 
intensity at 590 nm for CoxFluor treated with COX-2 (red) or COX-1 (blue) relative to a buffer control (black). (d) 
Relative selectivity for COX-2 over COX-1 as a function of time. Reactions were performed at room temperature 
using the fluorimeter assay protocol (submicroquartz cuvettes) with 10 mM CoxFluor and 250 nM enzyme (COX-1 
specific activity is 1.3-fold greater than COX-2 at this concentration) in 100 mM Tris-HCl (pH 8.0).  
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Figure A.3: (a) CoxFluor response to reactive carbonyl (AA: ascorbic acid; DHA: dehydroascorbic acid; FA: 
formaldehyde; glyoxal), reactive thiols (L-cysteine; GSH: reduced glutathione; NaSH), and metal species (500 μM, 
50 equiv). (b) Heat map of the mean fluorescence enhancement of CoxFluor following treatment with 1, 3, 5, or 50 
equivalents of RNS or ROS. (c) Representative time course of the relative turn on for COX-2 (250 nM, red) compared 
to a range of ROS and RNS (5 equivalents). The same results were observed for all other analyte concentrations. (d) 
Stability of resorufin in the presence of 1, 3, 5, and 50 equiv of ROS and RNS.  Fluorescence enhancements were 
measured for CoxFluor or resorufin (10 μM) using the plate reader assay. Endpoint assays were performed at 4 h and 
the fluorescence enhancement was calculated relative to a buffer control (100 mM Tris-HCl, pH 8.0) at the 
corresponding time point. Values are reported as the mean ± standard deviation (n = 3). 
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Figure A.4: Relative fluorescence for CoxFluor (10 μM) incubated with COX-2 (250 nM), GSH (1 mM) and hemin 
(1 μM) over the course of 4 h at room temperature in 100 mM Tris HCl buffer (pH 8.0). Assay was performed 
according to the fluorimeter assay. 
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Table A.1: Calculated root-mean-standard-deviation (RMSD, in Å) for the selected structure of COX-1 (PDB ID: 
5U6X) compared to a panel of other structures in the protein databank.  
 
PDB Alpha Carbons Backbone Heavy 
1PRH1 0.15 0.16 0.32 
1PTH2 0.13 0.15 0.28 
1PGE3 0.13 0.15 0.28 
1PGF3 0.13 0.15 0.28 
1PGG3 0.13 0.14 0.28 
1CQE1 0.18 0.18 0.34 
1EBV4 0.17 0.19 0.37 
1DIY5 0.17 0.19 0.33 
1EQG6 0.16 0.17 0.33 
1EQH6 0.16 0.17 0.32 
1HT56 0.20 0.22 0.38 
1HT86 0.19 0.20 0.36 
1FE27 0.17 0.19 0.33 
1IGX8 0.18 0.20 0.32 
1IGZ8 0.16 0.18 0.32 
1Q4G9 0.20 0.21 0.42 
1U6710 0.18 0.19 0.32 
2AYL11 0.19 0.19 0.41 
2OYE12 0.18 0.19 0.32 
2OYU12 0.16 0.18 0.34 
3KK613 0.19 0.22 0.31 
3N8V14 0.18 0.20 0.36 
3N8W14 0.18 0.19 0.37 
3N8X14 0.23 0.24 0.44 
3N8Y14 0.22 0.23 0.40 
3N8Z14 0.21 0.2 0.42 
4O1Z15 0.18 0.19 0.39 
5WBE16 0.09 0.10 0.19 
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Table A.2: Calculated RMSD (Å) for the selected structure of COX-2 (PDB ID: 5KIR) compared to a panel of other 
structures in the protein databank. 
 
PDB Alpha Carbons Back Bone Heavy 
1DDX17 0.15 0.17 0.28 
1PXX18 0.17 0.18 0.30 
3KRK19 0.21 0.21 0.44 
3LN020 0.12 0.14 0.28 
3LN120 0.14 0.15 0.27 
3MQE20 0.32 0.34 0.50 
3NT121 0.20 0.20 0.43 
3NTB21 0.18 0.19 0.46 
3NTG20 0.19 0.20 0.39 
3OLT22 0.24 0.25 0.41 
3OLU22 0.23 0.24 0.42 
3Q7D23 0.22 0.25 0.47 
3RR323 0.12 0.14 0.24 
3TZI24 0.23 0.23 0.47 
4FM525 0.15 0.20 0.36 
4M1015 0.18 0.19 0.39 
4M1115 0.19 0.21 0.49 
4OTJ26 0.17 0.18 0.38 
4OTY27 0.23 0.24 0.43 
4PH928 0.20 0.20 0.43 
4RRW29 0.15 0.15 0.28 
4RRX29 0.20 0.20 0.38 
4RRY29 0.19 0.21 0.41 
4RRZ29 0.15 0.15 0.28 
4RS029 0.23 0.23 0.42 
4RUT30 0.18 0.19 0.40 
4Z0L31 0.18 0.18 0.33 
5F1932 0.22 0.22 0.43 
5F1A32 0.20 0.20 0.43 
5FDQ32 0.20 0.21 0.44 
5IKQ33 0.18 0.19 0.42 
5IKR33 0.20 0.20 0.42 
5IKT33 0.15 0.16 0.36 
5IKV33 0.15 0.16 0.38 
5W5834 0.23 0.23 0.41 
6BL335 0.13 0.14 0.27 
6BL435 0.15 0.16 0.31 
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Figure A.5: RMSD of simulated (a) COX-1 and (b) COX-2 versus the initial crystal structure (PDB 5U6X or 5KIR) 
as a function of simulation time. Monomer A and B are plotted as black and red lines, respectively. 
 
 
Figure A.6: Percent of the total docked poses of CoxFluor bound within the (a) cyclooxygenase and (b) peroxidase 
active sites of COX-2 at a particular Vina AutoDock docking score binding affinity.  
 
 
Figure A.7: Comparison between CoxFluor (green, -7 kcal/mol docking score cutoff) bound to COX-2 and dansyl-
conjugated indomethacin either (a) without (PDB 6BL3) or (b) with a n-butyl-diamine linker (PDB 6BL4).35 
 
a b
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Figure A.8: Normalized ratio of cyclooxygenase to peroxidase binding modes for CoxFluor and PGG2-CoxFluor 
intermediate. 
 
 
Figure A.9: Stability of (a) CoxFluor and (b) resorufin in Tris-HCl (100 mM, pH 8.0, black) and serum-free DMEM 
(light red), DMEM with 10% FBS (red) after 8 h at room temperature with or without exposure to ambient light. 
Values are reported as the mean ± standard deviation (n = 3). 
 
 
Figure A.10: Cell viability for CoxFluor in (a) HEK 293T cells and (b) RAW 264.7 macrophage cells after 6 h 
incubation as measured by the trypan blue exclusion assay (black) and MTT assay (grey). Values are reported as the 
mean ± standard deviation (n = 3). 
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Figure A.11: Quantified confocal imaging of COX-2 activity after 3 h incubation in either non-transfected (control) 
or transfected HEK 293T cells. Indomethacin inhibition (Indo., 10 μM) was performed in transfected cells. Values are 
reported as the mean ± standard deviation (n = 3). 
 
 
Figure A.12: Confocal imaging of COX-2 activity in (a) control, (b) transfected, and (c) indomethacin-treated 
transfected HEK 293T cells after 3 or 4.5 h incubation with CoxFluor (10 μM) at 37 ºC (pre-treated with 1 mM NEM 
for 0.5 h prior to staining). (d) Quantification of images. Values are reported as the mean ± standard deviation (n = 3). 
Statistical analysis was performed using two-way ANOVA (α = 0.05). Fluorescence intensities were compared to the 
control at each time point using Sidak’s multiple comparison test (α = 0.05). *, p < 0.05; ***, p < 0.001. Scale bar 
(white) represents 10 μm. 
 143 
 
Figure A.13: Normalized fluorescence response for CoxFluor (10 μM) after incubation with COX-2 (250 nM) at 
varying concentrations of N-ethylmaleimide. Samples were incubated at room temperature for 4 h and normalized to 
the fluorescence with 0 mM N-ethylmaleimide. Assay was performed according to the plate reader assay. Values are 
reported as the mean ± standard deviation (n = 3).   
 
 
Figure A.14: RAW 264.7 macrophage cell lysate COX-2 activity as a function of LPS stimulation time. Enzymatic 
activity was measured at room temperature with CoxFluor (10 μM) in 89 mM Tris-HCl buffer (pH 8.0) containing 
10% CelLytic M and 1 mM N-ethylmaleimide. Initial rates were measured within the linear region (typically the first 
30 seconds) and protein concentration was measured using the BCA assay. Values are reported as the mean ± standard 
deviation (n = 3). 
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Figure A.15: (a) A schematic representation of the protocol for measuring time-dependent changes in LPS-activated 
RAW 264.7 macrophage COX-2 activity with flow cytometry. (b) Representative histogram and (c) quantified median 
fluorescence for unstained (black), and CoxFluor stained cells after 4 (salmon) and 19 h (red) LPS activation. (d) 
Quantified ratio of median fluorescence between cells stained with CoxFluor to cells stained with CoxFluor in the 
presence of indomethacin (20 μM). All staining was performed with 10 μM CoxFluor, 200 μM BSO was added 2 h 
prior to staining, and values are reported as the mean ± standard deviation (n = 3). Statistical analysis was performed 
using a two-way ANOVA (α = 0.05) with Tukey’s multiple t test (α = 0.05) for comparison of 19 h LPS-stimulation 
to both 0 and 4 h. **, p < 0.01. 
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Figure A.16: Representative density plot for LPS-activated RAW 264.7 macrophage cells with flow cytometry 
without BSO with (a) 4 h or (b) 19 h LPS-stimulation. (c) Quantified median fluorescence for CoxFluor (10 μM) 
stained cells after 4 (salmon) and 19 h (red) LPS activation. Percentages indicate the percent COX-2 positive cells, as 
defined by the green line. Values are reported as the mean ± standard deviation (n = 3). 
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APPENDIX B: MOLECULAR DYNAMICS AND ENSEMBLE DOCKING 
 
B.1 Introduction 
This appendix outlines the general procedures for performing molecular dynamic 
simulations and ensemble docking with NAMD/VMD1,2 and AutoDock Vina.3 The information in 
this section, as well as the scripts, were compiled with the help of Mr. Andres S. Arango 
(Tajkhorshid Laboratory, University of Illinois at Urbana-Champaign). 
 
B.2 Molecular dynamics  
The following discussion is with regards to performing molecular dynamics experiments 
in NAMD and VMD.1,2  Information about PSFGEN can be found in the tutorials (provided online 
from University of Illinois at Urbana-Champaign). If no molecular dynamics are required for the 
analysis, proceed directly to Appendix B.3 for discussions regarding docking. 
Load VMD and access QwikMD through extensions and simulation. Set up the dynamics 
experiment using either easy run (e.g., solvent, temperature, salt concentration, simulation time, 
equilibration times, etc.) or advanced run (e.g., steered MD, fitting into Cryo-EM densities, or 
quantum molecular dynamics for reactions). Load the PDB file through the browser. This will 
rename and prepare residues using NAMD conventions. If the structure contains problems, it will 
indicate them as flashing objects. These must be fixed before simulation. Typically, these are 
crystallographic molecules (e.g., sugars, cofactors, heme, etc.). To check this list, use structure 
manipulation to identify. This will list topologies and parameters that must be removed or modified 
(e.g., chiral centers, cis-peptide bonds, sequence gaps, torsion angle outliers, or torsion angle 
marginals). Delete all that are not required for the simulation (delete and apply). To add 
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parameters, select the molecule of interest and upload using TopoParam. If there is a reason that 
something needs to be altered (e.g., binding a ligand to the heme) it is necessary to create a psf file 
using psfgen. This defines connectivity, which is absent from pdb files, and requires tcl scripting 
that calls psfgen and all necessary CHARMM topology files4 (found on QwikMD or on CHARMM 
website), loads the original pdb and psf files, and then patch the desired structure to be at the 
specific location. 
 
If scripting, use: 
package require psfgen 
topology ../../par/filename 
mol new simulation.re.pdb 
readpsf Simulation.ref.psf 
 
coordinate Simulation.ref.pdb 
 
patch atomtype PROB:location 
guesscoord 
 writepsf ref.removed.psf 
 writepdb ref.removed.pdb 
exit 
 
The topology files and the term for the desired atom time atom type modification can be 
found in the parameter folders (made by user or from VMD). Search the files for the desired 
structure (e.g., using grep command). Be careful about the class of compounds that classifies the 
atom type (e.g., prot for proteins, lipid for lipids, etc.). Then open the file to determine the acronym 
for the atom type. It is imperative to check that it is correct after patching and after simulation 
(e.g., atoms should not overlap). One common problem is that several atoms will have coordinates 
at the origin (search for 0, 0, 0), which will cause NAMD to crash.  
After complete, ignore any structure alerts that are not relevant. Prepare the location for 
the files to be saved using the prepare tool. QwikMD will prepare the structure according to the 
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specifications as a config file (used in runs of NAMD and outputs visualized in VMD). 
Equilibrations and relaxation provide the protein with the ability to solvate and readjust amino acid 
side chains prior to releasing the backbone. This prevents undesirable deviation from the initial 
structure. A general method (gradual release) for this is outlined in Chapter 2 for simulating COX-
1 and COX-2 (see section 2.19.12 for additional information). A simpler alternative is to set an 
initial equilibration without the backbone and then proceeding directly to the simulation. Start 
equilibration simulation to begin. This can be performed directly in VMD/QwikMD or uploaded 
to a cluster (these submission commands are cluster-dependent).  
The simulation will output the simulation trajectory as separate files. You can look at the 
RMSD changes of the peptide backbone over time to confirm that any removed constituents (e.g., 
oligosaccharides) are non-essential during the time frame of the simulation. If this converges, one 
can assume that the protein structure was not significantly altered during the simulation 
(microsecond versus nanosecond for conformational changes and simulation).  
Note that it is possible to simulate the ligand within a static or dynamic protein. This should 
typically be performed after identifying the ideal ligand and it requires ligand parameterization. If 
the ligand is not currently in a database, it is necessary to generate parameters. In VMD, one can 
use the forcefield toolkit with Gaussian. This can be found under extensions, modeling, and then 
forcefield toolkit (FFTK). Alternatively, cgenff (CHARMM General Force Field) can be used 
online (cgenf.umaryland.edu) from a mol2 or pdb file. This creates parameters based off data from 
current databases and will indicate how reliable the generated forcefield is. Often cgenff is used as 
a starting point, and can be refined further with FFTK when needed. Always begin with FFTK. 
After the molecular dynamics are complete, continue to section B.2 for ensemble docking. 
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B.3 Static and ensemble docking 
The following discussion is regards to performing molecular docking in AutoDock Vina.3 
Protein modifications do not require PSFGEN patching if molecular dynamics are not being 
performed. Draw the modification using another program (e.g., Avogadro, Chimera),5,6 minimize 
with an appropriate forcefield, and save as a pdb file. This can be used directly for molecular 
docking experiments. Analysis is performed by docking the ligand of interest into each simulation 
trajectory pdb file. This can also be used for rigid docking (without molecular dynamic), although 
this would not enable docking into transient or cryptic pockets. This can be scripted or performed 
manually in AutoDockTools.  
Docking requires the following: simulation trajectory or protein structure, the ligand 
structure (pdbqt format), and the grid box for docking. Load the structures of the protein and ligand 
and alter any flexible residues using the embedded tools. For example, it is possible to enable or 
prevent bonds from rotating during docking (e.g., maintaining planarity in aromatic compounds). 
Initially, the simulation data will be a pdb file and it must be converted to a pdbqt file for docking. 
This can be achieved by loading into AutoDockTools, which initiates the conversion. To save it in 
the pdbqt format via Output, use the file and save as functions. Alternatively, this can be scripted. 
This file contains the coordinates for the atoms and the ligand name (typically included as UNK). 
If the docking experiments are to be scripted, it is necessary to change the name (either manually 
or with scripting).  
Next, it is necessary to define the area for docking (the grid box).  If simulations were 
performed, it is recommended to overlay the first and last pose to ensure proper orientation of the 
grid box for visualization (all poses should be aligned prior to loading in AutoDock tools). Grid 
box is prepared in Grid using the Grid Box tool. This allows the user to define the cartesian 
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coordinates for the box and the spacing in angstroms. Grid spacing of 1 angstrom is typically used 
as a starting point (decreasing will increase the computational cost with 1 being around the 
atomistic resolution). Exhaustiveness is defined as the maximum number of poses into each pdb 
file (typically 40). If you have a large docking box, use a small exhaustiveness (inversely related).  
After setting up the AutoDock experiment, a conf file will be generated for each pose and 
will contain the files for the ligand and receptor, the grid box information, exhaustiveness, number 
of modes, energy range and outputs for the pdbqt and log files. This can then be run and analyzed 
directly in the software, with the user option of how many CPUs to allocate. These can be 
submitted using a script (high-throughput) or directly performed in AutoDockTools (low-
throughput).  
 
If scripting, use: 
for i in (1..totalnumber)  
echo “Currently performing docking dock.$(i).conf”  
sourceforvina --config configurationfilename$(i).conf –cpu cpunumber 
done 
 
To use it without a script, only use the following when in the Vina location of the computer: 
sourceforvina --config configurationfilename$(number).conf –cpu cpunumber 
 
If you use the GUI for AutoDockTools, it is possible to output a configuration file after 
setting up the docking parameters, which can then be applied to all of the poses. After running the 
docking experiment, the data will be exported as log and pdbqt files. Analysis of the log file 
provides the affinity score (kcal/mol) and the distance RMSD from best pose (lower bound and 
upper bound). Structural data will be saved as pdbqt files for analysis in VMD. Note that several 
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issues can arise when opening this file type in VMD. It is recommended to convert to the pdb 
format prior to visualization. This can be generated by deleting the last two columns of the atom 
coordinate (corresponding to the qt). Load the protein frames onto the ligand structure using VMD. 
Assess the protein-ligand interactions by merging the pdb structures and visualizing in VMD. 
Important considerations include the frequency of docking at the particular site and the calculated 
affinity (docking score). Clustering provides a visual for the docking locations based on docking 
score (typically use RMSD-based clustering with the VMD command “measure cluster” although 
other clustering methods are possible).  
To determine the percent poses with a certain binding energy, search the ligand.pdb files 
and sum the number of Remark Vina Results with that number or less kcal/mol (note that 0 and -
0 are different and must be accounted for in the analysis). To assess the binding pocket, define the 
interaction between the ligand the protein as specific cutoff and then quantify the number of 
possess at each site; this can be done by measuring the distance from the center of mass of the 
desired receptor region to the center of mass of the docked ligand. When performing static docking, 
you can run the experiment several times or have a high exhaustiveness to increase sampling (will 
not show transient pockets). 
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APPENDIX C: CHAPTER 3 SUPPLMENTAL FIGURES, TABLES, AND DETAILED 
SYNTHETIC PROCEDURES5 
 
Table C.1: Photophysical characterization of APNO in chloroform. Fluorescent quantum yield measured relative to 
an indocyanine green standard. 
 
APNO 
λmax 
(nm) 
ε 
(M-1cm-1) Φ 
1 720 4.70 × 104 0.02 
2 735 8.70 × 104 0.0071 
3 684 3.50 × 104 0.0024 
4 755 6.80 × 104 0.0008 
5 755 3.43 × 104 0.0003 
 
 
 
 
 
 
 
5Portions of this chapter are reprinted or adapted with permissions from the following publications: (1) Reinhardt, C. 
J.; Zhou, E. Y.; Jorgensen, M. D.; Partipilo, G.; Chan, J. A Ratiometric Acoustogenic Probe for In Vivo Imaging of 
Endogenous Nitric Oxide. J. Am. Chem. Soc. 2018, 140, 1011–1018.11 Copyright © 2018 American Chemical 
Society. (2) Reinhardt, C. J.; Xu, R.; Chan, J. Nitric Oxide Imaging in Cancer Enabled by Steric Relaxation of a 
Photoacoustic Probe Platform. Chem. Sci. 2020, 11, 1587–1592.12 Copyright © 2020 Royal Society of Chemistry. 
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Figure C.1: UV-vis absorbance profiles for (a) APNO-1, (b) APNO-2, (c) APNO-4 (2 μM) in ethanolic 20 mM 
potassium phosphate buffer (pH 7.4, 50 % v/v). 
 
 
Figure C.2: PA spectra (a) APNO-1, (b) APNO-2 and their corresponding products (10 μM) in ethanolic 20 mM 
potassium phosphate buffer (pH 7.4, 50 % v/v). Data represented as mean ± standard deviation (n = 3). 
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Figure C.3: APNO (2 μM) pH profile in ethanolic 20 mM Britton-Robinson buffer (50 % v/v).1,2  
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Figure C.4: Effect of surfactant concentration on (a-b) APNO-4 and (c-d) APNO-5 aggregation/nanoparticle 
formation. UV-vis spectra were recorded of dye solutions (2 μM) in variable (a, c) Cremophor EL (CrEL) and (b, d) 
sodium dodecyl sulfate (SDS) solutions of phosphate buffer saline solution (pH 7.4).  
 
 
Table C.2: Tabulation of calculated partition coefficients (clogP) for APNO and tAPNO. Structures were draw in 
Avagadro3 and ChemDraw (version 15.0) for ALOGPS4 and ChemDraw predictions (Chemical Properties Tool), 
respectively. 
 
APNO ALOGPS ChemDraw tAPNO ALOGPS ChemDraw 
1 4.88 7 1 6.68 8.32 
2 5.05 7.53 2 7.38 8.38 
3 5.07 7.53 3 5.41 8.34 
4 7.6 8.66 4 7.26 8.66 
5 3.8 3.95 5 3.77 3.96 
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Figure C.5: Selectivity studies for (a) APNO-1, (b) ANPO-2, and (c) APNO-3. 2 µM dye was treated with excess 
(100 equiv) reactive metal (red), carbonyl (green), oxygen (blue), or nitrogen (purple) species in ethanolic 20 mM 
potassium phosphate buffer (pH 7.4, 50% v/v). Fluorescence turn-on was determined after 1 h incubation 37 °C. 
Data represented as mean ± standard deviation (n = 3). 
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Figure C.6: (a) Stability of APNO-5 (2 mM) in DMSO stock under ambient light and at room temperature. 
Measurements were acquired by preparing 2 μM solutions of the sample in ethanolic 20 mM potassium phosphate 
buffer (pH 7.4, 50 % v/v). (b) Stability of of APNO-5 (2 μM) in 0.1 % CrEL phosphate buffer saline (pH 7.4, v/v) at 
37 °C as measured by the maximal absorbance. (c) UV-vis spectra of APNO-5 (2 μM) in 0.1 % CrEL phosphate 
buffer saline (pH 7.4, v/v) at 37 °C. (d) Photostability of APNO-5 (red) and tAPNO-5 (blue) in 0.1 % CrEL 
phosphate buffer saline (pH 7.4, v/v). Data represented as mean ± standard deviation (n = 3). 
 
 
Figure C.7: APNO-5 (1 μM, black; 5 μM, red) biocompatibility according to (a) trypan blue dye exclusion assay 
and (b) MTT cell viability assay in RAW 264.7 macrophage cells. Data represented as mean ± standard deviation (n 
= 3). 
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Figure C.8: Colocalization studies of APNO-5 with (a) ER-Tracker™ Green, (b) LysoTracker® Green DND-26, 
and (c) MitoTracker® Green FM in RAW 264.7 macrophage cells. Pearson coefficients were calculated for as 0.6, 
0.8, and 0.7, respectively. 
 
 163 
 
Figure C.9: (a) Time dependent UV-vis absorbance profile of APNO-5 (50 μM) in saline with rat liver microsomes 
(10 μL). (b) Ratio of absorbance at 680 nm and 770 nm for APNO-5 (50 μM) either in the presence or absence of rat 
liver microsomes (10 μL) as a function of time. (c) Time dependent, normalized PA spectrum of APNO-5 (68 
μg/kg) following s.c. injection into the flank of a mouse. (d) Ratio of PAI680/PAI770 for APNO-5 (68 μg/kg) 
following s.c. injection into the flank of the mouse. Note that all in vitro experiments were incubated at 37 °C 
throughout the experiment and the mouse was allowed to wake up in between in vivo time points. Time points are 0 
(black), 30 (red), 60 (orange), and 120 (green) min for a/c. 
 
 
Figure C.10: In vivo PA spectra of mice treated with LPS (4 mg/kg) or saline (equal volume) both in the presence 
and absence of APNO-5 (68 μg/kg). Contrast-free images were acquired 9 h after the administration of LPS or 
saline. APNO-5 spectra were acquired 5 h after the administration of dye (9 h after the administration of LPS or 
saline). Note that background signals were comparable for all of the mice before treatment. 
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Figure C.11: (a) Chromatograph and (b) HR-MS of tAPNO-1 ESI-LC/MS analysis. tAPNO-1 was prepared by 
treating APNO-1 (20 μM) in ethanolic water (50 % v/v) with NO (g). Products were separated on a CORTECSTM 
UPLC C18 column (1.6 μm, 2.1 by 50 mm) with a linear gradient using a combination of solvent A (95% water, 5% 
acetonitrile, 0.1% TFA) and solvent B (95% acetonitrile, 5% water, 0.1% TFA) at a flow rate of 0.4 mL/minute. 
Linear gradient protocol in minutes: 0–1 (80% A); 1––8 (100% B); 8–8.1 (80% A); and 8.1–12 (80% A). Identified 
tAPNO-1 (calc’d [M]+H 569.2073, found 569.2078 Da). 
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Figure C.12: (a) Chromatograph and (b) HR-MS of tAPNO-2 ESI-LC/MS analysis. tAPNO-2 was prepared by 
treating APNO-2 (20 μM) in ethanolic water (50 % v/v) with NO (g). Products were separated on a CORTECSTM 
UPLC C18 column (1.6 μm, 2.1 by 50 mm) with a linear gradient using a combination of solvent A (95% water, 5% 
acetonitrile, 0.1% TFA) and solvent B (95% acetonitrile, 5% water, 0.1% TFA) at a flow rate of 0.4 mL/minute. 
Linear gradient protocol in minutes: 0–1 (80% A); 1––8 (100% B); 8–8.1 (80% A); and 8.1–12 (80% A). Identified 
tAPNO-2 (calc’d [M]+H 544.2008, found 544.2014 Da). 
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Figure C.13: (a) Chromatograph and (b) HR-MS of tAPNO-4 ESI-LC/MS analysis. tAPNO-4 was prepared by 
treating APNO-4 (20 μM) in ethanolic water (50 % v/v) with NO (g). Products were separated on a CORTECSTM 
UPLC C18 column (1.6 μm, 2.1 by 50 mm) with a linear gradient using a combination of solvent A (95% water, 5% 
acetonitrile, 0.1% TFA) and solvent B (95% acetonitrile, 5% water, 0.1% TFA) at a flow rate of 0.4 mL/minute. 
Linear gradient protocol in minutes: 0–1 (80% A); 1––8 (100% B); 8–8.1 (80% A); and 8.1–12 (80% A). Identified 
tAPNO-4 (calc’d [M]+H 616.2332, found 616.2338 Da). 
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Figure C.14: (a) Chromatograph and (b) HR-MS of tAPNO-5 ESI-LC/MS analysis. tAPNO-5 was prepared by 
treating APNO-5 (20 μM) in ethanolic water (50 % v/v) with NO (g). Products were separated on a CORTECSTM 
UPLC C18 column (1.6 μm, 2.1 by 50 mm) with a linear gradient using a combination of solvent A (95% water, 5% 
acetonitrile, 0.1% TFA) and solvent B (95% acetonitrile, 5% water, 0.1% TFA) at a flow rate of 0.4 mL/minute. 
Linear gradient protocol in minutes: 0–1 (80% A); 1––8 (100% B); 8–8.1 (80% A); and 8.1–12 (80% A). Identified 
tAPNO-5 (calc’d [M]+ 900.4180, found 900.4167 Da). 
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Figure C.15: Reactions between (a) TG-2 and (b) TG3 with DNIC under anoxic (black), anoxic then air (blue), or 
normoxic (red) conditions. Dye (1 μM) was added to mixtures (500 μM, 1:1:4, Fe:NO:RSH pre-incubated open for 5 
min) in 50 mM HEPES (pH 7.4) and the solution was incubated at room temperature for 1 h. Fluorescence is 
normalized to a dye control. 
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Figure C.16: (a-c) Representative structure and definition of planes for the aza-BODIPY and SR-aza-BODIPY 
platforms. Planes corresponding to the phenyl (Ph), thiophene (Thio), and aza-BODIPY core are defined by all 
heavy atoms in the plane. Dihedral angle is calculated between each ring and the core and reported as the average of 
the absolute values. (d) Tabulated average dihedral angles from reported X-ray crystallographic data (names defined 
as top-left/top-right: bottom-left/bottom-right: Ph/Ph:Ph/Ph, Ph/Ph:Thio-Br/Thio-Br, Ph/Ph:Thio/Thio, and 
Thio/Thio:Thio/Thio),5,6 APNO-5, and SR-APNO series after geometry optimization using B3LYP in implicit 
methanol with the corresponding time-dependent DFT calculation of absorption maxima with CAM B3LYP in 
implicit methanol. (e) Linear regressions for measured calculated absorbance maximum versus dihedral angle.  Note 
that poor correlation between the bottom dihedral angles and calculated absorption maxima was because this was 
not sampled with the structures. 
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Figure C.17: UV-Vis (2 µM) and PA spectra (10 µM) for (a-b) SR-APNO-1 and (c-d) SR-APNO-2 in ethanolic 20 
mM potassium phosphate buffer (pH 7.4, 50% v/v).  The probe and N-nitrosated products are depicted as red and 
blue, respectively. Data is reported as the mean ± standard deviation (n = 3).  
 
 
Figure C.18: The effect of pH on SR-APNO (2.5 µM) (a) absorbance (350–950 nm) and (b) fluorescence 
(excitation at 650 nm, emission collected from 660-950 nm) properties in ethanolic 20 mM Britton-Robinson buffer 
(50% v/v).1,7 Relative absorbance and fluorescence are calculated relative to the absorption maxima and sum 
fluorescence intensity at pH 7.4. SR-APNO-1, SR-APNO-2, and SR-APNO-3 are depicted as triangles, squares, and 
circles, respectively. No changes were observed in either the absorption or emission spectra. 
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Figure C.19: LC-HRMS analysis of the crude reaction (a) before and (b) after SR-APNO-1 (167 μM), and 
methanolic NO (~10 mM, ~60 equiv) in anhydrous methanol. The reaction was initiated with the addition of 
saturated methanolic nitric oxide and then allowed to react at room temperature for less than 5 minutes. The solution 
was purged under high vacuum and then concentrated under vacuum before analysis. Products were separated on a 
CORTECSTM UPLC C18 column (1.6 μm, 2.1 by 50 mm) with a linear gradient using a combination of solvent A 
(95% water, 5% acetonitrile, 0.1% TFA) and solvent B (95% acetonitrile, 5% water, 0.1% TFA) at a flow rate of 0.4 
mL/minute. Linear gradient protocol in minutes: 0–1 (80% A); 1–4 (40% A); 4–8 (100% B); 8–8.1 (80% A); and 
8.1–12 (80% A). LC was monitored using a PDA detector between 350 and 500 nm (left). Identified SR-APNO-1 
(calc’d [M]+ 877.3837, found 877.3893 Da), and t-SR-APNO-1 (calc’d [M]+ 906.3744, found 906.3820 Da). N-
nitrosated product was corroborated using ESI-HRMS t-SR-APNO-1 (calc’d [M]+ 906.3744, found 906.3757 Da). 
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Figure C.20: LC-HRMS analysis of the crude reaction (a) before and (b) after SR-APNO-2 (167 μM), and 
methanolic NO (~10 mM, ~60 equiv) in anhydrous methanol. The reaction was initiated with the addition of 
saturated methanolic nitric oxide and then allowed to react at room temperature for less than 5 minutes. The solution 
was purged under high vacuum and then concentrated under vacuum before analysis. Products were separated on a 
CORTECSTM UPLC C18 column (1.6 μm, 2.1 by 50 mm) with a linear gradient using a combination of solvent A 
(95% water, 5% acetonitrile, 0.1% TFA) and solvent B (95% acetonitrile, 5% water, 0.1% TFA) at a flow rate of 0.4 
mL/minute. Linear gradient protocol in minutes: 0–1 (80% A); 1–4 (40% A); 4–8 (100% B); 8–8.1 (80% A); and 
8.1–12 (80% A). LC was monitored using a PDA detector between 350 and 500 nm (left). Identified SR-APNO-2 
(calc’d [M]+ 877.3845, found 877.3853), t-SR-APNO-2 calc’d [M]+ 906.3744, found 906.3760 Da). N-nitrosated 
product was corroborated using ESI-HRMS t-SR-APNO-2 (calc’d [M]+ 906.3744, found 906.3762 Da). 
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Figure C.21: LC-HRMS analysis of the crude reaction (a) before and (b) after SR-APNO-3 (167 μM), and 
methanolic NO (~10 mM, ~60 equiv) in anhydrous methanol. The reaction was initiated with the addition of 
saturated methanolic nitric oxide and then allowed to react at room temperature for less than 5 minutes. The solution 
was purged under high vacuum and then concentrated under vacuum before analysis. Products were separated on a 
CORTECSTM UPLC C18 column (1.6 μm, 2.1 by 50 mm) with a linear gradient using a combination of solvent A 
(95% water, 5% acetonitrile, 0.1% TFA) and solvent B (95% acetonitrile, 5% water, 0.1% TFA) at a flow rate of 0.4 
mL/minute. Linear gradient protocol in minutes: 0–1 (80% A); 1–4 (40% A); 4–8 (100% B); 8–8.1 (80% A); and 
8.1–12 (80% A). LC was monitored using a PDA detector between 350 and 500 nm (left). Identified SR-APNO-3 
(calc’d [M]+ 883.3047, found 883.3458 Da), t-SR-APNO-3 (calc’d [M]+ 912.3308, found 912.3320 Da). N-
nitrosated product was corroborated using ESI-HRMS t-SR-APNO-3 (calc’d [M]+ 912.3308, 912.3321 found Da). 
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Figure C.22: Effect of ethanol content in 20 mM potassium phosphate buffer (pH 7.4, 0.1% CrEL v/v) on the (a) 
ratiometric absorbance response and (b) UV-vis spectra. Reactions were performed with SR-APNO-3 (4 µM) and 
DEA-NONOate (1.33 mM, 2 mM NO) at room temperature for 20 min (approximately 1.25 half-lives). (c) UV-vis 
spectra and (d) ratiometric absorbance responses for dilution experiments to investigate the source of ethanol effects. 
Reactions were performed with SR-APNO-3 (4 µM) and DEA-NONOate (1.33 mM in 10 mM KOH, 2 mM NO) or 
control (equal volume 10 mM KOH) in 20 mM potassium phosphate buffer (pH 7.4, 0.1% CrEL v/v) at room 
temperature for 1 h and then diluted in additional buffer (KPi) or ethanol (EtOH).  
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Figure C.23: (a) Fluorescence and (b) UV-vis analysis of SR-APNO-3’s (4 µM) selectivity against a panel of 
reactive metals (red), carbonyl (green), oxygen (blue), thiol (yellow) and nitrogen (purple) species (800 µM, 200 
equiv unless noted otherwise) in ethanolic 20 mM potassium phosphate buffer (pH 7.4, 50% v/v) or ethanolic 20 
mM HEPES buffer (pH 7.4, 50% v/v, Fe(II) only). Minor fluorescence enhancement (less than 15% of NO 
response) was observed after treatment with HNO. This, along with the lack of change in UV-vis, is consistent with 
the small quantities of NO that are released from Angeli’s salt (the nitroxyl donor).8 Note that the slight response 
from peroxynitrite is only observed in the UV-vis due to dye decomposition after treatment with minor reactivity 
from residual isoamyl nitrite. Data is reported as the mean ± standard deviation (n = 3). 
 
 
Figure C.24: APNO or SR-APNO and corresponding N-nitrosated product (25 µM) photostability at their PA 
maximum in ethanolic 20 mM potassium phosphate buffer (pH 7.4, 50% v/v) using the OPO laser used in the Nexus 
128+ PA tomographer. Samples were irradiated discontinuously, and measurements were acquired in continuous 
mode with a 6 s rotation time. APNO-5, SR-APNO-1, SR-APNO-2, and SR-APNO-3 are depicted as red, cayenne, 
light purple, and purple, respectively. Data is reported as the mean ± standard deviation (n = 3). 
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Figure C.25: MTT toxicity assay for SR-APNO-3 in 4T1 mouse mammary carcinoma cells (black, 24 h) and RAW 
264.7 macrophages (grey, 8 h). Data is reported as the mean ± standard deviation (n = 4). 
 
 
Figure C.26: (a) PA imaging of 4T1 murine breast cancer cells stained with SR-APNO-3 (15 µM) for 1 h, washed 
with PBS, and then treated with DEA-NONOate for 2 h (1 or 5 mM). Representatives images corresponding to the 
N-nitroso product (blue, 690 nm, top), SR-APNO-3 (red, 790 nm, middle), and the image fusion (blue/red, 690/790 
nm, bottom). (b) Quantified ratiometric PA response for the cell pellets. Statistical analysis was performed using a 
one-way ANOVA and Tukey’s multiple comparisons (α = 0.05). *, p < 0.05. Data is reported as the mean ± standard 
deviation (n = 3). Scale bar represents 4.0 mm. 
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Figure C.27: PA imaging of LPS-induced inflammation (4 mg/kg, i.m.) in BALB/c mice with APNO-5 (top) and 
SR-APNO-3 (bottom). After a 4 h induction period, APNO-5 or SR-APNO-3 (50 µM, 25 µL, i.m., final 
concentration of 15% DMF v/v) was administered. Inhibition was performed using L-NMMA (35 mM). 
Representatives images correspond to saline- (left), LPS- (middle) and LPS and L-NMMA-treated mice. The N-
nitroso product (blue, 690 nm) and SR-APNO-3 (red, 790 nm), are shown in a merged image (blue/red, 690/790 
nm). Scale bar represents 2.0 mm. 
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Figure C.28: PA imaging of cancer-derived NO in a 4T1 heterotopic allograft model of breast cancer. SR-APNO-3 
(50 µM, 25 µL, final concentration of 15% DMF v/v) was administered either subcutaneously or intratumorally. 
Inhibition was performed using L-NMMA (35 mM). Representatives images correspond to the N-nitroso product 
(blue, 690 nm, top), SR-APNO-3 (red, 790 nm, middle), and merged images (blue/red, 690/790 nm, bottom). Scale 
bar represents 2.0 mm. 
 
 
Figure C.29: PA imaging of 4T1 tumors following intratumoral treatment with 35 mM L-NMMA in sterile saline 
with 15% DMF. No change in signal was observed in the absence of SR-APNO-3. Data is reported as the mean ± 
standard deviation (n = 3). 
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Figure C.30: CyAPNO and tCyAPNO (5 μM) pH profile in 40 mM Britton-Robinson buffer1,2 containing 0.1% 
CrEL (v/v). Samples were allowed to solubilize for 2 h prior to acquiring spectra. CyAPNO and tCyAPNO are 
plotted as blue and red, respectively. Data is reported as the mean ± standard deviation (n = 3). pKa = 8.5 for both 
compounds. 
 
 
Figure C.31: (a) CyAPNO and (b) tCyAPNO (5 μM) stability under ambient conditions. Stability was assessed in 
DMSO (square), diluted human plasma (40% v/v, circle), diluted human serum (40% v/v, triangle), and 50 mM 
HEPES buffer (pH = 7.4) containing 0.1% CrEL (v/v, open circle). Data is reported as the mean ± standard 
deviation (n = 3). 
 
 
C.1 Detailed synthetic procedures 
 
Scheme C.1: Synthesis of compound 3.2. 
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[(E)-1-(4-methoxyphenyl)-3-phenylprop-2-en-1-one] (3.1): To a solution of 
4’methoxyacetophenone (10 g, 66.9 mmol, 1 equiv) and benzaldehyde (6.83 mL, 61.9 mmol, 0.9 
equiv), in EtOH (130 mL) at 0 °C was added a 10 M solution of aq. KOH (20.7 mL, 207 mmol, 
3.1 equiv). The reaction was allowed to warm to room temperature and stir for 1.5 h. The 
resulting white precipitate was collected via filtration to afford the product (13.9 g, 58.33 mmol, 
87% yield). Rf = 0.42 (3:14 v/v EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 8.07 – 8.02 (m, 
2H), 7.81 (d, J = 15.7 Hz, 1H), 7.67 – 7.62 (m, 2H), 7.55 (d, J = 15.6 Hz, 1H), 7.41 (tdd, J = 4.8, 
3.5, 1.4 Hz, 3H), 7.01 – 6.96 (m, 2H), 3.89 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 188.83, 
163.56, 144.08, 135.23, 131.24, 130.95, 130.45, 129.05, 128.49, 122.03, 113.98, 55.63. 
[1-(4-methoxyphenyl)-4-nitro-3-phenylbutan-1-one] (3.2): To a suspension of 3.1 (4.8 g, 20.1 
mmol, 1 equiv) and nitromethane (13.6 mL, 254 mmol, 13 equiv) in EtOH (35 mL) was added a 
10 M solution of aq. KOH (0.34 mL, 3.4 mmol, 0.2 equiv) and the was stirred at room 
temperature for 3 h.  The reaction was monitored via TLC. When complete, the reaction was 
quenched with sat. NH4Cl and extracted with EtOAc (3×). The combined organic fractions were 
dried over Na2SO4. The compound was concentrated to afford a white solid (5.48 g, 18.3 mmol, 
91% yield), which was used without further purification. Note that the compound decomposes on 
silica. Rf = 0.37 (1:3 v/v EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) 7.96 – 7.89 (m, 2H), 
7.40 – 7.33 (m, 2H), 7.33 – 7.26 (m, 3H), 6.99 – 6.91 (m, 2H), 4.86 (dd, J = 12.5, 6.4 Hz, 1H), 
4.71 (dd, J = 12.5, 8.1 Hz, 1H), 4.24 (tt, J = 7.9, 6.4 Hz, 1H), 3.89 (s, 3H), 3.44 (dd, J = 17.4, 6.3 
Hz, 1H), 3.39 (dd, J = 17.4, 7.7 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 195.43, 163.97, 139.42, 
130.49, 129.61, 129.18, 127.95, 127.59, 114.02, 79.76, 55.66, 41.31, 39.58. 
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Scheme C.2: Synthesis of APNO-1. 
 
4'-Amino-3'-nitroacetophenone (3.3): A solution of 4'-fluoro-3'-nitroacetophenone (11.5 g, 
63.0 mmol, 1.0 equiv) and 7 M solution of ammonia in methanol (90.0 mL, 15.0 equiv) in 1,4-
dioxane (85.0 mL) was stirred under nitrogen in a sealed pressure flask at 100 °C for 2 h. 
Reaction progress was monitored by TLC. When judged to be complete, the reaction was cooled 
to room temperature and sparged with nitrogen to remove excess ammonia. The solution was 
concentrated to afford a solid, suspended in sat. NaHCO3, and extracted with EtOAc (3×). The 
combined organic fractions were dried over Na2SO4, filtered, and concentrated to afford an 
orange solid (11.4 g, 63.0 mmol, 100 % yield), which was used without purification. Rf = 0.17 
(1:3 v/v EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 8.74 (d, J = 2.1 Hz, 1H), 8.00 (dd, J = 
8.8, 2.0 Hz, 1H), 6.86 (d, J = 8.8 Hz, 1H), 6.67 – 6.39 (bs, 2H), 2.57 (s, 3H). 13C NMR (125 
MHz, CDCl3) δ 195.11, 147.73, 134.65, 128.47, 126.84, 119.00, 26.15. 
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3',4'-Diaminoacetophenone (3.4): A suspension of 3.3 (2.5 g, 13.6 mmol, 1 equiv) and 10 wt. 
% Pd/C (0.25 g, 10 % w/w) in MeOH (70.0 mL) was stirred under a H2 (g) atmosphere 
maintained using a balloon at room temperature for 12 h. When the reaction was judged to be 
complete by TLC, it was filtered through a pad of Celite and washed with MeOH. The filtrate 
was concentrated and purified via silica gel column chromatography (1:9 v/v MeOH/CH2Cl2 
with 0.1 % TEA) to afford the product as a brown solid (1.26 g, 8.4 mmol, 62% yield). Rf = 0.45 
(3:97 v/v MeOH/CH2Cl2 with 0.1 % TEA). 1H NMR (500 MHz, MeOD) δ 7.36 – 7.31 (m, 2H), 
6.68 – 6.61 (m, 1H), 2.46 (s, 3H). 13C NMR (125 MHz, MeOD) δ 199.74, 143.70, 134.25, 
128.36, 123.75, 117.30, 114.66, 25.97. 
Di-tert-butyl (4-acetyl-1,2-phenylene)dicarbamate (3.5): A suspension of 3.4 (1.4 g, 9 mmol, 
1 equiv), K2CO3 (7.8 g, 36.0 mmol, 4 equiv), and di-tert-butyl-dicarbonate (3.8 g, 27.0 mmol, 3 
equiv) in EtOH (9 mL) was stirred at 45 °C for 18 h. When judged to be complete by TLC the 
reaction was quenched with sat. NaHCO3 and extracted with EtOAc (3×). The combined organic 
fractions were concentrated and purified via silica gel column chromatography (2:3 v/v 
EtOAc/Hexanes) to afford a white hygroscopic foam (3.2 g, 9.0 mmol, 100% yield). Rf = 0.20 
(3:17 v/v EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 7.92 (s, 1H), 7.83 (d, J = 8.6 Hz, 1H), 
7.73 (dd, J = 8.5, 2.0 Hz, 1H), 7.20 (bs, 1H), 6.67 (bs, 1H), 2.55 (s, 3H), 1.513 (s, 9H), 1.509 (s, 
9H). 13C NMR (125 MHz, CDCl3) δ 196.90, 154.21, 152.99, 136.57, 132.97, 128.04, 126.67, 
125.59, 121.84, 81.63, 28.36, 28.34, 26.59. 
Di-tert-butyl (4-cinnamoyl-1,2-phenylene) dicarbamate (3.6). A solution of 3.5 (2.7 g, 7.6 
mmol, 1 equiv) and benzaldehyde (0.78 mL, 7.6 mmol, 1 equiv) in EtOH (25.0 mL) was cooled 
to 0 °C in an ice bath and treated with a 10 M aq. solution of KOH (2.3 mL, 22.8 mmol, 3 
equiv). The reaction was allowed to stand in the refrigerator at 4 °C for 20 h. The reaction was 
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quenched with sat. NH4Cl and extracted with EtOAc (3×). The combined organic fractions were 
dried over Na2SO4, concentrated, and purified via silica gel column chromatography (3:17 v/v 
EtOAc/Hexanes) to afford an off-white solid (2.3 g, 5.3 mmol, 68% yield). Rf = 0.55 (3:7 v/v 
EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 7.95 (s, 1H), 7.93 – 7.86 (m, 1H), 7.82 (dd, J = 
8.5, 2.1 Hz, 1H), 7.78 (d, J = 15.7 Hz, 1H), 7.66 – 7.59 (m, 2H), 7.48 (d, J = 15.7 Hz, 1H), 7.40 
(dd, J = 4.9, 1.9 Hz, 3H), 7.33 (bs, 1H), 6.78 (bs, 1H), 1.524 (s, 9H), 1.520 (s, 9H). 13C NMR δ 
188.87, 154.30, 153.00, 144.81, 134.99, 133.79, 130.60, 129.03, 128.61, 126.89, 126.02, 125.99, 
125.93, 121.75, 81.62, 81.39, 77.36, 28.36, 28.34. 
Di-tert-butyl (4-(4-nitro-3-phenylbutanoyl)-1,2-phenylene)dicarbamate (3.7). A solution of 
3.6 (2.2 g, 5.0 mmol, 1 equiv) and nitromethane (0.6 g, 10.1 mmol, 2 equiv) in EtOH (10.0 mL) 
was cooled to 0 °C in an ice bath and treated with a 10 M aq. solution of KOH (0.1 mL, 1.0 
mmol, 0.2 equiv). The reaction was stirred at 40 °C for 20 h, diluted with brine, and extracted 
with EtOAc (3×). The combined organic fractions were dried over Na2SO4, concentrated, and 
purified via silica gel column chromatography (1:3 v/v EtOAc/Hexanes) to afford an off-white 
solid (1.7 g, 3.4 mmol, 67% yield). Rf = 0.38 (1:3 v/v EtOAc/Hexanes). 1H NMR (500 MHz, 
CDCl3) δ 7.86 (s, 1H), 7.84 – 7.79 (m, 1H), 7.66 (dd, J = 8.4, 2.1 Hz, 1H), 7.40 – 7.22 (m, 6H), 
6.72 (s, 1H), 4.84 (dd, J = 12.6, 6.4 Hz, 1H), 4.70 (dd, J = 12.6, 8.3 Hz, 1H), 4.22 (quint, J = 7.0 
Hz, 1H), 3.39 (qd, J = 17.6, 7.0 Hz, 2H), 1.55 (s, 9H), 1.54 (s, 9H).13C NMR (125 MHz, CDCl3) 
δ 195.46, 154.17, 152.92, 139.28, 137.02, 132.02, 129.12, 128.32, 128.12, 127.91, 127.59, 
126.23, 125.39, 125.27, 121.81, 81.71, 81.58, 79.62, 41.44, 39.40, 28.33, 28.31. 
tert-Butyl (Z)-(2-((tert-butoxycarbonyl)amino)-4-(5-((5-(4-methoxyphenyl)-3-phenyl-2H-
pyrrol-2-ylidene)amino)-4-phenyl-1H-pyrrol-2-yl)phenyl)carbamate (3.8): A solution of 3.7 
(0.4 g, 0.8 mmol, 1 equiv) and 3.2 (0.5 g, 1.6 mmol, 2 equiv) in n-butanol (16.0 mL) was heated 
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to 90 °C to ensure all reactants were dissolved. NH4OAc (1.0 g, 12.3 mmol, 15 equiv) was added 
and the reaction was stirred at 90 °C for 8 h. The reaction was concentrated under reduced 
pressure, suspended in brine, and extracted with CH2Cl2 (3×). The combined organic layers were 
dried over Na2SO4, concentrated, and purified via silica gel column chromatography (1:1 v/v 
CH2Cl2/Hexanes to CH2Cl2, step gradient). All fractions containing product were pooled and 
concentrated to afford a dark blue solid (0.05 g, 0.075 mmol, 9.2% yield), which was used 
without further purification. Rf = 0.57 (3:7 v/v EtOAc/Hexanes). 
APNO-1: A solution of 3.8 (0.05 g, 0.75 mmol, 1 equiv) and N,N-diisopropylethylamine (0.1 g, 
0.8 mmol, 10 equiv) in anhydrous CH2Cl2 was cooled to 0 °C in an ice bath and treated dropwise 
with boron trifluoride diethyl etherate (0.13 mL, 1.15 mmol, 15 equiv). The reaction was stirred 
at room temperature for 18 h under a nitrogen atmosphere, quenched with H2O (5.0 mL), and 
extracted with CH2Cl2 (3×). The combined organic layers were concentrated and purified via 
silica gel column chromatography (1:99 v/v MeOH/CH2Cl2 with 0.1 % TEA) to afford the 
product as a green solid (6.6 mg, 0.01 mmol, 16% yield). Rf = 0.35 (1:99 v/v MeOH/CH2Cl2). 1H 
NMR (500 MHz, CDCl3) δ 8.10 – 8.02 (m, 7H), 7.65 (d, J = 2.1 Hz, 1H), 7.61 (dd, J = 8.3, 2.0 
Hz, 1H), 7.48 – 7.37 (m, 7H), 7.10 (d, J = 1.0 Hz, 1H), 7.03 – 6.99 (m, 2H), 6.98 (s, 1H), 6.76 (d, 
J = 8.3 Hz, 1H), 3.89 (s, 3H). 11B NMR (161 MHz, CDCl3) δ 1.16 (t, J = 32.8 Hz). 19F NMR 
(471 MHz, CDCl3) δ -131.75 (dd, J = 64.1, 32.1 Hz). HR-MS (ESI, TOF) calc’d for [M+H]+ 
558.2277, found 558.2268.  
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Scheme C.3: Synthesis of APNO-2. 
 
Benzo[d]oxazol-2(3H)-one (3.9): A solution of 2-aminophenol (10.0 g, 92.0 mmol, 1 equiv) and 
di(1H-imidazol-1-yl)methanone (CDI) (37.0 g, 228.0 mmol, 2.5 equiv) in anhydrous MeCN 
(250.0  mL) was stirred at 70 °C for 4 h. When judged to be complete by TLC, the reaction was 
concentrated and suspended in EtOAc. Excess CDI was quenched with 2 M aq. HCl and the 
organic layer was washed sequentially with a 2 M solution of aq. HCl (3×), sat. NaHCO3, and 
H2O (2×). The organic fraction was dried over Na2SO4 and concentrated to afford an orange 
solid (10.5 g, 78.0 mmol, 85% yield), which was used without further purification. Rf = 0.39 (3:7 
v/v EtOAc/Hexanes). 1H NMR (500 MHz, DMSO-d6) δ 11.56 (bs, 1H), 7.29 – 7.24 (m, 1H), 
7.17 – 7.11 (m, 1H), 7.10 – 7.04 (m, 2H). 13C NMR (125 MHz, DMSO-d6) δ 154.43, 143.35, 
130.40, 123.75, 121.80, 109.76, 109.48. 
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6-Acetylbenzo[d]oxazol-2(3H)-one (3.10): The product was synthesized according to 
previously reported protocols.9 A flame-dried two-neck round bottom flask was charged with 
aluminum trichloride (156 g, 1.16 mol, 10 equiv). The solid was heated to 45 °C under a nitrogen 
atmosphere and treated with dropwise addition of anhydrous DMF (26.0 mL). Compound 3.9 
(15.7 g, 116.2 mmol, 1 equiv) was added portion-wise to the slurry. Acetyl chloride (50.0 mL, 
697.0 mmol, 6 equiv) was added dropwise via addition funnel then heated to 75 °C for 2 h. The 
reaction was slowly poured into ice and the resultant precipitate was filtered and rinsed with H2O 
to afford an orange solid (15.6 g, 88.0 mmol, 76% yield), which was used without further 
purification. Rf = 0.23 (1:1 v/v EtOAc/Hexanes) 11H NMR (500 MHz, DMSO-d6) δ 12.04 (s, 
1H), 7.83, (m, 2H), 7.20 – 7.17 (m, 1H), 2.56 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 196.30, 
154.41, 143.28, 134.81, 131.21, 125.33, 109.33, 109.03, 26.60. 
tert-Butyl 6-acetyl-2-oxobenzo[d]oxazole-3(2H)-carboxylate (3.11): Di-tert-butyl-dicarbonate 
(38.5 g, 175.9 mmol, 2 equiv) was added to a solution of 3.10 (15.6 g, 88.0 mmol, 1 equiv), TEA 
(8.8 g, 88.0 mmol, 1 equiv) and DMAP (10.7 g, 88.0 mmol, 1 equiv) in THF (250.0 mL). The 
reaction was stirred at room temperature for 1 h, poured into sat. NaHCO3, and extracted with 
EtOAc (3×). The combined organic fractions were dried over Na2SO4, concentrated under 
reduced pressure and purified via silica gel column chromatography (1:1 v/v EtOAc/Hexanes) to 
afford the product as a white solid (13.9 g, 50.1 mmol, 57% yield). Rf = 0.31 (3:17 v/v 
EtOAc/Hexanes). 1H NMR (400 MHz, CDCl3) δ 7.89 – 7.84 (m, 1H), 7.80 – 7.74 (m, 2H), 2.60 
(s, 3H), 1.66 (s, 9H). 13C NMR (100 MHz, CDCl3) δ196.25, 149.20, 147.38, 141.99, 134.26, 
131.56, 125.78, 114.48, 109.74, 87.16, 28.13, 26.83. 
tert-Butyl (4-acetyl-2-hydroxyphenyl)carbamate (3.12): A suspension of 3.11 (13.9 g, 50.1 
mmol, 1 equiv) and K2CO3 (6.96 g, 50.4 mmol, 1 equiv) in MeOH (250 mL) was stirred at room 
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temperature for 9 h under a nitrogen atmosphere. The volatiles were removed under reduced 
pressure and the resulting residue was dissolved in EtOAc, treated with sat. NH4Cl, and the 
product was extracted with EtOAc (3×). The combined organic fractions were dried over 
Na2SO4, concentrated, and purified via silica gel column chromatography (2:3 v/v 
EtOAc/Hexanes) to afford an orange solid (11.1 g, 44.0 mmol, 88% yield). Rf = 0.35 (3:7 v/v 
EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 8.46 (bs, 1H), 7.84 – 7.79 (m, 1H), 7.67 (d, J = 
2.0 Hz, 1H), 7.48 (dd, J = 8.5, 1.9 Hz, 1H), 2.56 (s, 1H), 1.53 (s, 5H). 13C NMR (125 MHz, 
CDCl3) δ 198.83, 153.35, 145.42, 132.23, 132.03, 122.79, 118.28, 115.42, 81.84, 28.40, 26.55. 
tert-Butyl (4-acetyl-2-(allyloxy)phenyl)carbamate (3.13): A suspension of 3.12 (3.6 g, 14.3 
mmol, 1 equiv), allyl bromide (3.1 mL, 35.8 mmol, 2.5 equiv) and K2CO3 (3.95 g, 28.6 mmol, 2 
equiv) in anhydrous MeCN (30.0 mL) was stirred at 45 °C for 3 h. The reaction was quenched 
with H2O and extracted with EtOAc (3×). The combined organic fractions were dried over 
Na2SO4, concentrated, and purified via silica gel column chromatography (3:17 v/v 
EtOAc/Hexanes) to afford the product as a white solid (2.6 g, 9.0 mmol, 63% yield). Rf = 0.39 
(3:17 v/v EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 8.19 (d, J = 8.4 Hz, 1H), 7.55 (dd, J = 
8.4, 1.8 Hz, 1H), 7.49 (d, J = 1.8 Hz, 1H), 7.31 (bs, 1H), 6.08 (ddt, J = 17.2, 10.7, 5.5 Hz, 1H), 
5.42 (dq, J = 17.3, 1.5 Hz, 1H), 5.34 (dq, J = 10.5, 1.3 Hz, 1H), 4.66 (dt, J = 5.5, 1.5 Hz, 2H), 
2.55 (s, 3H), 1.54 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 197.04, 152.41, 146.24, 133.32, 
132.58, 131.35, 123.52, 118.75, 116.72, 109.99, 81.26, 69.75, 28.43, 26.40. 
tert-Butyl (2-(allyloxy)-4-cinnamoylphenyl)(methyl)carbamate (3.14): A 10 M aq. solution of 
KOH (0.44 mL, 4.4 mmol, 1.2 equiv) was added dropwise to a solution of 3.13 (1.1 g, 3.65 
mmol, 1 equiv) and benzaldehyde (0.41 mL, 4.0 mmol, 1.1 equiv) in EtOH (8.0 mL). After 
stirring at room temperature for 12 h, the reaction was quenched with sat. NH4Cl and extracted 
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with EtOAc (3×). The organic layers were dried over Na2SO4, concentrated, and purified via 
silica gel column chromatography (3:17 v/v EtOAc/Hexanes) to afford the product as a yellow 
solid (1.3 g, 3.43 mmol, 96% yield). Rf = 0.41 (1:9 v/v EtOAc/Hex). 1H NMR (500 MHz, 
CDCl3) δ 8.24 (d, J = 8.5 Hz, 1H), 7.79 (d, J = 15.6 Hz, 1H), 7.67 (dd, J = 8.5, 1.9 Hz, 1H), 7.65 
– 7.61 (m, 2H), 7.59 (d, J = 1.8 Hz, 1H), 7.55 (d, J = 15.6 Hz, 1H), 7.43 – 7.38 (m, 3H), 7.36 (s, 
1H), 6.09 (ddt, J = 17.3, 10.7, 5.5 Hz, 1H), 5.43 (dq, J = 17.2, 1.6 Hz, 1H), 5.34 (dq, J = 10.5, 
1.3 Hz, 1H), 4.68 (dt, J = 5.6, 1.5 Hz, 2H), 1.54 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 188.58, 
152.30, 146.39, 144.06, 135.08, 133.17, 132.53, 132.09, 130.40, 128.95, 128.45, 123.11, 121.68, 
118.70, 116.59, 110.67, 81.15, 69.68, 28.35. 
tert-Butyl (2-(allyloxy)-4-(4-nitro-3-phenylbutanoyl)phenyl)carbamate (3.15): A solution of 
3.14 (1.8 g, 4.63 mmol, 1 equiv) and nitromethane (0.5 mL, 9.26 mmol, 2 equiv) in EtOH (15 
mL) was treated with a 10 M aq. solution of KOH (0.09 mL, 0.9 mmol, 0.2 equiv). The reaction 
was stirred at room temperature for 14 h and then quenched with sat. NH4Cl. The reaction 
mixture was extracted with EtOAc (3×). The combined organic fractions were dried over 
Na2SO4, concentrated, and purified via silica gel column chromatography (3:17 v/v 
EtOAc/Hexanes) to afford the product as a yellow foam (1.4 g, 3.18 mmol, 82% yield). Rf = 0.25 
(1:9 v/v EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 8.18 (d, J = 8.5 Hz, 1H), 7.51 (dd, J = 
8.5, 1.9 Hz, 1H), 7.44 (d, J = 1.9 Hz, 1H), 7.37 – 7.27 (m, 6H), 6.07 (ddt, J = 17.3, 10.7, 5.5 Hz, 
1H), 5.41 (dq, J = 17.2, 1.5 Hz, 1H), 5.34 (dq, J = 10.5, 1.2 Hz, 1H), 4.83 (dd, J = 12.5, 6.5 Hz, 
1H), 4.70 – 4.65 (m, 1H), 4.64 (dt, J = 5.5, 1.5 Hz, 2H), 4.21 (ddd, J = 14.4, 7.9, 6.5 Hz, 1H), 
3.43 (dd, J = 17.4, 6.4 Hz, 1H), 3.35 (dd, J = 17.4, 7.6 Hz, 1H), 1.54 (s, 9H). 13C NMR (125 
MHz, CDCl3) δ 195.60, 152.34, 146.33, 139.38, 133.80, 132.45, 130.44, 129.19, 127.96, 127.59, 
122.90, 118.86, 116.72, 110.03, 81.42, 79.76, 69.78, 41.28, 39.68, 28.43. 
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1-(3-(Allyloxy)-4-aminophenyl)-4-nitro-3-phenylbutan-1-one (3.16): A solution of 3.15 (2.4 
g, 6.4 mmol, 1 equiv) in CH2Cl2 (24.0 mL) was cooled to 0 °C in an ice bath and treated with 
dropwise addition of TFA (6.0 mL).  After stirring at room temperature for 2 h, the reaction was 
cooled to 0 °C in an ice bath and quenched by dropwise addition of sat. NaHCO3. The reaction 
was extracted with CH2Cl2 (3×). The combined organic layers were dried over Na2SO4 and 
concentrated to afford the product as a yellow oil (1.9 g, 5.58 mmol, 85% yield), which was used 
without further purification. Rf = 0.25 (3:17 v/v EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 
7.45 – 7.38 (m, 2H), 7.36 – 7.29 (m, 2H), 7.31 – 7.25 (m, 3H), 6.64 (d, J = 8.0 Hz, 1H), 6.06 
(ddt, J = 17.2, 10.6, 5.4 Hz, 1H), 5.41 (dq, J = 17.3, 1.6 Hz, 1H), 5.30 (dq, J = 10.5, 1.4 Hz, 1H), 
4.84 (dd, J = 12.5, 6.4 Hz, 1H), 4.67 (dd, J = 12.5, 8.4 Hz, 1H), 4.60 (dt, J = 5.4, 1.5 Hz, 2H), 
4.20 (tt, J = 8.2, 6.2 Hz, 1H), 3.36 (dd, J = 17.1, 6.2 Hz, 1H), 3.30 (dd, J = 17.1, 7.9 Hz, 1H).13C  
NMR (125 MHz, CDCl3) δ 194.95, 145.49, 142.45, 139.63, 132.97, 129.14, 127.87, 127.59, 
126.91, 123.89, 118.20, 112.83, 110.80, 79.84, 69.38, 40.96, 39.85. 
 (Z)-2-(Allyloxy)-4-(5-((5-(4-methoxyphenyl)-3-phenyl-2H-pyrrol-2-ylidene)amino)-4-
phenyl-1H-pyrrol-2-yl)aniline (3.17): A suspension of 3.16 (0.96 g, 2.8 mmol, 1 equiv) and 3.2 
(1.7 g, 5.6 mmol, 2 equiv) in n-butanol (50 mL) was heated to 110 °C to dissolve all solids. 
NH4OAc (3.3 g, 43.5 mmol, 15 equiv) was added in one portion and the reaction was stirred at 
the same temperature for 4 h. Volatiles were removed under reduced pressure, suspended in 
brine, and extracted with EtOAc (3×). The combined organic layers were dried over Na2SO4, 
concentrated, and purified via silica gel column chromatography (step gradient from 1:1 v/v 
CH2Cl2/Hexanes with 0.1 % TEA to 4:1 CH2Cl2/Hexanes with 0.1 % TEA) to afford the product 
as a blue solid (0.65 g, 1.18 mmol, 41% yield). Rf = 0.42 (3:7 v/v EtOAc/Hexanes). 1H NMR 
(500 MHz, DMSO-d6) δ 8.09 (dd, J = 13.1, 7.7 Hz, 4H), 7.82 (d, J = 7.9 Hz, 2H), 7.76 (s, 1H), 
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7.69 – 7.63 (m, 2H), 7.48 – 7.37 (m, 5H), 7.36 – 7.27 (m, 2H), 7.26 (s, 1H), 7.04 (d, J = 8.2 Hz, 
2H), 6.83 (d, J = 8.3 Hz, 1H), 6.20 (ddt, J = 16.0, 10.7, 5.4 Hz, 1H), 6.03 (s, 2H), 5.56 (d, J = 
17.8 Hz, 1H), 5.36 (d, J = 10.6 Hz, 1H), 4.78 (d, J = 5.3 Hz, 2H), 3.81 (s, 3H). 13C NMR (125 
MHz, DMSO-d6) δ 165.43, 159.82, 156.82, 145.28, 145.07, 143.99, 143.95, 143.45, 141.35, 
141.15, 134.14, 133.91, 133.68, 133.55, 133.15, 129.01, 128.72, 128.40, 128.22, 128.16, 127.78, 
127.11, 126.52, 124.51, 123.59, 121.07, 119.44, 118.21, 117.09, 114.77, 113.18, 109.53, 109.22, 
79.80, 79.17, 68.33, 55.38.  
2-(Allyloxy)-4-(5,5-difluoro-7-(4-methoxyphenyl)-1,9-diphenyl-5H-5l4,6l4-dipyrrolo[1,2-
c:2',1'-f][1,3,5,2]triazaborinin-3-yl)aniline (3.18): A solution of 3.17 (0.40 g, 0.72 mmol, 1 
equiv) and N,N-diisopropylethylamine (1.4 g, 10.8 mmol, 15 equiv) in anhydrous CH2Cl2 (30.0 
mL) was treated with the portion-wise addition of boron trifluoride diethyl etherate (2.6  mL, 
21.6 mmol, 30 equiv) at 0 °C. The reaction was stirred at room temperature for 24 h under a 
nitrogen atmosphere. The reaction progress was monitored via UV-Vis at 724 nm in chloroform 
indicating formation of the product. Upon completion the reaction was quenched with sat. 
NaHCO3 and extracted with CH2Cl2 (3×). The combined organic layers were dried over Na2SO4, 
concentrated, purified twice by silica gel column chromatography (1:19 v/v MeOH/ CH2Cl2 and 
4:1 CH2Cl2/Hexanes) to afford the product as a red solid (0.12 g, 0.2 mmol, 29% yield). Rf = 
0.17 (1:9 v/v MeOH/CH2Cl2). 1H NMR (500 MHz, DMSO-d6) δ 8.25 – 8.19 (m, 2H), 8.14 – 
8.11 (m, 2H), 8.10 – 8.07 (m, 2H), 8.02 (d, J = 1.9 Hz, 1H), 7.99 (dd, J = 8.8, 2.1 Hz, 1H), 7.98 
(s, 1H), 7.59 – 7.52 (m, 2H), 7.53 – 7.46 (m, 3H), 7.42 – 7.36 (m, 1H), 7.28 (s, 1H), 7.09 – 7.03 
(m, 2H), 6.83 (s, 2H), 6.81 (d, J = 8.7 Hz, 1H), 6.91 – 6.73 (m, 3H), 6.18 (ddt, J = 17.4, 10.6, 5.3 
Hz, 1H), 5.54 (dq, J = 17.3, 1.7 Hz, 1H), 5.34 (dd, J = 10.5, 1.6 Hz, 1H), 4.70 (dt, J = 5.3, 1.5 
Hz, 2H), 3.85 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 160.29, 159.76, 149.29, 146.58, 
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145.81, 144.45, 142.15, 141.57, 135.80, 133.24, 133.17, 133.06, 131.58, 130.57, 130.53, 130.49, 
129.58, 129.05, 128.88, 128.58, 128.51, 128.45, 128.19, 128.13, 127.77, 125.30, 124.76, 121.95, 
117.90, 116.32, 116.09, 113.90, 113.68, 113.52, 68.85, 55.33. 11B NMR (161 MHz, DMSO-d6) δ 
1.29 (t, J = 30.8 Hz). 19F NMR (471 MHz, DMSO-d6) δ -130.11 (dd, J = 67.0, 30.8 Hz). 
APNO-2: A suspension of 3.18 (0.047 g, 0.078 mmol, 1 equiv), 1,3-dimethylbarbituric acid 
(1,3-DMBA) (0.015 g, 0.12 mmol, 1.5 equiv), Pd(PPh3)4 (0.009 g, 0.008 mmol, 0.1 equiv), in 
anhydrous CH2Cl2 (10 mL) was stirred under nitrogen atmosphere at room temperature for 12 h. 
The reaction was treated with sat. NaHCO3 and extracted with CH2Cl2 (3×). The combined 
organic layers were dried over Na2SO4, concentrated, and purified via silica gel column 
chromatography (1:99 v/v MeOH/CH2Cl2) to afford the product as a red solid (0.033 g, 0.060 
mmol, 77% yield) Rf = 0.32 (1:99 v/v MeOH/CH2Cl2).  1H NMR (500 MHz, DMSO-d6) δ 9.95 
(s, 1H), 8.20 (dt, J = 6.4, 1.4 Hz, 2H), 8.14 – 8.09 (m, 2H), 8.07 – 8.04 (m, 2H), 7.90 – 7.81 (m, 
3H), 7.59 – 7.53 (m, 2H), 7.52 – 7.46 (m, 3H), 7.41 – 7.36 (m, 1H), 7.23 (s, 1H), 7.12 – 7.03 (m, 
2H), 6.77 (d, J = 8.4 Hz, 1H), 6.69 (s, 2H), 3.87 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 
160.14, 148.95, 146.76, 145.83, 143.62, 141.92, 141.47, 135.21, 133.19, 131.58, 130.57, 129.52, 
129.02, 128.59, 128.49, 128.40, 127.99, 124.96, 122.32, 116.91, 115.98, 115.73, 113.98, 113.51, 
55.35. 11B NMR (161 MHz, DMSO-d6) δ 1.21 (t, J = 33.7 Hz). 19F NMR (471 MHz, DMSO-d6) 
δ -130.00 (dd, J = 66.2, 31.3 Hz). HR-MS (ESI, TOF) calc’d [M+H]+ 559.2117, found 559.2125. 
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Scheme C.4: Synthesis of APNO-3. 
 
1-(4-(Allyloxy)-3-nitrophenyl)ethan-1-one (3.19): A suspension of 1-(4-hydroxy-3-
nitrophenyl)ethan-1-one (0.9 g, 5.0 mmol, 1 equiv) and K2CO3 (1.0 g, 7.5 mmol, 1.5 equiv) in 
anhydrous DMF (10 mL) was cooled to 0 °C in an ice bath. Allyl bromide (0.65 mL, 7.5 mmol, 
1.5 equiv) was added dropwise and the mixture was stirred at 55 °C for 16 h. Completion was 
observed via TLC. After cooling to room temperature, the reaction was diluted with brine and 
extracted with a 2:1 v/v mixture of CH2Cl2/isopropanol. The combined organic fractions were 
dried over Na2SO4 and concentrated to afford an oil that crystallized to a yellow solid (1.03 g, 
4.66 mmol, 93% yield). The product was used without further purification. Rf = 0.40 (3:7 v/v 
EtOAc/Hexanes).  1H NMR (500 MHz, CDCl3) δ 8.31 (d, J = 2.3 Hz, 1H), 8.04 (dd, J = 8.8, 2.2 
Hz, 1H), 7.09 (d, J = 8.8 Hz, 1H), 5.96 (ddt, J = 17.2, 10.3, 4.9 Hz, 1H), 5.43 (dq, J = 17.3, 1.6 
Hz, 1H), 5.28 (d, J = 10.6, 1H), 4.70 (d, J = 2.0 Hz, 2H), 2.52 (s, 3H). 13C NMR (125 MHz, 
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CDCl3) δ 194.77, 154.97, 139.29, 133.86, 130.89, 129.46, 125.89, 118.70, 114.38, 77.41, 77.16, 
76.90, 70.15, 26.24. 
1-(4-(Allyloxy)-3-aminophenyl)ethan-1-one (3.20): A flask was charged with 3.19 (220 mg, 
1.0 mmol, 1.0 equiv), NH4Cl (54.5 mg, 1.0 mmol, 1.0 equiv), H2O (2 mL) and EtOH (8 mL). 
Iron powder (560 mg, 10.0 mmol, 10 equiv) was added to the rapidly stirred reaction mixture 
which was then heated to 80 °C for 4 h. The mixture was diluted with brine and sequentially 
extracted with EtOAc and a 2:1 v/v mixture of CH2Cl2:isopropanol. The combined organic layers 
were dried over Na2SO4 and concentrated to an oil, which crystallized to a beige solid (179 mg, 
0.935 mmol, 94% yield). The product was used without further purification. Rf = 0.40 (1:3 v/v 
EtOAc/Hexanes).  1H NMR (500 MHz, CHCl3) δ 7.36 – 7.30 (m, 2H), 6.77 (d, J = 8.6 Hz, 1H), 
6.05 (ddt, J = 16.2, 10.5, 5.3 Hz, 1H), 5.40 (d, J = 17.3 Hz, 1H), 5.30 (d, J = 10.5 Hz, 1H), 4.61 
(d, J = 5.3 Hz, 2H), 2.50 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 197.43, 150.17, 136.42, 132.73, 
130.78, 120.36, 118.17, 114.19, 110.54, 69.22, 26.39. 
tert-Butyl (5-acetyl-2-(allyloxy)phenyl)carbamate (3.21): A suspension of 3.20 (179 mg, 0.935 
mmol, 1.0 equiv), di-tert-butyl-dicarbonate (408 mg, 1.87 mmol, 2.0 equiv), K2CO3 (194 mg, 1.4 
mmol, 1.5 equiv), and EtOH (2 mL) was stirred at 45 °C for 8 h, diluted with brine and extracted 
with EtOAc (3×). The organic layers were dried over Na2SO4 and concentrated to a thick yellow 
oil which solidified overnight (272.4 mg, 0.935 mmol, 100% yield). Rf = 0.31 (1:9 v/v 
EtOAc/Hexanes).  1H NMR (500 MHz, CDCl3) δ 8.72 (s, 1H), 7.64 (dd, J = 8.6, 2.1 Hz, 1H), 
7.08 (s, 1H), 6.89 (d, J = 8.6 Hz, 1H), 6.07 (ddt, J = 17.2, 10.8, 5.4 Hz, 1H), 5.41 (dd, J = 17.3, 
1.4 Hz, 1H), 5.36 (dd, J = 10.5, 1.3 Hz, 1H), 4.67 (dd, J = 5.3, 1.5 Hz, 2H), 2.58 (d, J = 0.7 Hz, 
3H), 1.55 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 197.41, 152.73, 150.13, 132.34, 130.83, 
128.26, 123.27, 118.92, 118.85, 110.83, 69.78, 28.51, 26.74. 
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tert-Butyl (2-(allyloxy)-5-cinnamoylphenyl)carbamate (3.22): A solution of 3.21 (217 mg, 
0.73 mmol, 1.0 equiv), EtOH (1.6 mL), benzaldehyde (82 μL, 0.8 mmol, 1.1 equiv), and a 10 M 
aq. solution of KOH (219 μL, 2.19 mmol, 3 equiv) was stirred at room temperature for 3.5 h. 
Upon consumption of 3.21, the reaction was concentrated, and the residue was taken up in brine 
and EtOAc. The aqueous layer was extracted with EtOAc; the organic layers were dried and 
concentrated to a pale yellow solid (230 mg, 0.60 mmol, 83% yield). Used without further 
purification. Rf = 0.20 (1:9 v/v EtOAc/Hexanes).  1H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 
15.6 Hz, 1H), 7.71 (dd, J = 8.6, 2.2 Hz, 1H), 7.64 (dd, J = 7.3, 2.2 Hz, 2H), 7.56 (d, J = 15.6 Hz, 
1H), 7.42 – 7.36 (m, 3H), 7.13 (s, 1H), 6.91 (d, J = 8.6 Hz, 1H), 6.06 (ddt, J = 17.3, 10.6, 5.4 Hz, 
1H), 5.40 (d, J = 17.4 Hz, 1H), 5.34 (d, J = 10.4 1H), 4.65 (dd, J = 5.4, 1.6 Hz, 2H), 1.56 (s, 9H). 
13C NMR (125 MHz, CDCl3) δ 215.81, 188.97, 152.59, 150.03, 144.02, 143.99, 135.11, 132.22, 
132.19, 131.51, 130.29, 128.88, 128.50, 128.26, 123.83, 122.01, 118.77, 118.50, 110.85, 69.65, 
28.39. 
tert-Butyl (2-(allyloxy)-5-(4-nitro-3-phenylbutanoyl)phenyl)carbamate (3.23): To a round 
bottom flask was added 3.22 (458 mg, 1.21 mmol, 1.0 equiv), EtOH (2.5 mL), nitromethane (0.2 
mL), and a 10 M aq. solution of KOH (0.12 mL, 1.20 mmol, 1.0 equiv). The reaction mixture 
was stirred 45 °C for 5 h. The reaction mixture was diluted in brine and extracted with EtOAc. 
The organic layers were dried over Na2SO4, concentrated, and purified by silica gel column 
chromatography (3:17 v/v EtOAc/Hexanes to 1:4 v/v EtOAc/Hexanes) to afford the product as a 
clear oil (370 mg, 0.84 mmol, 70% yield). Rf = 0.28 (1:9 v/v EtOAc/Hexanes).  1H NMR (500 
MHz, CD2Cl2) δ 8.72 (s, 1H), 7.60 (d, J = 8.55, 1H), 7.33 (m, 4 h), 7.19 (s, 1H), 6.91 (d, J = 
8.63, 1H), 6.09 (ddt, J = 16.53, 10.83, 5.43, 1H), 5.40 (d, J = 13.94, 1H), 5.36 (d, J = 13.94, 1H), 
4.88 (dd, J = 12.65, 6.01, 1H), 4.72 (dd, J = 12.65, 6.01), 4.68 (d, J = 5.42, 2H), 4.23 (p, J = 
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6.82, 1H), 3.41 (m, 2H), 3.36 (ddd, J = 17.63, 7.69, 1.59), 1.57 (s, 9H). 13C NMR (125 MHz, 
CD2Cl2) δ 196.00, 152.96, 150.96, 140.25, 132.78, 130.20, 129.37, 128.97, 128.10, 123.66, 
119.011, 118.22, 118.02, 111.20, 81.16, 80.20, 70.22, 41.82, 40.01, 28.57. 
tert-Butyl (Z)-(2-(allyloxy)-5-(5-((5-(4-methoxyphenyl)-3-phenyl-2H-pyrrol-2-
ylidene)amino)-4-phenyl-1H-pyrrol-2-yl)phenyl)carbamate (3.24): A suspension of 3.23 (207 
mg, 0.47 mmol, 1.0 equiv) and 3.2 (281 mg, 0.94 mmol, 2.0 equiv) in n-butanol (9 mL) was 
heated to 70 °C until the solids were dissolved. NH4OAc (543 mg, 7.05 mmol, 15 equiv) was 
added in one portion and the reaction mixture stirred at 120 °C for 5 h. Then, the reaction was 
cooled, concentrated via rotary evaporation, and taken up in CH2Cl2. The organic layer was 
washed with brine (5×), dried, concentrated, and purified by silica gel column chromatography 
(1:1 v/v CH2Cl2/Hexanes) to obtain a blue solid with a reddish shine (81.5 mg, 0.125 mmol, 27% 
yield). Rf = 0.71 (8:2 v/v CH2Cl2/Hexanes).  1H NMR (500 MHz, CDCl3) δ 8.05 (ddd, J = 8.3, 
3.3, 1.3 Hz, 4H), 7.94 (d, J = 8.8 Hz, 2H), 7.50 (dd, J = 8.5, 2.2 Hz, 1H), 7.41 (td, J = 7.6, 2.5 
Hz, 4H), 7.34 (ddd, J = 7.2, 4.4, 1.7 Hz, 2H), 7.17 (s, 1H), 7.14 (d, J = 2.3 Hz, 2H), 7.03 (d, J = 
8.8 Hz, 2H), 6.92 (d, J = 8.5 Hz, 1H), 6.10 (ddt, J = 17.3, 10.6, 5.4 Hz, 1H), 5.44 (dq, J = 17.2, 
1.5 Hz, 1H), 5.37 (dt, J = 10.5, 1.4 Hz, 1H), 4.66 (dt, J = 5.4, 1.5 Hz, 2H), 3.86 (s, 3H), 1.59 (s, 
9H). 13C NMR (125 MHz, CDCl3) δ161.37, 155.69, 153.52, 152.61, 150.22, 148.53, 147.92, 
142.65, 141.38, 134.16, 134.08, 132.69, 129.23, 129.21, 129.17, 128.52, 128.28, 128.24, 127.86, 
127.73, 125.68, 125.22, 120.95, 118.64, 115.97, 115.02, 114.80, 114.49, 111.67, 80.59, 69.81, 
55.57, 28.59. 
2-(Allyloxy)-5-(5,5-difluoro-7-(4-methoxyphenyl)-1,9-diphenyl-5H-5l4,6l4-dipyrrolo[1,2-
c:2',1'-f][1,3,5,2]triazaborinin-3-yl)aniline (3.25): A solution of 3.24 (48.5 mg, 0.075 mmol, 
1.0 equiv) and N,N-diisopropylethylamine (0.195 mL, 1.12 mmol, 15 equiv) in anhydrous 
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CH2Cl2 was treated with boron trifluoride diethyl etherate (0.142 mL, 1.12 mmol, 15 equiv). The 
reaction mixture was stirred under a nitrogen atmosphere at room temperature for 1 h. Upon 
consumption of 3.24, as judged by TLC (2:1 v/v CH2Cl2/Hexanes), the reaction mixture was 
diluted in CH2Cl2 and washed with sat. NaHCO3. The organic layer was dried over Na2SO4, 
concentrated, and purified by silica gel column chromatography (2:1 v/v CH2Cl2/toluene) to 
afford the product as a blue-green solid (17 mg, 0.028 mmol, 38% yield). Rf = 0.35 (8:2 v/v 
CH2Cl2/Hexanes).  1H NMR (500 MHz, CDCl3) δ 7.98 (ddd, J = 8.2, 2.8, 1.3 Hz, 4H), 7.83 (d, J 
= 8.9 Hz, 2H), 7.34 (td, J = 7.6, 1.6 Hz, 4H), 7.27 (dd, J = 7.3, 1.6 Hz, 2H), 7.24 (tt, J = 4.1, 2.0 
Hz, 2H), 7.06 (s, 1H), 7.01 (s, 1H), 6.97 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.9 Hz, 1H), 6.05 (ddt, J 
= 17.3, 10.6, 5.3 Hz, 1H), 5.39 (dq, J = 17.3, 1.6 Hz, 1H), 5.28 (dq, J = 10.5, 1.4 Hz, 1H), 4.60 
(dt, J = 5.4, 1.5 Hz, 2H), 3.83 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 161.40, 154.90, 154.07, 
149.97, 148.92, 148.30, 142.44, 141.81, 137.10, 134.12, 134.09, 133.11, 129.17, 129.15, 128.33, 
127.91, 127.87, 125.58, 125.40, 118.15, 117.87, 114.75, 114.65, 114.27, 112.81, 112.09, 69.49, 
55.66, 29.86. 19F NMR (471 MHz, CDCl3) δ -131.69 (dd, J = 63.7, 31.6 Hz). 
APNO-3. To a round bottom flask was added 3.25 (17 mg, 28.0 μmol, 1.0 equiv), 1,3-
dimethylbarbituric acid (6.6 mg, 43.0 μmol, 1.5 equiv), and Pd(PPh3)4 (3.3 mg, 3 μmol, 0.1 
equiv) under nitrogen, followed by anhydrous CH2Cl2 (3 mL). The reaction mixture was stirred 
at room temperature for 11 h. Upon consumption of 31 as judged by TLC, the reaction mixture 
was diluted in CH2Cl2 and washed with brine and sat. NaHCO3. The organic layers were dried 
over Na2SO4, concentrated, and purified by silica gel column chromatography (1:99 v/v MeOH/ 
CH2Cl2) to afford the product as a green solid (7.9 mg, 0.014 mmol, 50% yield). Rf = 0.21 (1:1 
v/v CH2Cl2/Hexanes).   1H NMR (500 MHz, CDCl3) δ 8.12 – 7.99 (m, 6H), 7.53 (s, 1H), 7.49 – 
7.36 (m, 7H), 7.05 – 6.95 (m, 4H), 6.77 (d, J = 8.1 Hz, 1H), 3.87 (s, 3H). 11B NMR (161 MHz, 
 197 
CDCl3) 1.05 (t, J = 32.00). 19F NMR (471 MHz, CDCl3) δ -131.49 (dd, J = 63.04, 32). HR-MS 
(ESI, TOF) calc’d [M+H]+ 559.2117, found 559.2112. 
 
Scheme C.5: Synthesis of APNO-4. 
 
6-Cinnamoylbenzo[d]oxazol-2(3H)-one (3.26): A solution of 3.10 (8.0 g, 45.3 mmol, 1 equiv) 
and benzaldehyde (4.8 g, 45.3 mmol. 1 equiv) in EtOH (100 mL) was treated with dropwise 
addition of a 10 M solution of aq. KOH (13.6 mL, 136.0 mmol, 3 equiv). The reaction was 
allowed to stir at room temperature for 4 h. The slurry was concentrated to an orange solid and 
recrystallized in EtOH to yield the product as a yellow solid (8.3 g, 48.4 mmol, 68% yield). Rf = 
0.48 (2:1:7 v/v Acetone/MeOH/Hexanes). 1H NMR (400 MHz, DMSO-d6) δ 12.11 (s, 1H), 8.10 
(d, J = 1.4 Hz, 1H), 8.06 (dd, J = 8.2, 1.6 Hz, 1H), 7.98 (d, J = 15.6 Hz, 1H), 7.89 (dd, J = 6.7, 
2.9 Hz, 2H), 7.73 (d, J = 15.5 Hz, 1H), 7.45 (m, 3H), 7.23 (d, J = 8.1 Hz, 1H). 13C NMR (100 
MHz, DMSO-d6) δ 187.30, 154.49, 143.78, 143.50, 134.98, 134.76, 131.85, 130.58, 128.93, 
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128.91, 125.78, 125.74, 121.77, 109.60, 109.56, 109.54. 
tert-Butyl (4-cinnamoyl-2-hydroxyphenyl) carbamate (3.27): A suspension of 3.26 (0.9 g, 3.4 
mmol, 1 equiv), K2CO3 (1.4 g, 10 mmol, 3 equiv), and di-tert-butyl dicarbonate (1.5 g, 7 mmol, 
2 equiv) in MeOH (16 mL) was stirred at 45 °C for 3 h. The reaction was diluted with sat. 
NaHCO3 and extracted with EtOAc (3×). The combined organic layers were dried over Na2SO4, 
concentrated, and purified via silica gel column chromatography (3:7 v/v EtOAc/Hexanes) to 
afford the product as a yellow solid (0.8 g, 2.3 mmol, 69% yield). Rf = 0.44 (3:7 v/v 
EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 8.51 (bs, 1H), 7.93 – 7.88 (m, 2H), 7.81 (d, J = 
15.6 Hz, 1H), 7.67 – 7.59 (m, 3H), 7.56 (d, J = 15.7 Hz, 1H), 7.43 – 7.39 (m, 3H), 7.30 (s, 1H), 
1.55 (s, 9H). 13C NMR (125 MHz, CDCl3) δ189.94, 153.28, 145.71, 145.04, 134.97, 132.88, 
132.26, 130.76, 129.09, 128.70, 122.66, 121.71, 118.18, 116.10, 81.77, 28.42. 
tert-Butyl (4-cinnamoyl-2-methoxyphenyl)(methyl) carbamate (3.28): A 38 mL pressure 
flask under nitrogen was charged with 3.27 (0.6 g, 1.8 mmol, 1 equiv), anhydrous DMF (8 mL), 
MeI (1.2 g, 8.8 mmol, 5 equiv), and NaH (60 % w/w, 2 g, 5.5 mmol, 3 equiv) at 0 °C. The 
reaction was allowed to warm to room temperature and was stirred for 1 h. The reaction was then 
heated to 70 °C for 3 h. The reaction was quenched with water and extracted with EtOAc (3×). 
The organic layers were combined, concentrated, and purified via silica gel column 
chromatography (3:17 v/v EtOAc/Hexanes) to afford the product as a yellow solid (5.9 g, 1.6 
mmol, 91% yield). Rf = 0.24 (1:9 v/v EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 7.85 (d, J 
= 15.7 Hz, 1H), 7.70 – 7.63 (m, 4H), 7.58 (d, J = 15.6 Hz, 1H), 7.43 (qd, J = 3.8, 1.7 Hz, 3H), 
7.32 (d, J = 8.4 Hz, 1H), 3.94 (s, 3H), 3.21 (s, 3H), 1.45 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 
189.15, 155.05, 154.77, 144.64, 137.50, 136.91, 134.71, 130.45, 128.84, 128.36, 128.32, 121.65, 
121.20, 111.14, 79.86, 55.50, 36.65, 28.13. 
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1-(3-Methoxy-4-(methylamino)phenyl)-4-nitro-3-phenylbutan-1-one (3.29): A solution of 
3.28 (0.53 g, 1.4 mmol, 1 equiv) and nitromethane (0.87 g, 14 mmol, 10 equiv) in EtOH (3 mL) 
was treated with a 1 M solution of aq. KOH (0.29 mL, 0.2 equiv). The reaction was stirred at 60 
°C for 7 h. The reaction was diluted with brine, extracted with EtOAc (3×), and concentrated. 
The crude intermediate was dissolved in CH2Cl2 (8 mL) and cooled to 0 °C in an ice bath. 
Trifluoroacetic acid (2 mL) was added dropwise and the reaction was allowed to stir at room 
temperature for 3 h. The reaction was quenched with sat. NaHCO3 and extracted with CH2Cl2 
(3×). The combined organic fractions were dried over Na2SO4, concentrated, and purified via 
silica gel column chromatography (3:7 v/v EtOAc/Hexanes) to afford the product as a brown 
solid (0.40 g, 1.2 mmol, 86% yield). Rf = 0.47 (3:7 v/v EtOAc/Hexanes). 1H NMR (500 MHz, 
CDCl3) δ 7.45 (dd, J = 8.3, 1.9 Hz, 1H), 7.28 (d, J = 1.9 Hz, 1H), 7.27 – 7.16 (m, 6H), 6.40 (d, J 
= 8.3 Hz, 1H), 4.82 (s, 1H), 4.78 (dd, J = 12.5, 6.3 Hz, 1H), 4.60 (dd, J = 12.5, 8.5 Hz, 1H), 4.13 
(tt, J = 8.3, 6.1 Hz, 1H), 3.79 (s, 3H), 3.30 (dd, J = 16.9, 6.2 Hz, 1H), 3.23 (dd, J = 16.9, 8.0 Hz, 
1H), 2.85 (s, 3H). 13C NMR (125 MHz, CDCl3) δ194.87, 146.29, 144.41, 139.75, 129.11, 
127.81, 127.60, 124.86, 124.62, 107.80, 106.78, 79.88, 55.69, 40.82, 40.00, 29.81.  
1-(3-Methoxy-4-(methylamino)phenyl)-4-nitro-3-phenylbutan-1-one (3.30): A suspension of 
3.29 (0.211 g, 0.641 mmol, 1 equiv) and 3.2 (0.387 g, 1.29 mmol, 2 equiv) in n-butanol (15 mL) 
was heated to 110 °C until all of the solids dissolved. NH4OAc (0.749 g, 9.71 mmol, 15 equiv) 
was added to the reaction in one portion. The reaction was stirred at 110 °C for 4 h. After 
complete, the solution was concentered as an azeotrope with toluene to afford a blue-green solid. 
The crude residue was diluted with brine and extracted with CH2Cl2 (3×). The combined organic 
fractions were dried over Na2SO4 and purified via silica gel column chromatography (13:7 v/v 
CH2Cl2/Hexanes). The fractions containing product were collected, precipitated from 
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CH2Cl2/Hexanes at 0 °C (3×), filtered, and collected. The filtrate was re-purified via silica gel 
column chromatography (3:7 v/v EtOAc/Hexanes) to afford the product as a dark red solid 
(0.196 g, 0.184 mmol, 29% yield). Rf = 0.39 (3:7 v/v EtOAc/Hexanes). 1H NMR (500 MHz, 
DMSO-d6) δ 12.84 (s, 1H), 8.12 (dd, J = 16.9, 7.6 Hz, 4H), 7.89 – 7.78 (m, 4H), 7.68 (d, J = 1.8 
Hz, 1H), 7.52 – 7.38 (m, 5H), 7.35 – 7.29 (m, 2H), 7.07 (d, J = 8.4 Hz, 2H), 6.69 (d, J = 8.3 Hz, 
1H), 6.41 (q, J = 5.1 Hz, 1H), 4.07 (s, 3H), 3.86 (s, 3H), 2.88 (d, J = 4.9 Hz, 3H). 13C NMR (125 
MHz, DMSO-d6) δ 165.90, 159.80, 157.31, 146.55, 145.46, 143.80, 140.84, 140.62, 134.20, 
133.46, 133.15, 128.72, 128.28, 128.23, 128.10, 127.07, 126.40, 125.04, 123.59, 121.37, 118.81, 
117.04, 114.75, 108.86, 108.17, 107.09, 55.40, 55.18, 29.37. 
APNO-4. Boron trifluoride diethyl etherate (0.15 mL, 1.2 mmol, 15 equiv) was added to a 
solution of 3.30 (0.043 g, 0.079 mmol, 1 equiv) and N,N-diisopropylethylamine (0.21 mL, 1.2 
mmol, 15 equiv) in anhydrous CH2Cl2 (3.2 mL). The reaction was stirred at room temperature 
for 14 h under a nitrogen atmosphere, quenched with sat. NaHCO3, and extracted with CH2Cl2 
(3×). The combined organic layers were dried over Na2SO4, concentrated, and purified by silica 
gel column chromatography (step gradient, 3:7 v/v EtOAc/Hexanes then 13:7 v/v 
CH2Cl2/Hexanes) to afford the product as a red solid (0.044 g, 0.075 mmol, 95% yield). Rf = 
0.22 (1:1 v/v CH2Cl2/Hexanes). 1H NMR (500 MHz, DMSO-d6) δ 8.23 (d, J = 8.7 Hz, 2H), 8.15 
(d, J = 8.8 Hz, 1H), 8.12 (d, J = 7.7 Hz, 2H), 8.08 (d, J = 8.7 Hz, 2H), 8.04 (s, 1H), 7.98 – 7.95 
(m, 1H), 7.55 (t, J = 7.5 Hz, 2H), 7.52 – 7.45 (m, 3H), 7.38 (t, J = 7.4 Hz, 1H), 7.26 (s, 1H), 7.20 
– 7.14 (m, 1H), 7.07 (d, J = 8.5 Hz, 2H), 6.74 (d, J = 8.8 Hz, 1H), 3.94 (s, 3H), 3.86 (s, 3H), 2.93 
(d, J = 5.1 Hz, 3H).  13C NMR (125 MHz, DMSO-d6) δ 160.70, 160.22, 149.36, 147.20, 146.51, 
145.87, 142.52, 141.96, 135.88, 133.62, 132.09, 130.97, 130.93, 130.89, 130.03, 129.54, 129.04, 
128.97, 128.89, 128.52, 125.32, 122.62, 116.45, 116.41, 114.40, 109.49, 56.07, 55.83, 29.79. 11B 
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NMR (161 MHz, DMSO-d6) δ 1.40 (t, J = 34.5 Hz). 19F NMR (471 MHz, DMSO-d6) δ -130.04 
(dd, J = 67.0, 30.6 Hz). HR-MS (ESI, TOF)  calc’d for [M+H]+ 587.2430, found 587.2440. 
 
Scheme C.6: Synthesis of compound 3.33. 
 
(E)-1-(4-Hydroxyphenyl)-3-phenylprop-2-en-1-one (3.31): A solution of 1-(4-
hydroxyphenyl)ethan-1-one (10.0 g, 73.8 mmol, 1 equiv) and benzaldehyde (7.8 g, 73.8 mmol, 1 
equiv) in EtOH (140 mL) was cooled to 0 °C in an ice bath and treated with dropwise addition of 
a 10 M aq. solution of KOH (22.1 mL, 221 mmol, 3 equiv). The reaction was stirred at room 
temperature for 24 h. The reaction was quenched with conc. HCl to a pH of approximately 1. 
The mixture was stirred at 0 °C for 30 min then filtered to afford the product as a light yellow 
solid (18.7g, 73.8 mmol, 100% yield). Rf = 0.39 (3:7 v/v EtOAc/Hexanes). 1H NMR (500 MHz, 
DMSO-d6) δ 10.54 (s, 1H), 8.07 (d, J = 8.4 Hz, 2H), 7.92 (d, J = 15.6 Hz, 1H), 7.88 – 7.84 (m, 
2H), 7.68 (d, J = 15.6 Hz, 1H), 7.48 – 7.38 (m, 3H), 6.92 (d, J = 8.4 Hz, 2H). 13C NMR (125 
MHz, DMSO-d6) δ 187.12, 162.31, 142.70, 134.89, 131.18, 130.32, 129.03, 128.89, 128.72, 
122.12, 115.42. 
(E)-3-Phenyl-1-(4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (3.32): A flame-dried round 
bottom flask was charged with 3.31 (3.1 g, 13.7 mmol, 1 equiv), K2CO3 (2.4 g, 17.1 mmol, 1.25 
equiv), and DMF (30 mL) under nitrogen. Propargyl bromide (3.2 mL, 17.2 mmol, 1.25 equiv) 
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was added and the reaction was stirred at room temperature for 24 h. The reaction was quenched 
in sat. NaHCO3, extracted with EtOAc, and washed with sat. NaHCO3 (3×). The combined 
organic layers were collected, dried over Na2SO4, concentrated, and purified via silica gel 
column chromatography (gradient from 1:9 v/v EtOAc/Hexanes to 1:3 v/v EtOAc/Hexanes) to 
afford the product as a white solid (3.0 g, 11.7 mmol, 85% yield). Rf = 0.24 (1:9 v/v 
EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 8.10 – 8.01 (m, 2H), 7.81 (d, J = 15.7 Hz, 1H), 
7.67 – 7.61 (m, 2H), 7.54 (d, J = 15.7 Hz, 1H), 7.46 – 7.39 (m, 3H), 7.13 – 7.04 (m, 2H), 4.78 (d, 
J = 2.4 Hz, 2H), 2.57 (t, J = 2.4 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 188.84, 161.32, 144.31, 
135.15, 131.98, 130.85, 130.52, 129.06, 128.50, 121.94, 114.85, 77.93, 77.91, 76.34, 76.28, 
56.00. 
4-Nitro-3-phenyl-1-(4-(prop-2-yn-1-yloxy)phenyl)butan-1-one (3.33): A mixture of 3.32 
(1.18 g, 4.5 mmol, 1 equiv) and nitromethane (3.6 mL, 66.8 mmol, 15 equiv) in EtOH (9.0 mL) 
was dropwise treated with 10 M aq. solution of KOH (0.090 mL, 0.2 equiv). The resulting 
mixture was stirred at room temperature for 24 h. After complete, the reaction was quenched 
with sat. NaHCO3 and extracted with EtOAc (3×). The organic fraction was washed with sat. 
NaHCO3 (3×), concentrated, and purified via silica gel column chromatography (1:3 v/v 
EtOAc/Hexanes) to afford an off-white solid (1.18 g, 3.63 mmol, 81% yield). Rf = 0.39 (3:7 v/v 
EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 7.97 – 7.91 (m, 2H), 7.39 – 7.33 (m, 2H), 7.32 
– 7.27 (m, 3H), 7.06 – 7.00 (m, 2H), 4.86 (dd, J = 12.5, 6.5 Hz, 1H), 4.78 (d, J = 2.4 Hz, 2H), 
4.71 (dd, J = 12.5, 8.1 Hz, 1H), 4.24 (tt, J = 7.9, 6.4 Hz, 1H), 3.45 (dd, J = 17.5, 6.4 Hz, 1H), 
3.39 (dd, J = 17.5, 7.6 Hz, 1H), 2.58 (t, J = 2.4 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 195.41, 
161.73, 139.35, 130.40, 130.31, 129.18, 127.96, 127.57, 114.89, 79.73, 77.74, 76.41, 56.01, 
41.34, 39.52. 
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Scheme C.7: Synthesis of compound 3.37. 
 
[2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate] (3.34): The 
product was synthesized according to previously reported protocols.7 Briefly, tetraethyleneglycol 
(8.67 g, 44.6 mmol, 8.4 equiv) was dissolved in THF (2.1  mL) followed by the addition of a 4 M 
aq. solution of sodium hydroxide (2.13  mL, 8.52 mmol, 1.6 equiv). The reaction was cooled to 0 
°C and tosyl chloride (1.01 g, 5.31 mmol, 1 equiv) in THF (6 mL) was added dropwise. The 
reaction was allowed to stir for 3 h at the same temperature. The product was extracted with 
CH2Cl2 (3×) from cold water. The combined organic fractions were washed with water (2×) and 
dried over Na2SO4. The organic fractions were concentrated to afford a clear oil (1.66 g, 4.76 
mmol, 90% yield), which was used without further purification.  Rf = 0.25 (3:97 v/v 
MeOH/CH2Cl2). 
[2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-1-ol] (3.35). The product was synthesized 
according to previously reported protocols.7 Briefly, a solution of 3.34 (3.96 g, 11.38 mmol, 1 
equiv) and sodium azide (1.85g, 28.5 mmol, 2.5 equiv)  in EtOH (45 mL) was refluxed at 80 °C 
under a nitrogen atmosphere for 14 h. The reaction was cooled to room temperature, diluted with 
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water, and volatiles were removed. The product was extracted with EtOAc (3×) from the water. 
The organic fractions were dried over Na2SO4 and concentrated to afford a yellow oil (2.05 g, 
9.36 mmol, 82% yield), which was used without further purification. Rf (1:9 v/v MeOH/CHCl3) 
0.70. 1H NMR (500 MHz, CDCl3) δ 3.73 (dd, J = 5.3, 3.7 Hz, 2H), 3.67 (d, J = 1.5 Hz, 10H), 
3.63 – 3.59 (m, 2H), 3.40 (t, J = 5.1 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ 72.63, 70.81, 70.78, 
70.70, 70.44, 70.16, 61.87, 50.80. 
[2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-N,N-dimethylethan-1-amine] (3.36). A solution of 
3.35 (0.75 g, 3.42 mmol, 1 equiv), and triethylamine (1.4 mL, 10.3 mmol, 3 equiv) in anhydrous 
THF (17.1  mL) was cooled to 0 °C  in an ice bath. Methanesulfonyl chloride (Mesyl-Cl, 0.54 
mL, 2 equiv) was added dropwise under a nitrogen atmosphere and stirred at 0 °C for 1 h. 40 % 
w/w aq. dimethylamine (4.3 mL, 34.2 mmol, 10 equiv) was added dropwise and stirred for an 
additional 24 h at room temperature. The product was purified by silica gel column 
chromatography (1:4 v/v MeOH/CHCl3) to afford a brown oil (0.807 g, 3.28 mmol, 96% yield). 
Rf (1:4 v/v MeOH/CHCl3) 0.52. 1H NMR (500 MHz, DMSO-d6) δ 3.61 – 3.59 (m, 2H), 3.58 – 
3.45 (m, 10H), 3.39 (dd, J = 5.6, 4.4 Hz, 2H), 2.41 – 2.37 (m, 2H), 2.15 (s, 6H). 13C NMR (125 
MHz, DMSO-d6) δ 69.81, 69.80, 69.70, 69.64, 69.62, 69.25, 68.60, 58.29, 49.99, 45.53. 
[2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-N,N,N-trimethylethan-1-aminium iodide] (3.37) - A 
pressure vial was charged with 3.36 (0.51 g, 2  mmol, 1 equiv), anhydrous acetonitrile (4  mL), 
and MeI (0.64  mL, 10.2 mmol, 5 equiv) under nitrogen. The reaction was heated to 60 °C for 72 
h. When complete according to TLC, the product was loaded onto celite and purified by silica 
gel chromatography (1:4 v/v MeOH/CHCl3) to afford a pale yellow solid (0.81 g, 1.7 mmol, 82% 
yield). Rf (1:4 v/v MeOH/CHCl3) 0.40. 1H NMR (500 MHz, CD3CN) δ 3.88 (m, 2H), 3.65 – 3.57 
(m, 10H), 3.54 – 3.51 (m, 2H), 3.37 (t, J = 4.9 Hz, 2H), 3.15 (s, 9H). 13C NMR (125 MHz, 
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CD3CN) δ 71.08, 71.05, 70.96, 70.78, 70.42, 66.50, 66.48, 66.45, 65.41, 55.01, 54.97, 54.94, 
51.44. 
 
Scheme C.8: Synthesis of APNO-5. 
 
(Z)-2-Methoxy-N-methyl-4-(4-phenyl-5-((3-phenyl-5-(4-(prop-2-yn-1-yloxy)phenyl)-2H-
pyrrol-2-ylidene)amino)-1H-pyrrol-2-yl)aniline (3.38): A suspension of 3.29 (0.40 g, 1.2 
mmol, 1 equiv) and 3.33 (0.80 g, 2.5 mmol, 2 equiv) in n-butanol (25 mL) was heated to 110 °C 
to dissolve all solids. NH4OAc (1.4 g, 19 mmol, 15 equiv) was added in one portion and the 
reaction stirred at the same temperature for 5 h. The reaction was azeotroped with PhMe and 
dried to a blue-green solid. The product was extracted from brine with CH2Cl2 (3×). The 
combined organic fractions were dried over Na2SO4 and purified twice via silica gel column 
chromatography (3:7 v/v EtOAc/Hexanes then 4:1 CH2Cl2/Hexanes) to afford the product as a 
dark green solid (340 mg, 0.60 mmol, 48% yield). Rf = 0.50 (3:7 v/v EtOAc/Hexanes). 1H NMR 
(500 MHz, CDCl3) δ 8.07 – 8.03 (m, 4H), 7.67 – 7.63 (m, 2H), 7.52 – 7.48 (m, 2H), 7.43 – 7.33 
(m, 5H), 7.32 – 7.27 (m, 1H), 7.24 (s, 1H), 6.91 (d, J = 2.0 Hz, 1H), 6.89 (s, 1H), 6.54 (d, J = 8.1 
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Hz, 1H), 4.66 (d, J = 2.5 Hz, 2H), 3.93 (s, 3H), 2.90 (s, 3H), 2.56 (t, J = 2.4 Hz, 1H). 13C NMR 
(125 MHz, CDCl3) 165.10, 157.81, 157.16, 146.83, 146.36, 142.93, 142.52, 141.97, 135.43, 
134.75, 133.79, 129.30, 128.78, 128.26, 128.22, 128.12, 128.12, 127.09, 126.44, 125.66, 124.00, 
120.73, 119.45, 115.39, 108.94, 108.27, 106.90, 78.46, 75.98, 55.98, 55.30, 29.91. 
4-(5,5-Difluoro-1,9-diphenyl-7-(4-(prop-2-yn-1-yloxy)phenyl)-5H-5l4,6l4-dipyrrolo[1,2-
c:2',1'-f][1,3,5,2]triazaborinin-3-yl)-2-methoxy-N-methylaniline (3.39): A solution of 7 
(0.077 g, 0.14 mmol, 1 equiv) and N,N-diisopropylethylamine (0.36  mL, 2.1 mmol, 15 equiv) in 
anhydrous CH2Cl2 (5.5 mL) was cooled to 0 °C in an ice bath and treated portion-wise with 
boron trifluoride diethyl etherate (0.18 mL × 3, 4.3 mmol, 45 equiv) over 24 h. After each 
addition, the reaction was allowed to warm to room temperature. When complete, the reaction 
was diluted with sat. NaHCO3 and extracted with CH2Cl2 (3×). The combined organic fractions 
were dried over Na2SO4, concentrated, and purified via silica gel column chromatography (3:7 
v/v EtOAc/Hexanes) to afford the product as a dark purple solid (0.027 g, 0.045 mmol, 33% 
yield). Rf = 0.29 (3:7 v/v EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 8.11 - 8.03 (m, 7H), 
7.96 (s, 1H), 7.78 (dd, J = 8.6, 2.0 Hz, 1H), 7.49 – 7.39 (m, 6H), 7.36 (t, J = 7.3 Hz, 1H), 7.07 – 
7.02 (m, 2H), 6.93 (s, 1H), 6.64 – 6.57 (m, 1H), 4.76 (d, J = 2.4 Hz, 2H), 3.94 (s, 3H), 2.97 (s, 
3H), 2.57 (q, J = 2.6 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 160.63, 158.78, 152.53, 147.06, 
146.35, 143.84, 143.69, 143.52, 139.05, 133.54, 132.43, 131.07, 129.58, 129.44, 129.39, 129.08, 
128.81, 128.77, 128.61, 128.55, 128.39, 127.42, 126.40, 120.09, 118.38, 116.69, 115.27, 114.76, 
110.96, 108.45, 78.45, 75.96, 55.97, 55.78, 29.85. 11B NMR (161 MHz, CDCl3) δ 1.34 (t, J = 
32.8 Hz). 19F NMR (471 MHz, CDCl3) δ -131.51 (dd, J = 66.0, 32.9 Hz). 
APNO-5: Compound 3.39 (0.046 g, 0.076 mmol, 1 equiv), tris(3-
hydroxypropyltriazolylmethyl)amine (0.007 g, 0.015, 0.2 equiv), 3.37 (0.099 g, 0.25 mmol, 3.5 
 207 
equiv), and copper sulfate pentahydrate (0.095g, 0.38 mmol, 5 equiv), were dissolved in 
degassed THF (3.8 mL), then sodium ascorbate (0.023 g, 0.11 mmol, 1.5 equiv) in degassed 
water (0.8 mL) was added under nitrogen. The reaction was allowed to stir at room temperature 
for 3 h. When the reaction was complete, the product was extracted with 3:7 v/v MeOH/CH2Cl2 
(3×) from sat. aq. NaI. The combined organic layers were dried over Na2SO4 and concentrated 
under reduced pressure. The crude residue was purified via preparatory TLC (1:9 v/v 
H2O/MeCN). The product was recovered in 1:9 v/v MeOH/CH2Cl2 with sonication, filtered, and 
dried to afford the product as a red solid (0.077 g, 0.076 mmol, 100% yield). Rf = 0.55 (1:9 v/v 
H2O/MeCN). 1H NMR (500 MHz, DMSO-d6) δ 8.26 (s, 1H), 8.25 – 8.22 (m, 2H), 8.16 (dd, J = 
8.8, 2.0 Hz, 1H), 8.14 – 8.11 (m, 2H), 8.09 (d, J = 9.0 Hz, 2H), 8.06 (s, 1H), 7.99 – 7.96 (m, 1H), 
7.56 (dd, J = 8.2, 6.6 Hz, 2H), 7.49 (td, J = 7.5, 5.7 Hz, 3H), 7.41 – 7.35 (m, 1H), 7.27 (s, 1H), 
7.23 – 7.16 (m, 3H), 6.75 (d, J = 8.9 Hz, 1H), 5.27 (s, 2H), 4.57 (t, J = 5.2 Hz, 2H), 3.95 (s, 3H), 
3.84 (t, J = 5.2 Hz, 2H), 3.82 – 3.77 (m, 2H), 3.58 – 3.51 (m, 5H), 3.50 – 3.48 (m, 5H), 3.06 (s, 
9H), 2.94 (d, J = 5.2 Hz, 3H). 13C NMR (125 MHz, DMSO-d6) δ 159.42, 149.00, 147.30, 146.52, 
145.96, 142.83, 142.61, 141.90, 135.72, 133.62, 132.04, 130.88, 130.19, 130.08, 129.55, 129.06, 
128.99, 128.87, 128.53, 125.67, 125.49, 116.42, 116.35, 115.10, 109.53, 70.24, 70.04, 70.00, 
69.88, 69.80, 69.14, 64.89, 64.49, 61.71, 56.10, 53.60, 53.57, 53.54, 49.93, 29.81. 11B NMR (161 
MHz, DMSO-d6) δ 1.33 (t, J = 34.5 Hz). 19F NMR (471 MHz, DMSO-d6) δ -129.98 (dd, J = 
67.0, 29.9 Hz). HR-MS (ESI, TOF) calc’d [M]+ 902.4258, found 902.4345. 
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Scheme C.9: Synthesis of tAPNO-5. 
 
tAPNO-5. To a solution of APNO-5 (15.6 mg, 15.6 μmol, 1 equiv) in THF (3.2 mL), acetic acid 
(0.4 mL), and CH2Cl2 (0.8 mL) at 0 °C was added sodium nitrite (5.6 mg, 81.5 μmol, 5.2 equiv) 
and the reaction was allowed to stir at the same temperature for 30 minutes. The reaction was 
warmed to room temperature, additional acetic acid (0.4 mL) and sodium nitrite (2.6 mg, 37.8 
μmol, 2.4 equiv) were added and allowed to stir for 2.5 h. The reaction was diluted in CH2Cl2 
and washed with sat. NaHCO3. The organic layer was dried over Na2SO4 and concentrated to a 
green solid. The product was purified via alumina column chromatography (1:19 v/v 
MeOH/CH2Cl2) to afford a green solid (22.6 mg, 13.2 μmol, 85% yield). 1H NMR (500 MHz, 
DMSO-d6) δ 8.33 (d, J = 8.8 Hz, 2H), 8.27 (s, 1H), 8.22 (d, J = 7.5 Hz, 2H), 8.17 (d, J = 7.8 Hz, 
2H), 7.93 (s, 1H), 7.87 (s, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.64 – 7.46 (m, 8H), 7.31 (d, J = 8.9 Hz, 
2H), 5.33 (s, 2H), 4.56 (t, J = 5.2 Hz, 2H), 3.98 (s, 3H), 3.83 (t, J = 5.2 Hz, 2H), 3.80 (m, 2H), 
3.53 (m, 4H), 3.50 – 3.46 (m, 6H), 3.36 (s, 3H), 3.07 (s, 9H). 19F NMR (470 MHz, DMSO-d6) δ -
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130.14 (dd, J = 64.2, 31.4 Hz). HR-MS (ESI, TOF) calc’d for [M]+ 900.8153, found 900.4191. 
 
Scheme C.10: Synthesis of TG-2 and TG-3. 
 
N-(4-bromo-3-methylphenyl)-2,2,2-trifluoroacetamide (3.40):  To a solution of 4-bromo-3-
methylaniline (0.209 g, 1.12 mmol, 1 equiv) and TEA (0.31 mL, 2.27 mmol, 2 equiv) in 
anhydrous THF (6 mL) was added trifluoroacetic anhydride (dropwise, 0.19 mL, 2.83 mmol, 1.2 
equiv) at room temperature. The reaction was allowed to stir at the same temperature for 0.5 h. 
The reaction was diluted with EtOAc, quenched with water, and the organic layer was washed 
with water (3×) and then brine (1×). The organic layer was dried over Na2SO4 and concentrated 
to a solid and used without purification (0.292 g, 1.04 mmol, 92 % yield). 
2,2,2-trifluoro-N-(4-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-methylphenyl)acetamide (3.41):  
A solution of 3.40 (0.659 g, 2.34 mmol, 1.5 equiv) in anhydrous THF (4 mL) was treated 
dropwise with n-BuLi (2.5 M in hexanes, 0.94 mL, 0.15 g, 2.30 mmol, 1.5 equiv) at -78 °C and 
the reaction was allowed to proceed at the same temperature for 20 min before the addition of t-
BuLi (1.7 M in pentanes, 2.1 mL, 0.23 g, 3.6 mmol, 2.3 equiv). After an additional 15 min. 3,6-
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bis((tert-butyldimethylsilyl)oxy)-9H-xanthen-9-one10 (0.713 g, 1.56 mmol, 1 equiv) in anhydrous 
THF (4 mL) was added and the reaction was allowed to stir at the same temperature for 1 h 
before allowing it to warm to room temperature for an additional 2.5 h. The reaction was 
quenched by the addition of 2 M aq. HCl and heated at 50 °C for 14 h. The reaction was diluted 
with brine and extracted with 40% isopropanol/CH2Cl2 (3×). The organic layer was dried over 
Na2SO4, concentrated, and purified via silica gel chromatography (7.5% MeOH/CH2Cl2) to 
afford an orange solid (0.570 g, 1.38 mmol, 88 % yield). 1H NMR (500 MHz, CD3OD) δ 7.73 (s, 
1H), 7.67 (dd, J = 8.2, 2.2 Hz, 1H), 7.53 (s, 1H), 7.16 (d, J = 8.5 Hz, 2H), 7.02 (d, J = 9.2 Hz, 
2H), 6.71 – 6.63 (m, 6H), 2.03 (s, 3H). 
TG-2: A solution of 3.41 (0.122 mg, 296 μmol, 1 equiv) in EtOH (0.75 mL) was treated with 
dipropylamine (0.3 mL, 0.22 g, 2.2 mmol, 7.4 equiv) and the reaction was heated to 80 °C for 24 
h. The reaction was cooled to room temperature, dissolved in MeOH, and loaded onto celite. 
Purification via silica chromatography (7.5% MeOH/CH2Cl2) afforded the product as an orange 
solid (60.7 mg, 191 μmol, 65% yield). 1H NMR (500 MHz, CD3OD) δ 7.20 (d, J = 9.0 Hz, 2H), 
6.92 (d, J = 8.1 Hz, 1H), 6.77 (d, J = 2.2 Hz, 1H), 6.74 – 6.67 (m, 6H), 1.93 (s, 3H). 
TG-3: To a solution of TG-2 (60.7 mg, 191 μmol, 1 equiv) and K2HPO4 (70.4 mg, 404 μmol, 
2.1 equiv) in anhydrous DMF (1 mL) was added ethyl iodide (19 μL, 37 mg, 240 μmol, 1.2 
equiv) and the reaction was heated to 70 °C for 18 h. The reaction was cooled to room 
temperature, quenched in brine, and extracted with 10% MeOH/CH2Cl2 (3×). The organic layer 
was concentrated and purified via silica chromatography (7.5% Me MeOH/CH2Cl2) to afford an 
orange solid (5.5 mg, 16 μmol, 8.3%) with starting material recollected (13.5 mg, 42.5 μmol, 
22%). 1H NMR (500 MHz, MeOD) δ 7.24 – 7.18 (m, 2H), 6.92 (d, J = 8.2 Hz, 1H), 6.70 (d, J = 
8.3 Hz, 4H), 6.67 – 6.60 (m, 2H), 3.18 (q, J = 7.1 Hz, 2H), 1.92 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H). 
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Scheme C.11: Synthesis of compound 3.45. 
 
(E)-6-(3-(thiophen-2-yl)acryloyl)benzo[d]oxazol-2(3H)-one (3.42): A solution of 3.10 (3.49 g, 
19.7 mmol, 1.0 equiv) and 2-thiophenecarboxaldehyde (2.03 mL, 21.7 mmol, 1.1 equiv) in EtOH 
(100.0 mL) was treated with dropwise addition of aq. KOH (10 M, 5.92 mL, 59.2 mmol, 3.0 
equiv). The reaction was allowed to stir at room temperature for 12 h. After completion, the 
mixture was concentrated and purified via silica gel column chromatography (1% 
MeOH/CH2Cl2) to afford the product as a yellow solid (2.88 g, 10.6 mmol, 54% yield). Rf = 0.09 
(25% Acetone/Hexanes). 1H NMR (500 MHz, DMSO-d6) δ 12.06 (s, 1H), 8.01 (d, J = 1.5 Hz, 
1H), 7.99 (dd, J = 8.1, 1.7 Hz, 1H), 7.90 (d, J = 15.2 Hz, 1H), 7.78 (d, J = 4.9 Hz, 1H), 7.69 – 
7.68 (m, 1H), 7.60 (d, J = 15.2 Hz, 1H), 7.22 (d, J = 8.1 Hz, 1H), 7.19 (dd, J = 5.0, 3.6 Hz, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 187.30, 154.89, 143.94, 140.23, 136.90, 135.35, 133.12, 
132.24, 130.87, 129.14, 126.05, 120.59, 109.97, 109.80. HRMS (ESI, TOF) calc’d for [M+H]+ 
272.0381, found 272.0387. 
tert-butyl (E)-(2-hydroxy-4-(3-(thiophen-2-yl)acryloyl)phenyl)carbamate (3.43). A solution 
of 3.42 (2.63 g, 9.69 mmol, 1.0 equiv), K2CO3 (4.01 g, 29.0 mmol, 3.0 equiv), di-tert-butyl 
dicarbonate (8.50 g, 38.9 mmol, 4.0 equiv) in MeOH (50.0 mL) was heated to 45 ˚C for 7 h. The 
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reaction was quenched with sat. ammonium chloride and then the product extracted with EtOAc 
(3×). The organic layers were combined, dried over anhydrous Na2SO4, concentrated, and 
purified via silica gel column chromatography (30% EtOAc/Hexanes with 0.1% AcOH) to afford 
the product as a yellow solid (2.69 g, 7.80 mmol, 81% yield). Rf = 0.28 (30% EtOAc/Hexanes). 
1H NMR (500 MHz, CDCl3) δ 8.34 (s, 1H), 7.94 (d, J = 15.2 Hz, 1H), 7.85 (d, J = 1.9 Hz, 1H), 
7.81 (d, J = 8.4 Hz, 1H), 7.59 (dd, J = 8.4, 1.8 Hz, 1H), 7.43 (d, J = 5.1 Hz, 1H), 7.21 (s, 1H), 
7.12 – 7.07 (m, 1H), 1.55 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 189.02, 153.29, 145.69, 
140.43, 137.21, 133.04, 132.14, 131.80, 128.99, 128.36, 122.31, 120.40, 118.43, 116.35, 81.79, 
28.28. HRMS (ESI, TOF) calc’d for [M+H]+ 346.1113, found 346.1119. 
tert-butyl (E)-(2-methoxy-4-(3-(thiophen-2-yl)acryloyl)phenyl)(methyl)carbamate (3.44): A 
pressure flask was charged with 3.43 (2.63 g, 7.62 mmol, 1.0 equiv), anhydrous DMF (38.0 mL), 
MeI (2.43 mL, 38.2 mmol, 5.0 equiv), and NaH (60 wt %, 9.18 mg, 23.0 mmol, 3.0 equiv) at 0 
˚C. The reaction was allowed to warm to room temperature and stirred for 1 h before heating to 
70 ˚C for 12 h. The reaction cooled to room temperature and then was diluted in brine. The 
product was extracted with EtOAc (3×), the organic layers were combined, dried over anhydrous 
Na2SO4, concentrated and purified via silica gel column chromatography (25% EtOAc/Hexanes) 
to afford the product as a yellow solid (1.60 g, 4.30 mmol, 56% yield). Rf = 0.13 (10% 
EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 7.94 (d, J = 15.3 Hz, 1H), 7.58 – 7.54 (m, 2H), 
7.43 – 7.39 (m, 1H), 7.36 (d, J = 3.6 Hz, 1H), 7.31 (d, J = 15.3 Hz, 1H), 7.28 – 7.24 (m, 1H), 
7.08 (dd, J = 5.1, 3.6 Hz, 1H), 3.91 (s, 3H), 3.15 (s, 3H), 1.39 (s, 9H). 13C NMR (125 MHz, 
CDCl3) δ 188.96, 155.29, 155.05, 140.46, 137.67, 137.34, 137.14, 132.20, 128.98, 128.49, 
121.25, 120.66, 111.29, 80.15, 55.78, 36.87, 28.35. HRMS (ESI, TOF) calc’d for [M+H]+ 
374.1426, found 374.1432. 
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tert-butyl (2-methoxy-4-(4-nitro-3-(thiophen-2-yl)butanoyl)phenyl)(methyl)carbamate 
(3.45): A solution of 3.42 (1.00 g, 2.68 mmol, 1.0 equiv), nitromethane (0.72 mL, 13.0 mmol, 
5.0 equiv), and diethylamine (0.83 mL, 8.10 mmol, 3.0 equiv) in MeOH (30.0 mL) was heated to 
65 ˚C for 14 h. The reaction was concentrated and purified via silica gel column chromatography 
(30% EtOAc/Hexanes) to afford the product as a yellow solid (0.62 g, 2.68 mmol, 53% yield). Rf 
= 0.34 (30% EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 7.46 (d, J = 7.4 Hz, 2H), 7.19 (d, J 
= 8.0 Hz, 1H), 7.13 (d, J = 5.1 Hz, 1H), 6.91 (d, J = 3.4 Hz, 1H), 6.86 (t, J = 4.4 Hz, 1H), 4.78 
(dd, J = 12.7, 6.3 Hz, 1H), 4.66 (dd, J = 12.8, 7.8 Hz, 1H), 4.49 (p, J = 6.9 Hz, 1H), 3.82 (s, 3H), 
3.45 (qd, J = 17.7, 6.7 Hz, 2H), 3.09 (s, 3H), 1.34 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 
195.63, 155.05, 154.67, 141.87, 137.66, 135.57, 128.56, 127.06, 125.45, 124.61, 120.95, 110.56, 
80.02, 79.80, 55.55, 42.23, 36.64, 34.77, 28.15. HRMS (ESI, TOF) calc’d for [M+H]+ 435.1590, 
found 435.1601. 
 
Scheme C.12: Synthesis of compound 3.48. 
 
1-(4-(prop-2-yn-1-yloxy)phenyl)ethan-1-one (3.46): A suspension of 1-(4-
hydroxyphenyl)ethan-1-one (575 mg, 4.23 mmol, 1.0 equiv), K2CO3 (759 mg, 5.49 mmol, 1.3 
equiv) in anhydrous DMF (10.0 mL) was treated with 3-bromoprop-1-yne (0.52 mL, 5.49 mmol, 
1.3 equiv) and heated to 65 ˚C for 1 h. The reaction was added with water and filtered by 
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vacuum to afford the product as a pale yellow solid (603 mg, 4.23 mmol, 82% yield). Rf = 0.24 
(10% EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 7.86 (d, J = 9.0 Hz, 2H), 6.64 (d, J = 9.1 
Hz, 2H), 3.04 (s, 6H), 2.50 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 196.36, 153.39, 130.51, 
125.36, 110.60, 40.02, 25.98. HRMS (ESI, TOF) calc’d for [M+H]+ 175.0759, found 175.0764. 
(E)-1-(4-(prop-2-yn-1-yloxy)phenyl)-3-(thiophen-2-yl)prop-2-en-1-one (3.47): A solution of 
3.46 (1.69 g, 9.72 mmol, 1.0 equiv) and thiophene-2-carbaldehyde (1.0 mL, 11.0 mmol, 1.2 
equiv) in EtOH (50.0 mL) was treated dropwise with an aq. solution of KOH (10 M, 2.90 mL, 
29.2 mmol, 3.0 equiv). The reaction was allowed to stir at room temperature for 1 h before the 
resulting yellow precipitate was collected via filtration to afford the product as a yellow solid 
(2.32 g, 9.72 mmol, 89% yield). Rf = 0.26 (10% EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 
8.03 (d, J = 8.6 Hz, 2H), 7.93 (d, J = 15.3 Hz, 1H), 7.40 (d, J = 5.0 Hz, 1H), 7.36 – 7.30 (m, 2H), 
7.10 – 7.04 (m, 3H), 4.77 (d, J = 2.4 Hz, 2H), 2.56 (t, J = 2.4 Hz, 1H). 13C NMR (125 MHz, 
CDCl3) δ 188.10, 161.22, 140.54, 136.62, 131.85, 131.78, 130.64, 128.55, 128.33, 120.59, 
114.74, 77.82, 76.18, 55.89. HRMS (ESI, TOF) calc’d for [M+H]+ 269.0636, found 269.0623. 
4-nitro-1-(4-(prop-2-yn-1-yloxy)phenyl)-3-(thiophen-2-yl)butan-1-one (3.48): A solution of 
3.47 (3.41 g, 12.7 mmol, 1.0 equiv), nitromethane (3.44 mL, 63.6 mmol, 5.0 equiv), and 
diethylamine (4.0 mL, 38.17 mmol, 3.0 equiv) in MeOH (130.0 mL) was heated to 65 ˚C for 14 
h. The reaction was concentrated and purified via silica gel column chromatography (20% 
EtOAc/Hexanes) to afford the product as a yellow solid (2.30 g, 6.98 mmol, 54% yield). Rf = 
0.27 (20% EtOAc/Hexanes). 1H NMR (500 MHz, CDCl3) δ 7.95 – 7.92 (m, 2H), 7.21 (dt, J = 
5.0, 1.2 Hz, 1H), 7.04 – 7.01 (m, 2H), 6.97 – 6.93 (m, 2H), 4.87 – 4.82 (m, 1H), 4.76 (dd, J = 
2.4, 1.0 Hz, 2H), 4.70 (ddd, J = 12.6, 7.6, 1.0 Hz, 1H), 3.52 – 3.40 (m, 2H), 2.55 (t, J = 2.4 Hz, 
1H), 2.17 (s, 1H), 1.54 (s, 1H). 13C NMR (125 MHz, CDCl3) δ 206.89, 194.85, 161.71, 142.01, 
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130.31, 130.06, 127.12, 125.53, 124.66, 114.81, 79.92, 76.28, 55.89, 41.97, 34.86, 30.91. HRMS 
(ESI, TOF) calc’d for [M+H]+ 330.0800, found 330.0790.  
 
Scheme C.13: Synthesis of SR-APNO-1. 
 
tert-butyl (Z)-(2-methoxy-4-(4-phenyl-5-((5-(4-(prop-2-yn-1-yloxy)phenyl)-3-(thiophen-2-
yl)-2H-pyrrol-2-ylidene)amino)-1H-pyrrol-2-yl)phenyl)(methyl)carbamate (3.49): A 
suspension of 3.29 (267.7 mg, 815.2 µmol, 1.0 equiv), and 3.48 (805.5 mg, 2.45 mmol, 3.0 
equiv) in n-butanol (16.0 mL) was heated to 110 ˚C to dissolve all solids. NH4OAc (942.6 mg, 
12.23 mmol, 15 equiv) was added in a single portion and the reaction was stirred at the same 
temperature for 5 h. Volatiles were removed under reduced pressure, the residue was suspended 
in brine, and the product was extracted with CH2Cl2 (3×). The combined organic layers were 
dried over anhydrous Na2SO4, concentrated, and purified via silica gel column chromatography 
(90% CH2Cl2/Hexanes) to afford the product as blue solid (219.8 mg, 0.82 mmol, 48% yield). Rf 
=  0.32 (50% CH2Cl2/Hexanes) 1H NMR (500 MHz, CDCl3) δ 8.12 – 8.09 (m, 2H), 7.77 – 7.73 
(m, 2H), 7.65 (dd, J = 3.6, 1.2 Hz, 1H), 7.58 (dd, J = 8.2, 1.8 Hz, 1H), 7.55 (d, J = 1.8 Hz, 1H), 
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7.47 (dd, J = 8.2, 7.0 Hz, 2H), 7.41 – 7.36 (m, 1H), 7.33 (dd, J = 5.0, 1.1 Hz, 1H), 7.08 (dd, J = 
5.1, 3.6 Hz, 1H), 7.02 – 6.98 (m, 2H), 6.88 (s, 1H), 6.64 (d, J = 8.3 Hz, 1H), 4.93 – 4.85 (m, 1H), 
4.75 (d, J = 2.4 Hz, 2H), 4.03 (s, 3H), 3.01 – 2.95 (m, 3H), 2.58 (t, J = 2.3 Hz, 1H). 13C NMR 
(125 MHz, CDCl3) δ 163.62, 158.13, 156.09, 146.95, 146.30, 144.15, 143.13, 142.90, 136.97, 
133.80, 131.23, 129.68, 128.31, 128.24, 127.40, 126.81, 126.35, 125.87, 125.77, 123.86, 120.70, 
119.05, 115.50, 108.47, 108.21, 106.97, 78.37, 76.08, 56.08, 55.47, 30.02, 29.85. HRMS (ESI, 
TOF) calc’d for [M+H]+ 569.1987, found 569.1994. 
4-(5,5-difluoro-1-phenyl-7-(4-(prop-2-yn-1-yloxy)phenyl)-9-(thiophen-2-yl)-5H-5λ4,6λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,5,2]triazaborinin-3-yl)-2-methoxy-N-methylaniline (3.50): A 
solution of 3.49 (97.2 mg, 0.17 mmol, 1.0 equiv) and N,N-diisopropylethylamine (0.45 mL, 2.56 
mmol, 15.0 equiv) in anhydrous CH2Cl2 (8.5 mL) was treated with boron trifluoride diethyl 
etherate (0.33 mL, 2.56 mmol, 15.0 equiv). The reaction was allowed to stir at room temperature 
for 3 h under a nitrogen atmosphere. After completion, the reaction was quenched with minimal 
sat. aq. NaHCO3 and diluted in brine. The product was extracted with CH2Cl2 (3×), the combined 
organic layers were dried over anhydrous Na2SO4, concentrated, and purified via silica gel 
column chromatography (80% CH2Cl2/Hexanes) to afford the product as a purple solid (62.3 mg, 
0.10 mmol, 59% yield). Rf = 0.31 (50% CH2Cl2/Hexanes) 1H NMR (500 MHz, CDCl3) δ 8.15 – 
8.12 (m, 2H), 8.05 – 8.02 (m, 2H), 7.96 (d, J = 1.9 Hz, 1H), 7.78 (dd, J = 8.5, 2.0 Hz, 1H), 7.69 
(dd, J = 3.7, 1.1 Hz, 1H), 7.53 – 7.49 (m, 2H), 7.47 – 7.43 (m, 2H), 7.25 (s, 1H), 7.12 (dd, J = 
5.1, 3.7 Hz, 1H), 7.04 (d, J = 9.0 Hz, 2H), 6.83 (s, 1H), 6.63 (d, J = 8.6 Hz, 1H), 4.76 (d, J = 2.4 
Hz, 2H), 3.94 (s, 3H), 2.99 (d, J = 5.3 Hz, 3H), 2.56 (t, J = 2.4 Hz, 1H). 13C NMR (125 MHz, 
CDCl3) δ 160.44, 158.84, 152.94, 146.38, 143.81, 143.14, 135.83, 132.45, 131.03, 129.77, 
129.41, 128.66, 128.60, 128.38, 127.77, 127.48, 127.38, 126.23, 125.49, 120.29, 118.54, 115.64, 
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114.76, 114.46, 110.94, 108.47, 78.43, 75.96, 55.98, 55.80, 31.74, 29.81, 22.81, 14.27. 19F NMR 
(471 MHz, CDCl3) δ -131.18 (dd, J = 65.4, 32.5 Hz). 11B NMR (161 MHz, CDCl3) δ 1.28 (t, J = 
32.7 Hz). HRMS (ESI, TOF) calc’d for [M+H]+ 616.1916, found 616.1988. 
SR-APNO-1: A solution of 3.50 (18.2 mg, 28.8 µmol, 1.0 equiv), 3,3',3''-
((nitrilotris(methylene))tris(1H-1,2,3-triazole-4,1-diyl))tris(propan-1-ol) (4.50 mg, 10.4 µmol, 
0.4 equiv), 3.37 (38.3 mg, 98.5 µmol, 3.4 equiv), and copper(II) sulfate pentahydrate (36.0 mg, 
144.1 µmol, 5.0 equiv), in anhydrous THF (6.0 mL) was treated with dropwise sodium ascorbate 
(8.6 mg, 43.2 µmol, 1.5 equiv) in water (0.7 mL, degassed) at room temperature for 3 h under 
nitrogen atmosphere. The volatiles were removed by reduced pressure and the residual was 
diluted in 50% MeOH/CH2Cl2 and washed with sat. aq. sodium iodide (2×). The combined 
organic layers were dried over anhydrous Na2SO4, concentrated, and purified via silica gel 
column chromatography (10% MeOH/CHCl3) to afford the product as a purple solid (20.3 mg, 
19.9 µmol, 69% yield).  Rf = 0.22 (10% MeOH/CHCl3). 1H NMR (500 MHz, CD2Cl2) δ 8.18 – 
8.13 (m, 2H), 8.08 – 8.02 (m, 1H), 7.91 (s, 1H), 7.83 (dd, J = 8.6, 2.0 Hz, 1H), 7.71 (dd, J = 3.7, 
1.2 Hz, 1H), 7.54 (dd, J = 8.2, 6.7 Hz, 2H), 7.50 – 7.45 (m, 2H), 7.32 (s, 1H), 7.17 – 7.10 (m, 
3H), 6.90 (s, 1H), 6.68 (s, 0H), 5.29 (s, 2H), 4.62 – 4.52 (m, 2H), 3.96 (s, 3H), 3.90 (q, J = 4.9, 
4.4 Hz, 2H), 3.75 (dq, J = 7.5, 2.7 Hz, 2H), 3.64 – 3.50 (m, 7H), 3.42 – 3.35 (m, 2H), 3.04 (s, 
8H), 3.00 (d, J = 4.8 Hz, 3H). 13C NMR (125 MHz, CD2Cl2) δ 160.25, 159.50, 146.85, 146.23, 
144.14, 143.60, 135.30, 133.31, 132.02, 130.88, 129.57, 129.50, 128.84, 128.62, 127.71, 127.61, 
127.49, 125.65, 124.45, 120.52, 117.92, 114.73, 114.08, 110.65, 108.37, 70.49, 70.39, 70.22, 
70.11, 69.30, 66.23, 64.87, 61.80, 55.86, 55.04, 55.01, 54.98, 50.55, 29.69. 19F NMR (471 MHz, 
CD2Cl2) δ -130.30 (dd, J = 65.4, 32.3 Hz). 11B NMR (161 MHz, CD2Cl2) δ 1.27 (t, J = 32.9 Hz). 
HRMS (ESI, TOF) calc’d for [M]+ 877.3837, found 877.3842. 
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Scheme C.14: Synthesis of SR-APNO-2. 
 
tert-butyl (Z)-(2-methoxy-4-(5-((3-phenyl-5-(4-(prop-2-yn-1-yloxy)phenyl)-2H-pyrrol-2-
ylidene)amino)-4-(thiophen-2-yl)-1H-pyrrol-2-yl)phenyl)(methyl)carbamate (3.51): A 
suspension of 3.33 (415.5 mg, 956.2 µmol, 1.0 equiv), and  3.45 (947.6 mg, 2.93 mmol, 3.1 
equiv) in n-butanol (19.0 mL) was heated to 110 ˚C to dissolve all solids. NH4OAc (1.106 g, 
14.34 mmol, 15 equiv) was added in a single portion and reaction was stirred at the same 
temperature for 6 h. Volatiles were removed under reduced pressure, the residue was suspended 
in brine, and the product was extracted with CH2Cl2 (3×). The combined organic layers were 
dried over anhydrous Na2SO4, concentrated, and purified via silica gel column chromatography 
(90% CH2Cl2/Hexanes) to afford the product as a blue solid (131.2 mg, 0.96 mmol, 24% yield). 
Rf =  0.48 (100% CH2Cl2) 1H NMR (500 MHz, CDCl3) δ 8.08 – 8.05 (m, 2H), 7.94 – 7.91 (m, 
2H), 7.73 – 7.71 (m, 1H), 7.47 (dd, J = 8.4, 6.9 Hz, 2H), 7.44 (d, J = 7.5 Hz, 2H), 7.41 – 7.37 (m, 
2H), 7.15 (s, 1H), 7.10 (dd, J = 5.1, 3.7 Hz, 1H), 7.09 – 7.03 (m, 2H), 4.79 (d, J = 2.4 Hz, 2H), 
4.01 (s, 3H), 3.20 (s, 3H), 2.60 – 2.58 (m, 1H), 1.43 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 
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159.46, 158.78, 155.30, 155.24, 144.06, 136.07, 135.74, 133.57, 131.55, 129.52, 128.32, 128.28, 
128.20, 127.50, 127.33, 126.98, 125.84, 119.20, 115.83, 115.49, 111.77, 108.61, 80.01, 77.98, 
76.17, 55.97, 55.42, 47.43, 29.72, 28.34, 14.14. HRMS (ESI, TOF) calc’d for [M+H]+ 668.2457, 
found 669.2540. 
4-(5,5-difluoro-9-phenyl-7-(4-(prop-2-yn-1-yloxy)phenyl)-1-(thiophen-2-yl)-5H-5λ4,6λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,5,2]triazaborinin-3-yl)-2-methoxy-N-methylaniline (3.52): A 
solution of 3.51 (183.6 mg, 0.32 mmol, 1.0 equiv) and N,N-diisopropylethylamine (0.84 mL, 
4.84 mmol, 15 equiv) in anhydrous CH2Cl2 (16.0 mL) was treated with boron trifluoride diethyl 
etherate (0.62 mL, 4.84 mmol, 15 equiv). The reaction was stirred at room temperature for 6 h 
under a nitrogen atmosphere and then was quenched with minimal sat. aq. NaHCO3. The 
solution was then diluted with brine and the product was extracted with CH2Cl2 (3×). The 
combined organic layers were dried over anhydrous Na2SO4, concentrated, and purified via silica 
gel column chromatography (80% CH2Cl2/Hexanes) to afford the product as a purple solid 
(128.7 mg, 0.32 mmol, 65% yield). Rf = 0.36 (50% CH2Cl2/Hexanes) 1H NMR (500 MHz, 
CDCl3) δ 8.11 – 8.08 (m, 2H), 8.07 – 8.04 (m, 2H), 7.93 (s, 1H), 7.83 (dd, J = 3.7, 1.1 Hz, 1H), 
7.75 (dd, J = 8.5, 2.0 Hz, 1H), 7.52 (dd, J = 5.0, 1.1 Hz, 1H), 7.48 (t, J = 7.7 Hz, 2H), 7.39 (td, J 
= 7.1, 1.3 Hz, 1H), 7.17 – 7.12 (m, 2H), 7.06 – 7.02 (m, 2H), 6.92 (s, 1H), 6.61 (d, J = 8.5 Hz, 
1H), 5.10 (s, 1H), 4.76 (d, J = 2.4 Hz, 2H), 3.93 (s, 3H), 2.97 (s, 3H), 2.56 (t, J = 2.4 Hz, 1H). 
13C NMR (125 MHz, CDCl3) δ 160.88, 158.67, 152.43, 146.39, 146.20, 143.66, 143.25, 139.16, 
138.02, 134.41, 133.42, 130.97, 129.91, 129.34, 128.89, 128.46, 128.29, 127.82, 127.08, 126.32, 
118.22, 116.99, 116.86, 114.62, 110.71, 108.30, 78.31, 75.83, 55.84, 55.66, 31.61, 29.66, 22.67, 
14.14. 19F NMR (471 MHz, CDCl3) δ -131.08 (dd, J = 65.3, 32.4 Hz). 11B NMR (161 MHz, 
CDCl3) δ 1.29 (t, J = 32.7 Hz). HRMS (ESI, TOF) calc’d for [M+H]+ 569.1987, found 569.1994. 
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SR-APNO-2: A solution of 3.52 (28.2 mg, 44.7 µmol, 1.0 equiv), 3,3',3''-
((nitrilotris(methylene))tris(1H-1,2,3-triazole-4,1-diyl))tris(propan-1-ol) (5.60 mg, 12.9 µmol, 
0.3 equiv), 3.37 (57.2 mg, 147 µmol, 3.3 equiv), and copper(II) sulfate pentahydrate (55.7 mg, 
223 µmol, 5.0 equiv), in anhydrous THF (8.9 mL) was treated with dropwise sodium ascorbate 
(46.2 mg, 233.0 µmol, 5.2 equiv) in water (1.1 mL, degassed) at room temperature under 
nitrogen atmosphere. The reaction was allowed to stir at the same temperature for 2 h before 
heating to 65 ˚C for an additional 4 h. The volatiles were removed by reduced pressure, the 
reaction was diluted in 50% MeOH/DCM, and the organic layer was washed with sat. aq. sodium 
iodide (2×). The combined organic layers were dried over anhydrous Na2SO4, concentrated, and 
purified via silica gel column chromatography (10% MeOH/CHCl3) to afford the product as a 
purple solid (17.6 mg, 17.3 µmol, 39% yield).  Rf = 0.25 (10% MeOH/CHCl3). 1H NMR (500 
MHz, CD2Cl2) δ 8.14 – 8.10 (m, 2H), 8.07 (d, J = 8.4 Hz, 2H), 7.94 (bs, 1H), 7.89 (d, J = 1.9 Hz, 
1H), 7.86 (dd, J = 3.8, 1.1 Hz, 1H), 7.81 (dd, J = 8.5, 2.0 Hz, 1H), 7.60 (dd, J = 5.0, 1.1 Hz, 1H), 
7.51 (t, J = 7.6 Hz, 2H), 7.44 – 7.39 (m, 1H), 7.23 (s, 1H), 7.19 (dd, J = 5.1, 3.7 Hz, 1H), 7.14 (d, 
J = 8.5 Hz, 2H), 6.98 (s, 1H), 6.67 (d, J = 8.5 Hz, 1H), 4.57 (t, J = 4.9 Hz, 2H), 3.97 (s, 3H), 3.91 
(t, J = 4.9 Hz, 2H), 3.74 (dt, J = 6.8, 3.0 Hz, 2H), 3.62 – 3.58 (m, 2H), 3.54 (m, 6H), 3.39 – 3.35 
(m, 2H), 3.05 (s, 9H), 3.01 (s, 3H). 13C NMR (126 MHz, CD2Cl2) δ 160.87, 159.46, 151.66, 
146.37, 146.21, 144.09, 142.95, 138.84, 133.98, 133.18, 130.98, 130.52, 129.23, 129.13, 128.56, 
128.46, 127.92, 127.32, 125.88, 117.77, 117.19, 116.67, 114.72, 110.56, 108.31, 70.56, 70.36, 
70.30, 70.17, 69.19, 66.20, 64.86, 61.84, 55.85, 55.00, 54.97, 54.95, 50.62, 31.93, 29.68, 22.69, 
13.87. 19F NMR (471 MHz, CD2Cl2) δ -130.31 (dd, J = 60.0, 27.5 Hz). 11B NMR (161 MHz, 
CD2Cl2) δ 1.27 (t, J = 32.8 Hz). HRMS (ESI, TOF) calc’d for [M]+ 877.3845, found 877.3844. 
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Scheme C.15: Synthesis of SR-APNO-3. 
 
tert-butyl (Z)-(2-methoxy-4-(5-((5-(4-(prop-2-yn-1-yloxy)phenyl)-3-(thiophen-2-yl)-2H-
pyrrol-2-ylidene)amino)-4-(thiophen-2-yl)-1H-pyrrol-2-yl)phenyl)(methyl)carbamate 
(3.53): A suspension of 3.45 (0.24 g, 0.55 mmol, 1.0 equiv), and 3.48 (0.49 g, 1.50 mmol, 2.7 
equiv) in n-butanol (11.0 mL) was heated to 110 ˚C to dissolve all solids. NH4OAc (0.84 g, 11.0 
mmol, 20 equiv) was added in a single portion and reaction was stirred at the same temperature 
for 6 h. Volatiles were removed under reduced pressure, the resulting solid was suspended in 
brine, and the product was extracted with CH2Cl2 (3×). The combined organic layers were dried 
over anhydrous Na2SO4, concentrated, and purified via silica gel column chromatography (step 
gradient: 90% CH2Cl2/Hexanes, 100% CH2Cl2, then 1% MeOH/CH2Cl2) to afford the product as 
a blue solid (0.11 g, 0.55 mmol, 29% yield). Rf = 0.63 (100 % CH2Cl2) 1H NMR (500 MHz, 
DMSO-d6) δ 12.77 (s, 1H), 8.17 – 8.12 (m, 2H), 7.97 (d, J = 3.6 Hz, 1H), 7.90 – 7.86 (m, 1H), 
7.76 (d, J = 5.0 Hz, 1H), 7.72 (d, J = 5.0 Hz, 1H), 7.64 (d, J = 1.8 Hz, 1H), 7.62 – 7.57 (m, 2H), 
7.52 (s, 1H), 7.40 (d, J = 8.1 Hz, 1H), 7.24 (ddd, J = 6.8, 5.0, 3.6 Hz, 2H), 7.17 (d, J = 8.8 Hz, 
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2H), 4.97 (d, J = 2.4 Hz, 2H), 4.06 (s, 3H), 3.69 (t, J = 2.3 Hz, 1H), 3.11 (s, 3H), 1.37 (s, 9H). 
13C NMR (125 MHz, DMSO-d6) δ 159.77, 159.49, 154.86, 154.07, 151.63, 149.52, 145.08, 
138.12, 135.19, 134.78, 133.70, 133.64, 130.32, 129.07, 128.98, 128.27, 128.24, 127.95, 127.82, 
127.41, 126.89, 124.69, 118.87, 115.67, 115.56, 112.14, 108.82, 79.12, 78.80, 78.76, 55.78, 
55.49, 55.45, 27.90.HRMS (ESI, TOF) calc’d for [M+H]+ 675.2100, found 675.2103. 
4-(5,5-difluoro-7-(4-(prop-2-yn-1-yloxy)phenyl)-1,9-di(thiophen-2-yl)-5H-5λ4,6λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,5,2]triazaborinin-3-yl)-2-methoxy-N-methylaniline (3.54): A 
solution of 3.53 (0.24 g, 0.35 mmol, 1.0 equiv) and N,N-diisopropylethylamine (0.92 mL, 5.20 
mmol, 15 equiv) in anhydrous CH2Cl2 (15.0 mL) was treated with boron trifluoride diethyl 
etherate (0.67 mL, 5.20 mmol, 15 equiv). The reaction was stirred at room temperature for 3 h 
under a nitrogen atmosphere. The reaction was quenched with minimal sat. aq. NaHCO3 and 
then extracted with CH2Cl2 (3×) from brine. The combined organic layers were dried over 
anhydrous Na2SO4, concentrated, and purified via silica gel column chromatography (step 
gradient: 20% CH2Cl2/Hexanes to 60% CH2Cl2/Hexanes, 10% steps) to afford the product as a 
purple solid (0.12 g, 0.19 mmol, 55% yield). Rf = 0.25 (50% CH2Cl2/Hexanes) 1H NMR (500 
MHz, CD2Cl2) δ 8.04 (d, J = 2.1 Hz, 1H), 8.02 (d, J = 3.0 Hz, 2H), 7.91 (d, J = 1.9 Hz, 1H), 7.85 
– 7.79 (m, 2H), 7.60 (dd, J = 5.0, 1.2 Hz, 1H), 7.51 (dd, J = 5.1, 1.1 Hz, 1H), 7.25 – 7.21 (m, 
2H), 7.19 (dd, J = 5.1, 3.6 Hz, 1H), 7.08 – 7.03 (m, 2H), 6.88 (s, 1H), 6.66 (d, J = 8.6 Hz, 1H), 
5.27 (q, J = 5.5 Hz, 1H), 4.79 (d, J = 2.4 Hz, 2H), 3.94 (s, 3H), 2.99 (d, J = 5.0 Hz, 3H), 2.63 (t, 
J = 2.3 Hz, 1H). 13C NMR (125 MHz, CD2Cl2) δ 161.22, 159.27, 152.39, 146.97, 146.83, 
144.74, 142.99, 138.35, 136.15, 134.81, 133.42, 131.40, 131.36, 130.38, 130.09, 128.82, 128.70, 
128.45, 128.30, 128.05, 126.61, 118.36, 115.14, 111.23, 108.83, 78.85, 76.14, 56.43, 56.24, 
30.26, 30.07. 19F NMR (471 MHz, CD2Cl2) δ -130.74 (dd, J = 65.4, 32.6 Hz). 11B NMR (161 
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MHz, CD2Cl2) δ 1.22 (t, J = 32.7 Hz). HRMS (ESI, TOF) calc’d for [M+H]+ 623.1558, found 
623.1568. 
SR-APNO-3: A solution of 3.55 (23.8 mg, 38.0 µmol, 1.0 equiv), 3,3',3''-
((nitrilotris(methylene))tris(1H-1,2,3-triazole-4,1-diyl))tris(propan-1-ol) (3.15 mg, 7.25 µmol, 
0.2 equiv), 3.37 (44.0 mg, 114 µmol, 2.97 equiv), copper(II) sulfate pentahydrate (96.1 mg, 385 
µmol, 10 equiv), and anhydrous THF (1.9 mL) was treated dropwise with a solution of sodium 
ascorbate (15.8 mg, 79.8 µmol, 2.1 equiv) in water (382 µL, degassed). The reaction was then 
heated to 65 ˚C for 3 h under nitrogen atmosphere. The volatiles were removed under reduced 
pressure, the residue was diluted in 50% MeOH/CH2Cl2, and the organic layer was washed with 
sat. aq. sodium iodide (2×). The organic layer was collected, dried over anhydrous Na2SO4, 
concentrated, and purified via silica gel column chromatography (5 
% MeOH/CHCl3) to afford the product as a purple solid (31.8 mg, 31.5 µmol, 82% yield).  Rf = 
0.09 (5% MeOH/CHCl3). 1H NMR (500 MHz, DMSO-d6) δ 8.33 (s, 1H), 8.26 (s, 1H), 8.15 (d, J 
= 3.7 Hz, 1H), 8.13 – 8.08 (m, 1H), 8.05 (d, J = 8.5 Hz, 2H), 7.98 – 7.87 (m, 4H), 7.74 (d, J = 
5.0 Hz, 1H), 7.34 – 7.29 (m, 1H), 7.25 – 7.22 (m, 1H), 7.22 – 7.15 (m, 4H), 6.74 (d, J = 8.9 Hz, 
1H), 5.26 (s, 2H), 4.57 (t, J = 5.2 Hz, 2H), 3.94 (s, 3H), 3.84 (t, J = 5.3 Hz, 2H), 3.82 – 3.77 (m, 
2H), 3.57 – 3.46 (m, 12H), 3.32 (s, 3H), 3.08 (s, 9H), 2.93 (d, J = 5.1 Hz, 3H). 13C NMR (125 
MHz, DMSO-d6) δ 159.89, 158.99, 148.74, 146.10, 146.02, 145.41, 142.34, 140.59, 136.89, 
134.90, 133.06, 131.53, 130.40, 130.16, 130.01, 129.52, 128.95, 128.21, 127.99, 127.55, 125.03, 
119.35, 116.01, 114.60, 114.12, 110.84, 109.01, 79.20, 69.56, 69.52, 69.40, 69.32, 68.67, 64.39, 
64.02, 61.23, 55.62, 53.07, 53.04, 49.45, 29.33, 18.55. 19F NMR (471 MHz, DMSO-d6) δ -
129.11 (dd, J = 66.4, 29.7 Hz). 11B NMR (161 MHz, DMSO-d6) δ 1.26 (t, J = 33.1 Hz). HRMS 
(ESI, TOF) calc’d for [M]+ 883.3047, found 883.3395. 
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Scheme C.16: Synthesis of CyAPNO. 
 
1-nitro-4-(prop-2-yn-1-yloxy)benzene (3.55): A solution of 4-nitrophenol (1.00g, 7.20 mmol, 1 
equiv) in anhydrous acetonitrile (10 mL) was treated with potassium carbonate (1.09 g, 7.92 
mmol, 1.1 equiv) and propargyl bromide (0.96 mL, 1.29 g, 8.65 mmol, 1.2 equiv). The reaction 
was allowed to proceed at 80 °C for 19 h before cooling to room temperature and diluting with 
EtOAc. The solution was washed with sat. aq. sodium bicarbonate (2×) and then brine (1×). The 
organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to 
afford the product as a white solid (1.22 g, 6.91 mmol, 95% yield). 1H NMR (500 MHz, CDCl3) 
δ 8.26 – 8.20 (m, 2H), 7.09 – 7.03 (m, 2H), 4.80 (d, J = 2.4 Hz, 2H), 2.58 (t, J = 2.4 Hz, 1H). 13C 
NMR (125 MHz, CDCl3) δ 162.48, 142.34, 126.00, 115.14, 56.45. HRMS (EI-TOF) for [M+] 
calc’d 177.04260, found 177.04267. 
4-(prop-2-yn-1-yloxy)aniline (3.56): To a mixture of 3.55 (0.199 g, 1.13 mmol, 1 equiv) and 
stannous chloride dihydrate (1.91 g, 8.47 mmol, 7.5 equiv) were added EtOAc (2.3 mL) and then 
conc. aq. HCl (11.7 M, 0.96 mL, 0.41 g, 11 mmol, 10 equiv). The reaction was heated to 80 °C 
for 12 h before cooling to room temperature. The reaction was quenched with sat. aq. sodium 
bicarbonate and then extracted with CH2Cl2 (3×). The organic layer was dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. The product was purified via silica 
chromatography (75% EtOAc/Hexanes) to afford the product as a yellow-brown oil (0.132 g, 
0.896 mmol, 80% yield). 1H NMR (500 MHz, CDCl3) δ 6.86 – 6.79 (m, 2H), 6.68 – 6.61 (m, 
NO2
OH
NO2
O
NH2
O
SnCl2•2H2O
HCl
EtOAc
K2CO3
MeCN
NH
O
N NI
Cyanine-Cl
TEA
DMF
95% 16%80%
Br
3.55 3.56 CyAPNO
 225 
2H), 4.61 (d, J = 2.4 Hz, 2H), 3.49 (bs, 1H), 2.49 (t, J = 2.4 Hz, 1H). 13C NMR (125 MHz, 
CDCl3) δ 150.87, 141.06, 116.57, 116.38, 79.27, 75.26, 56.90. HRMS (ESI-TOF) for [M+H] 
calc’d 148.0762, found 148.0755. 
CyAPNO: Cy7-Cl1 (509 mg, 0.80 mmol, 1 equiv) and 3.56 (147 mg, 1.0 mmol, 1.3 equiv) were 
dissolved in anhydrous DMF (15 mL) and then treated with TEA (0.12 mL, 89 mg, 0.88 mmol, 
1.1 equiv). The reaction was heated at 55 °C for 3 h before cooling to room temperature and 
diluting with excess brine. The product was extracted with CH2Cl2 (3×). The organic layer was 
dried over anhydrous Na2SO4 and concentrated under reduced pressure. The product was 
purified via silica chromatography (7.5% MeOH/CH2Cl2). Pure fractions were pooled, 
concentrated and re-dissolved in CH2Cl2. The organic layer was washed once with sat. aq. 
potassium iodide, 1M aq. HCl, dried over minimal Na2SO4, and concentrated to afford the 
product as a blue solid (95.2 mg, 0.127 mmol, 16% yield). 1H NMR (400 MHz, CDCl3) δ 8.07 
(d, J = 14.2 Hz, 2H), 7.49 – 7.37 (m, 2H), 7.30 – 7.16 (m, 6H), 7.07 (t, J = 7.5 Hz, 2H), 6.93 – 
6.87 (m, 4H), 5.74 (dd, J = 13.7, 3.6 Hz, 2H), 4.57 (d, J = 2.4 Hz, 1H), 3.95 (q, J = 7.3 Hz, 4H), 
2.54 (t, J = 6.4 Hz, 5H), 2.45 (t, J = 2.4 Hz, 1H), 1.91 (q, J = 6.5 Hz, 2H), 1.40 (s, 12H), 1.34 (t, 
J = 7.2 Hz, 6H). HRMS (ESI-TOF) for [M+] calc’d 622.3797, found 622.3798. 
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Scheme C.17: Synthesis of F2-Cyanine-Cl. 
 
Methyl 2-(2-nitrophenyl)acetate (3.57). The compound was prepared according to a modified 
procedure by Sulikowski and coworkers.2 A solution of 2-nitrophenylacetic acid (32.3 g, 178 
mmol, 1.0 equiv) in anhydrous MeOH (180 mL), was treated with concentrated sulfuric acid 
(18.4 M, 1.94 mL, 35.7 mmol, 0.2 equiv) and refluxed for 5 h. The reaction was then cooled to 
room temperature, concentrated under reduced pressure and diluted in EtOAc. The organic layer 
was washed with sat. aq. sodium bicarbonate (2×) and brine (1×), and then dried over anhydrous 
Na2SO4. The solution was concentrated under reduced pressure to afford the product as a light-
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yellow oil (32.9 g, 169 mmol, 95%), which was used without further purification. Spectroscopic 
analyses were consistent with previous reports. 
Methyl 2-methyl-2-(2-nitrophenyl)propanoate (3.58). The compound was prepared according 
to a modified procedure by Glorius and coworkers.3 To solution of 3.57 (32.9 g, 169 mmol, 1.0 
equiv) and MeI (26.4 mL, 422 mmol, 2.5 equiv) in anhydrous DMF (300 mL) was added NaH 
(60 wt. %, 20.2 g, 506 mmol, 3.0 equiv) portion-wise at 0 °C.  After the evolution of gas 
subsided, additional MeI (26.4 mL, 422 mmol, 2.5 equiv) was added at the same temperature and 
then the reaction was allowed to warm to room temperature and continue stirring for 13 h. The 
reaction was quenched by adding it to ice and then the mixture was diluted in EtOAc. The 
mixture was further diluted with brine and the product was extracted with EtOAc (3×). The 
organic layers were combined, dried over anhydrous Na2SO4, concentrated under reduced 
pressure, and the product was purified via silica chromatography (20% EtOAc/hexanes) to afford 
the product as yellow oil (34.1 g, 153 mmol, 91%). Spectroscopic analyses were consistent with 
previous reports. 
2-methyl-2-(2-nitrophenyl)propanoic acid (3.59). To a 250 mL pressure flask were added 3.58 
(17.1 g, 76.6 mmol, 1.0 equiv), 1,4-dioxane (3.83 mL) and aq. potassium hydroxide (10 M, 38.3 
mL, 38. mmol, 5.0 equiv). The vessel was sealed and then heated to 130 °C for 3 h. When the 
reaction was complete according to TLC, it was cooled to room temperature over the course of 1 
h and then acidified with aq. HCl (2 M, 250 mL, 6.5 equiv) to a pH of ~1. The product was 
collected via filtration as an light red solid (16.2 g, 72.5 mmol, 95%). Note that the product can 
be further purified by recrystallization in hexanes with a minimal amount of EtOAc to afford an 
off-white solid, although it is not necessary for subsequent reactions. 1H NMR (500 MHz, 
CDCl3) δ 11.42 (s, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.60 (d, J = 4.3 Hz, 2H), 7.44 – 7.37 (m, 1H), 
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1.68 (s, 6H). 13C NMR (125 MHz, CDCl3) δ 181.98, 148.37, 138.78, 133.54, 128.22, 128.03, 
125.80, 46.43, 27.18. 
N-methoxy-N,2-dimethyl-2-(2-nitrophenyl)propanamide (3.60). A solution of 3.59 (29.3 g, 
140 mmol, 1.0 equiv) in thionyl chloride (100 mL) was refluxed at 80 °C overnight under a 
nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure and cooled 
to 0 °C before potassium iodide (7.4 g, 45 mmol, 0.3 equiv), N,O-dimethylhydroxylamine 
hydrochloride (28.9 g, 296 mmol, 2.1 equiv) and acetonitrile (200 mL) were added. Dropwise 
addition of TEA (97 mL, 700 mmol, 5 equiv) in acetonitrile (170 mL) initiated the reaction at the 
same temperature. The reaction was allowed to warm to room temperature and proceed for 3 h. 
The reaction was quenched with minimal water and concentrated under reduced pressure. The 
reaction was acidified with aq. HCl (1M) to a pH of less than 3 and then extracted with CH2Cl2 
(3×). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. The product was purified via silica chromatography (50% EtOAc/hexanes) to afford an 
orange-red oil (20.3 g, 80.5 mmol, 58%). 1H NMR (500 MHz, CDCl3) δ 7.76 – 7.67 (m, 1H), 
7.57 – 7.48 (m, 2H), 7.34 (m, 1H), 3.10 (s, 3H), 2.90 (s, 3H), 1.57 (s, 6H). 
2-methyl-2-(2-nitrophenyl)propanal (3.61). To a solution of 3.60 (10.1 g, 40.0 mmol, 1.0 
equiv) in toluene (130 mL) at -78 °C was added DIBAL-H (1M in heptane, 140 mL, 140mmol, 
3.5 equiv) over 30 min. After addition, the reaction was allowed to stir at the same temperature 
for 3 h. The reaction was quenched by slow addition of methanol (32 mL) and then it was diluted 
with EtOAc. The mixture was treated with sat. aq. Rochelle’s salt and allowed to stir until all the 
solids dissolved. The organic layer was washed with sat. aq. Rochelle’s salt (2×) and brine (1×). 
The solution was dried over anhydrous Na2SO4 and then the product was purified via silica 
chromatography (20% EtOAc/hexanes) to afford an orange-red oil (5.2 g, 40.0 mmol, 67%). 1H 
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NMR (400 MHz, CDCl3) δ 9.61 (s, 1H), 7.93 (dd, J = 8.1, 1.5 Hz, 1H), 7.64 (ddd, J = 7.9, 7.2, 
1.5 Hz, 1H), 7.57 (dd, J = 8.0, 1.5 Hz, 1H), 7.46 (ddd, J = 8.1, 7.3, 1.5 Hz, 1H), 1.53 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 200.67, 137.74, 133.64, 129.35, 128.45, 125.88, 49.64, 24.37. 
2-(2-(2-nitrophenyl)propan-2-yl)oxirane (3.62). To a mixture of NaH (60 wt. %, 3.4 g, 84.9 
mmol, 2 equiv), and trimethylsulfonium iodide (17.3 g, 84.9 mmol, 2 equiv) in anhydrous THF 
(70 mL) at 0 °C, was added 3.61 (8.2 g, 42.4 mmol, 1 equiv) in anhydrous DMSO (70 mL) and 
anhydrous THF (36 mL) dropwise. After addition, the reaction was allowed to warm to room 
temperature and stir for 5 h. The reaction solution was then cooled to at 0 °C and quenched with 
aq. HCl (2M, 35 mL). The resulting solution was diluted in 1:1 EtOAc/diethyl ether and washed 
with brine (3×). The organic layer was dried over Na2SO4 and concentrated under reduced 
pressure. The product was purified via silica chromatography (20% EtOAc/hexanes) to afford a 
yellow-brown oil (4.4 g, 21.2 mmol, 50%). 1H NMR (400 MHz, CDCl3) δ 7.65 (dd, J = 7.8, 1.0 
Hz, 1H), 7.49 (ddd, J = 8.1, 6.2, 2.7 Hz, 1H), 7.39 – 7.33 (m, 2H), 3.12 (dd, J = 3.9, 2.8 Hz, 1H), 
2.82 (t, J = 4.3 Hz, 1H), 2.74 (dd, J = 4.5, 2.8 Hz, 1H), 1.41 (s, 3H), 1.27 (s, 3H). 
1-fluoro-3-methyl-3-(2-nitrophenyl)butan-2-ol (3.63). A Teflon vial was charged with 3.62 
(2.4 g, 11.5 mmol, 1 equiv), triethylamine trihydrofluoride (TREAT-HF, 9.26 mL, 57.4 mmol, 5 
equiv) and TEA (16 mL, 114.9 mmol, 10 equiv) and sealed in a high pressure bomb and the 
reaction was heated to 115 °C for 72 h. The reaction was cooled to room temperature before it 
was diluted by EtOAc and quenched with sat. aq. calcium chloride. The organic layer was 
washed with sat. aq. calcium chloride (2×), and then brine (1×). The organic layer was dried over 
anhydrous Na2SO4, concentrated under reduced pressure, and purified via silica chromatography 
(20% EtOAc/hexanes) to afford an oil (1.1 g, 4.7 mmol, 41%). 1H NMR (400 MHz, CDCl3) δ 
7.60 (d, J = 8.1 Hz, 1H), 7.49 (ddd, J = 8.3, 5.3, 3.5 Hz, 1H), 7.41 – 7.32 (m, 2H), 4.56 – 4.47 
 230 
(m, 1H), 4.44 – 4.26 (m, 2H), 1.42 (d, J = 7.3 Hz, 6H). 19F NMR (376 MHz, CDCl3) δ -230.14 – 
-230.91 (m). 
1-fluoro-3-methyl-3-(2-nitrophenyl)butan-2-one (3.64). 3.63 (1.1 g, 4.7 mmol, 1 equiv) in 
DCM (10 mL) was added dropwise to a mixture of PCC (1.2 g, 5.7 mmol, 1.2 equiv) and celite 
(200% w/w relative to PCC) in CH2Cl2 (20 mL). The reaction was then allowed to stir for 16 h at 
room temperature. The reaction was filtered through a bed of celite and washed with EtOAc 
(3×). The filtrate was purified via silica chromatography (10% EtOAc/hexanes) to afford the 
product as a solid (0.81 g, 3.6 mmol, 77%). 1H NMR (400 MHz, CDCl3) δ 7.58 (dd, J = 7.9, 1.4 
Hz, 1H), 7.47 (dd, J = 8.0, 1.7 Hz, 1H), 7.38 (td, J = 7.6, 1.4 Hz, 1H), 7.22 – 7.14 (m, 1H), 4.94 
(d, J = 47.2 Hz, 2H), 1.60 (s, 6H). 19F NMR (376 MHz, CDCl3) δ -228.97 (t, J = 47.2 Hz). 
2-(fluoromethyl)-3,3-dimethyl-3H-indole (3.65). To a solution of 3.64 (98.7 mg, 438 μmol, 1.0 
equiv) in EtOAc (4.38 mL) and EtOH (4.38 mL) was added titanium(III) chloride (2.79 mL, 2.63 
mmol, 6 equiv), dropwise, at -20 °C. The reaction was allowed to proceed at 4 °C for 16 h 
without stirring. The reaction was then allowed to warm to room temperature before it was 
quenched with brine containing 10% sat. bicarbonate. The product was extracted with 
chloroform (3×). The organic layer was dried over anhydrous Na2SO4 and purified via silica 
chromatography (20% EtOAc/hexanes) to afford an oil (59.9 mg, 338 μmol, 77%). 1H NMR 
(500 MHz, CDCl3) δ 7.68 – 7.58 (m, 1H), 7.36 – 7.27 (m, 3H), 5.47 (d, J = 46.7 Hz, 2H), 1.44 (s, 
6H). 19F NMR (470 MHz, CDCl3) δ -229.01 (t, J = 46.8 Hz). HRMS (ESI-TOF) for [M+] calc’d 
178.1032, found 178.1032. 
2-(fluoromethyl)-3,3-dimethylindoline (3.66). To a solution of 3.65 (69.9 mg, 394 μmol, 1.0 
equiv) in MeOH (20 mL) and water (10 mL), was added sodium borohydride (17.9 mg, 473 
μmol, 1.2 equiv), portion-wise, at 0 °C. The reaction was allowed to stir for 4 h at the same 
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temperature. After completion, the product was extracted with DCM (3×) and the organic layer 
was dried over anhydrous Na2SO4. Concentration under reduced pressure afforded the product as 
a white solid (30.8 mg, 172 μmol, 44%), which was used without further purification. 1H NMR 
(400 MHz, CDCl3) δ 7.12 – 6.96 (m, 2H), 6.79 (td, J = 7.4, 1.1 Hz, 1H), 6.71 – 6.65 (m, 1H), 
4.72 – 4.54 (m, 1H), 4.51 – 4.37 (m, 1H), 3.76 (ddd, J = 15.0, 8.8, 4.1 Hz, 1H), 1.41 (s, 3H), 1.15 
(s, 3H). 19F NMR (376 MHz, CDCl3) δ -227.38 (td, J = 47.3, 15.1 Hz). 
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APPENDIX D: ELECTRON PARAMAGNETIC RESONANCE SPECTROSCOPY FOR 
MONITING NITRIC OXIDE RELEASE6 
 
D.1 Introduction 
tAPNO-5’s photodecomposition was hypothesized to occur via photoinduced electron 
transfer from the electron rich aryl to the N-nitroso. This would then result in cleavage of the sessile 
bond to release APNO-5 (after protonation) and NO. A redshifted chromophore (λmax = 676 nm) 
was observed after prolonged light irradiation, consistent with this proposal.1,2 
 
Figure D.1: UV-Vis spectra of tAPNO-5 before and after acquiring a PA spectrum from 680 – 900 nm. Authentic 
APNO-5 solution for comparison. All dye solutions were 10 μM and were prepared in 20 mM ethanolic potassium 
phosphate buffer (pH = 7.4, 50% v/v). 
 
This light-induced decomposition was leveraged to develop the first single-photon NIR 
small-molecule NO donors with an integrated PA readout (photoNOD-1 and photoNOD-2). To 
decrease the propensity of capturing the release NO, the o-methoxy substituent was removed from 
the trigger. This enabled monitoring of analyte release in deep tissue following light irradiation. 
The utility was highlighted in a proof-of-concept small-animal model. Subcutaneous 4T1 tumors 
 
6Portions of this chapter are reprinted or adapted with permissions from the following publication: (1) Zhou, E. Y.; 
Knox, H. J.; Reinhardt, C. J.; Partipilo, G.; Nilges, M. J.; Chan, J. Near-Infrared Photoactivatable Nitric Oxide Donors 
with Integrated Photoacoustic Monitoring. J. Am. Chem. Soc. 2018, 140 (37), 11686–11697.3 Copyright © 2018 
American Chemical Society.  
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were established on the outer flanks of BALB/c mice. photoNOD-1 was administered 
systemically, via retroorbital injection, and only one of the tumors was irradiated. Under these 
conditions, it was possible to selectively induce apoptosis in the irradiated tumor with no affects 
in the non-irradiated tumor.3,4 
This section outlines the general procedures for confirming and quantifying nitric oxide 
release from small molecule donors using the iron-N-methyl-D-glucamine dithiocarbamate 
complex, Fe(MGD)2, as a NO-selective trap for electron paramagnetic resonance (EPR) 
spectroscopy. This can be used to either evaluate the stability of probes or the release of NO 
donors. The following protocols correspond to the Varian E-line 12" Century Series X-band CW 
EPR (VarianXBand) spectrometer.  
 
D.2 Electron paramagnetic resonance for monitoring nitric oxide release 
Degas septum-capped vials containing water, an organic cosolvent (typically the donor or 
probe should be soluble at 2 – 5 mM, DMF will be used for this example), or 10 mM potassium 
hydroxide for 30 minutes at room temperature with a steady stream of nitrogen gas. It is imperative 
to exclude oxygen contaminations until completing the irradiation because Fe(MGD)2 is only 
specific for NO under anoxic conditions. It is important to note that nitrite can also produce 
detectable amounts of NO under anoxic conditions, so proper conditions are required to prevent 
false positives.5,6 
Prepare the probe or donor solution (5 mM) in a septum-capped vial using degassed DMF 
and seal under nitrogen atmosphere. In a separate vial, transfer solid iron sulfate heptahydrate or 
MGD, evacuate the container, and then place the sample under nitrogen. Repeat this process three 
times to minimize contamination by molecular oxygen. Dissolve the solids with the appropriate 
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amount of degassed water for a final concentration of (8 mM Fe(II) and 40 mM MGD). These 
stock solutions are used to prepare each sample in sealed, degassed septum-capped vials. Final 
ratios of 1:4:20 (donor/probe:Fe(II):MGD) are used to maximize complex formation and trapping 
efficiency. A 50% cosolvent solution was selected to ensure solubility of the constituents while 
limiting sample heating during EPR measurements. The ratio of the donor to Fe(MGD)2 and 
cosolvent percentage can be all modified, as necessary. 
Irradiate each sample with an appropriate excitation source (e.g., a pre-warmed 
photoacoustic tomographer, LED light) at the wavelength of interest. Irradiation times can be 
varied to monitor release kinetics (e.g., 0, 5, and 40 min irradiations). After complete, open the 
vials and collect the sample using capillary action into a hematocrit. Seal both the top and bottom 
with wax tube sealant and place the capillary tube in a quartz EPR tube for acquisition.  
 
D.3 Acquiring electron paramagnetic resonance spectra 
 The following protocol has been adapted, with permission, from Dr. Mark J. Nilges (EPR 
Research Center, University of Illinois at Urbana-Champaign). 
 First, sign into ChemFOM to turn on the instrument and begin the setup process. Turn on 
the water flow to cool the magnetic jackets of the instrument. It is essential to ensure that the water 
continues to flow throughout the experiment to prevent overheating. Turn on the console power 
switch, magnet switch (on Field dial, set 10,000 position to 0), amplifier, and set the microwave 
bridge for the following settings: power 30 dB; reference arm off, and mode to tune. Then turn on 
the microwave frequency counter, insert the sample, and begin tuning the cavity. Center the 
klystron mode pattern (on the scope) using the frequency knob. Maximize the cavity resonance 
dip using the iris, then lower the power to 40 dB. Turn the reference arm to on and adjust the phase 
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to make the dip symmetrical. After it is satisfactorily symmetrical, turn the reference arm off and 
turn the klystron mode to operate. Center the needle on the AFC meter with the frequency. Once 
centered, turn on the reference arm and adjust the phase to maximize the detected current reading. 
Increase the power to the desired level (provided below for the nitric oxide trapping experiments) 
while keeping the detected current between 200 and 250 A) with the iris. Verify that the AFC has 
not shifted (repeat if it has, proceed if it has not). Record the modulation frequency and power for 
reference. Set the modulation amplitude, gain; sweep width, scan time, and number of scans. The 
measurement can then be performed.  
 When changing samples, it is necessary to return the power to 30 dB, turn off the reference 
arm, and change the mode to tune. Change the sample and then center the klystron pattern on the 
scope using the frequency knob. Confirm that the cavity resonance dip is maximized (it should if 
the samples are similar). Change the klystron mode to operate and center the needle on the AFC 
meter using the frequency. Turn the reference arm on and adjust the phase to maximize the 
determined current reading. Reperform the power adjustment while maintaining the determined 
current using the iris and acquire. Note that minor to no changes are required if the samples are 
similar. To turn off the instrument: turn the power down to 30 dB, turn the reference arm to off, 
the mode to tune and then standby, and then turn off the microwave frequency counter, amplifier, 
magnet switch (on field dial), the console power switch, the water, and sign out of the ChemFOM 
system.  
Acquire the EPR spectra of each sample at room temperature using the following 
parameters:  Modulation frequency: 100 kHz; Modulation amplitude: 2.5 G; Gain: 4000; Sweep 
width: 100 G; Scan time: 0.5 min per scan, 6 scans; Microwave power: 12 dB; Microwave 
frequency, 9.30 GHz  
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Generate a calibration curve for quantification using an established NO donor (e.g., 
MAHMA-NONOate) or saturated aqueous solution. NONOate donors should be prepared in 
degassed, aqueous potassium hydroxide (10 mM) at a range of concentrations. Prepare the samples 
in an identical fashion to probe/donor allow the sample to incubate for at least 20 half-lives. 
Confirm NO-release by the characteristic MGD2-Fe-NO triplet (g = 2.04) and quantify using the 
calibration curve (EPR intensity peak height to NO concentration). Representative data is provided 
in Figure D.2. 
 
Figure D.2: (a) Calibration curve for NO from MAHMA-NONOate using the Fe(MGD)2 NO-selective spin trap. (b) 
EPR spectra collected after 0, 5, and 40 min of irradiation of (b) photoNOD-1 (690 nm) or (c) photoNOD-2 (680 nm) 
(200 μM in water containing 50% DMF v/v) in the presence of Fe(MGD)2. (d) Quantification of NO release. Data 
presented as mean ± standard deviation (n = 3). 
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